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SUMMARY.
1. The aim of this work was to investigate any interaction(s) between the 
p-adrenoceptor blocker atenolol and the calcium antagonist nitrendipine, 
following chronic administration, using in-sltu methods where possible. 
Blood pressure and heart rate were investigated in conscious normotensive 
and hypertensive rats, followed by examination of adrenergic 
neurotransmission in the mesenteric vascular bed in both rats and dogs.
2. Work has shown that daily oral administration of atenolol administered 
alone or in combination produces a significant degree of p-blockade, and a 
reduction of heart rate and blood pressure in the conscious normotensive 
and hypertensive rat. Work with hypertensive rats, and normotensive rats 
and dogs, indicated that following chronic treatment atenolol had some
presynaptic effect. This conclusion was supported by the examination of
stimulus induced 3H~noradrenaline overflow. The size and time course of
this effect suggests that it may be important in the reduction in blood
pressure observed clinically.
3. Nitrendipine treatment has been shown to be effective in reducing 
blood pressure in normotensive and hypertensive rats. However, a reflex 
tachycardia was observed in normotensive animals. Nitrendipine treatment 
appeared to act post-synaptically to reduce mesenteric responses to both 
endogenous and exogenous noradrenaline.
4. Treatment with the combination of atenolol and nitrendipine reduced 
both blood pressure and heart rate in normotensive and hypertensive rats. 
There was, however, no evidence of an additive hypotensive effect. This 
may have been due to the complex changes in adrenergic neurotransmission 
observed with the combination. These suggested, that following chronic 
administration, non-noradrenergic neurotransmission was involved in 
maintaining responses to electrical stimulation. This could be the result 
of the “unmasking” of a co-transmitter following the profound reduction in 
response to noradrenaline. The interaction between atenolol and
nitrendipine did, however, prevent the reflex tachycardia observed with 
nitrendipine alone.
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1. 1 Aims of the investigation.
Two of the most important groups of antihypertensive drugs, p- 
adrenoceptor blockers and calcium antagonists, are increasingly used in 
combination. The rationale for their combined use is based on the 
theoretical consideration that these agents produce a similar hypotensive 
effect via their interaction at different sites of action. The clinical 
observation of their increased efficacy and a reduced incidence of side 
effects when given in combination supports this view. The pharmacological 
knowledge of the sites and mechanisms of action of these agents comes 
largely from the examination of one or other of the groups in isolation. 
Additionally, in the clinical control of hypertension, these drugs are 
likely to be administered for long periods of time, whereas the majority of 
the pharmacological investigations have examined the effects of only acute 
administration.
Previous work at the University of Bath has examined the effects of 
various p-adrenoceptor blocking drugs following chronic administration. 
One of the important considerations to come from this work is that the 
in vitro investigations can often be complicated by the “wash-out" of the 
p-blocker following tissue removal.
The initial aims of this present work were to examine the possible 
interactions between p-adrenoceptor blocking drugs and calcium antagonists 
following their chronic administration, and to investigate the mechanisms 
involved, using in situ experimental techniques where possible.
3The investigation was undertaken using the {3-adrenoceptor blocker 
atenolol and the calcium antagonist nitrendipine. The pharmacology of 
these two drugs is such that they appear particularly well suited for use 
in combination.
1.2 An introduction to the scheme of the investigation.
The first stage of the investigation was to examine the effects of the 
drugs on the blood pressure and heart rate of conscious rats over a three 
week period of daily administration.
The next stage was an investigation of the presence of {3-adrenoceptor 
blockade by examining the response to a standard isoprenaline challenge. 
This was carried out after 7 and 21 days treatment.
After this, the effect of 7 and 21 days pretreatment on adrenergic 
neurotransmission was examined using an in situ mesentery preparation. 
Finally, this preparation was used in a preliminary examination of 
3H-noradrenaline overflow.
This plan was followed using normotensive and hypertensive rats and 
normotensive dogs, after pretreatment with atenolol and nitrendipine alone 




FIGURE 1: A schematic diagram of the work undertaken in the investigation.
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51.3 Introduction to the scheme of the thesis.
The schematic representation of the investigation, shown in figure 1, 
shows that the work can most easily be divided into three sections 
according to the three treatment regimes. In order to set out the 
information in a logical order the main body of this thesis is divided into 
three chapters, each corresponding to a treatment group. Each of these 
three chapters is further divided to include: introduction, methods,
results and conclusions sections. This initial chapter aims to introduce 
the general items which do not fall into the three treatment chapters. The 
main body of the thesis is followed by a final chapter which brings 
together the conclusions from each of the treatment chapters and attempts 
to discuss them further and suggest future work.
1.4 Introduction to some general points of methodology.
1.4.1 Blood pressure measurement in conscious animals.
Arterial blood pressure is the hydrostatic pressure generated within 
the arterial system by the heart pumping blood against the peripheral 
resistance of the vessels. The direct measurement of blood pressure 
requires surgical cannulation of a major artery and subsequent connection 
to a recording system. While this approach provides the most accurate 
method of measurement and is ideal for anaesthetised acute work, it has 
several drawbacks. The main disadvantages for chronic work in conscious
animals are the preparation time involved and the problems in maintaining 
infection free postoperative animals with “unclogged" cannulas.
The indirect measurement of blood pressure allows repeated 
measurements in a large number of animals but is less accurate. Despite 
this somewhat reduced accuracy, reliable comparative measurements can be 
made if the experimental conditions are strictly controlled.
The indirect method of blood pressure measurement was chosen for use 
in this study. The exact method used follows the principle of occluding 
the blood flow to the tail with a pneumatic cuff and recording the pressure 
pulses in the caudal artery as the cuff pressure is increased and released. 
In order to be able to record the pulse pressure of the caudal artery, it 
has to be dilated, and to facilitate this the rats are pre-warmed at 39*C 
(Lovenberg 1987). Every effort is made to ensure the results are as 
accurate and reproducible as possible by: habituating the rats to the
procedure, warming, and placing the cuff and probe consistently, and 
avoiding extraneous activity whilst recording, (for details see section 
2.2.1) Despite every effort, animals can become stressed by the warming 
and this may increase the variability of the results. This can be avoided 
to some extent by the latest probes which use photoelectric rather than 
pressure sensors. Such photoelectric probes can detect pulsatile flow 
without the necessity of dilating the caudal artery, and thus negate the 
need for warming. Unfortunately such a system was not available for use in 
this study.
1.4.2 Anaesthesia and choice of anaesthetic agent.
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Anaesthesia for laboratory animals should provide humane restraint and 
prevent the perception of painful stimuli. Surgical anaesthesia is 
attained when pain perception is completely suppressed. In addition, it is 
desirable that the animal has a decreased perception of other external 
stimuli such as noise, and that there is a suppression of reflex activity 
and loss of skeletal muscle tone. The choice of a particular method of 
anaesthesia depends on a variety of factors, the most important being the 
humane treatment of the animal and safety of the operator CStrobel & 
Woolman 1969, Chenoweth & Van Dyke 1969, Ben et al 1969).
Inhalation anaesthesia was rejected as a method for this 
investigation, as it is not suitable for the sustained periods required by 
the subsequent operative procedures (Miller 1969, Leash 1969).
Theoretical considerations led to the choice of the neurolept- 
analgesic combination of hypnorm and midazolam. Midazolam hydrochloride is 
a benzodiazepine and produces good muscle relaxation. Hypnorm is a 
combination of fluanisone, a neuroleptic, and fentanyl, a potent narcotic 
analgesic. The narcotic analgesic is included to abolish the perception of 
pain, and the neuroleptic, which is a tranquillizer, to suppress some of 
the undesirable effects of the narcotic such as vomiting or excitement. 
This cocktail has been widely reported as being a good, stable long- 
/medium- term anaesthetic with the advantage of having an analgesic action. 
It has also been reported as having few side effects and producing a stable 
respiratory and cardiovascular state (Schmitt 1969, Erhardt et al 1977, 
Flecknell et al 1983, Svendsen & Carter 1984).
Initial work with this anaesthetic regime produced some surprising 
effects; the mesenteric response to noradrenaline and electrical 
stimulation was less than expected (Jackson & Campbell 1980a). Further 
investigation led to the discovery that fluanisone (a constituent of 
hypnorm) is a potent a-adrenoceptor antagonist. The affinity of fluanisone 
for a-adrenoceptors is greater than that of the classical a-antagonist 
phentolamine when measured by competition with 3H-WB-4101 binding (Janssen 
1961, Peroutka et al 1976). This a-adrenoceptor activity prevented further 
use of this otherwise excellent anaesthetic regime in this investigation.
Pentobarbitone is probably the most widely used agent in laboratory 
animal anaesthesia. However, it has little analgesic action and surgical 
anaesthesia is attained only at doses close to those that cause respiratory 
failure. This can be a problem, especially when it is administered i. p. , 
as the variability in action can lead to overdose. This agent was chosen 
for use in dogs, where the relative ease of i. v. administration allowed the 
quick induction of anaesthesia with a small dose, and maintenance with a 
carefully controlled infusion (Leash 1969).
The anaesthetic inactin, a thiobarbiturate, was chosen for use in the 
work with rats. This agent has been shown to produce relatively reliable 
and prolonged anaesthesia following i.p. administration to rats. The dose 
required to induce surgical anaesthesia is less than that causing 
significant respiratory depression, so fatal overdose is less likely than 
with pentobarbitone. The drug has been shown to produce a stable state of 
anaesthesia with less undesirable effects than pentobarbitone (Buelke-Sam 
et al 1978, Tucker et al 1982, Torlinska et al 1984). It has, however, 
been shown to cause significant alterations in kidney function (Elmer et al 
1972, Knight et al 1978, Thomsen & Olesen 1981, Holstein-Rathlou et al 
1982, Leyssac et al 1986).
91. 4. 3 Measurement of blood flow using ultrasonic Doppler probes.
The need to be able to measure flow through a blood vessel using an 
easy, reliable and “bloodless" method poses problems. Initially, these 
problems were solved by using electromagnetic flowmeters, and although 
these are accurate, they have a relatively large power requirement and so 
are unsuitable for telemetric recording. The ultrasonic Doppler flow 
probes are as accurate as electromagnetic versions, and are more suitable 
for use on very small vessels and for use with a telemetric system (Vatner 
et al 1970a, 1970b). The principle behind the Doppler flow probes is
relatively simple. The Doppler effect occurs when ultrasound, transmitted 
by a crystal, strikes a moving particle (eg a blood cell). The particle 
scatters the ultrasound, causing a change in frequency which is 
proportional to the particle's velocity. This enables the velocity of 
blood passing through the cross-section of vessel beneath the probe to be 
calculated. Knowing this average velocity and the diameter of the vessel 
the flow can be computed (Arts & Roevros 1972).
1.5 An introduction to hypertension.
1.5.1 Clinical hypertension.
Systemic hypertension can be regarded as a quantitative disorder of 
blood pressure regulation. The simplicity of this statement is belied by 
the fact that the pathophysiology of hypertension is complicated. Blood
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pressure is continuously variable both within a population and an 
individual. This makes the diagnosis of hypertension difficult. Blood 
pressure may be raised as a result of many conditions such as renal 
disease, Cushing's syndrome and primary aldosteronism. However, in about 
80% of cases the cause is unknown; this is classified as essential 
hypertension. In its early phase (labile or borderline hypertension) it is 
characterised by intermittently raised cardiac output, with little change 
in vascular resistance. As the condition develops, the cardiac output 
returns to normal but the total peripheral resistance is raised.
The pathophysiological changes that occur in, or contribute to 
hypertension are complex. They include: changes in the number and diameter 
of arterioles, increase in blood viscosity, increased levels of 
catecholamines and angiotensin II, changes in membrane permeability, 
increased excitation-contraction coupling and changes in the number/ 
affinity of receptors (Pickering 1986). The condition is further 
complicated by environmental influences such as salt intake, diet, smoking 
and stress; a genetic predisposition also plays an important role.
Although the presence of hypertension may have little apparent effect 
on a patient, it is important to treat it, as it significantly lowers life 
expectancy. As, early in its development, there are few symptoms of 
hypertension, it is important that the drug regimes used- to combat it are 
both effective and relatively free from side effects. Research into 
hypertension and its treatment, is necessary both to improve treatment and 
decrease its unwanted side effects thereby increasing patient compliance 
and decreasing mortality.
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1. 5. 2 Animal models of hypertension.
The major difficulty in developing an animal model of hypertension 
arises from the heterogeneity of the disease. There are many animal models 
of hypertension, from surgically induced renal hypertension to genetically 
hypertensive rats. While no model can provide an exact counterpart for the 
human disease, genetically hypertensive rat models have several important 
features found in human hypertension. Despite these similarities, they 
provide only a “narrow” view of the wide spectrum of clinical hypertension. 
The overlap is however, broadened by the different genetic hypertensive rat 
models available.
The model of hypertension chosen for use in this work, was the 
spontaneously hypertensive Japanese Okamoto rat (SHR), developed in Kyoto 
(Okamoto & Aoki 1963). The normotensive Wistar rat, from which they were 
developed, were used as controls.
The time course of hypertension in these rats is similar to that in 
man, that is, blood pressure is initially normal and increases with age. 
The changes in cardiac output and peripheral resistance also follow a 
similar pattern to that observed in hypertensive patients (Richer et al 
1978, 1980).
The major cardiovascular complications in primary hypertension include 
left ventricular hypertrophy and accelerated atherosclerosis which may lead 
to congestive heart failure. These same features are also present in the 
SHR. In addition to this, there is a great deal of evidence to suggest 
that there are structural abnormalities in the resistance vessels in both 
the SHR and in hypertensive man (Safar et al 1987). There is evidence that 
both hyperplasia and hypertrophy occur in the media of the vessel wall.
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This leads to an increase in the media/lumen ratio and a decrease in wall 
distensibility (Seidel 1981, Mulvany 1984, Folkow et al 1984). The 
increased thickness and strength of the wall of hypertensive vessels may 
partly explain the increased contraction to stimuli in such vessels (Finch 
& Haeusler 1974, Folkow et al 1984). The question remains, whether the 
increase in both ventricular mass and vessel wall thickness, observed in 
hypertension, is a cause of that hypertension or merely a result of other 
changes. That is, do these structural changes cause the increased pressure 
or are they an attempt to keep wall tension constant (Laplace's law) in 
response to the increased pressure?
There is also widespread evidence of abnormalities in cellular ionic 
transport in the SHR, and these changes may play a role in the development 
and maintenance of hypertension. The most general manifestations of the 
altered ionic transport across the membrane, are an increase in passive 
permeability, a decrease in Ca^-binding ability and a defect in the 
ability to accumulate Ca-*"". These factors cause an increase in free 
intracellular Ca++; this combined with alterations in intracellular Ca^^- 
distribution result in an increased sensitivity to Ca“^  in the SHR (Wei 
et al 1976, Folkow et al 1977, Me Carron et al 1981 Postnov & Orlov 1985). 
This, together with other alterations in cation transport across the 
membrane, can combine with alterations in sympathetic neurotransmission, 
resulting in an increase in transmitter release and postsynaptic effect 
(Postnov & Orlov 1985). This may be an important aspect of the cause and 
maintenance of hypertension in both the SHR and clinical hypertension.
Available evidence suggests that there is an increase in sympathetic 
nerve activity in the development and maintenance of hypertension in both 
the SHR and human essential hypertension (Westfall & Meldrum 1985). There 
are several studies suggesting that there is an increase in sympathetic
activity in the SHR; some of these indicate that there is an increase in 
the release of noradrenaline in the SHR (Yamamoto & Cline 1987). Other 
studies suggest that there is a reduction in presynaptic inhibition 
(Pipilli et al 1988) or an increase in presynaptic facilitation (Rand et al 
1983, Cline 1985, Borkowski & Quinn 1985). While others suggest that the 
increase in activity is caused, at least partly, by a decrease in the re­
uptake of noradrenaline in the SHR (Yamamoto & Cline 1987). The changes in 
sympathetic neurotransmission are complicated but very important to both 
the cause and maintenance of hypertension; the details that may be 
important in this investigation are discussed further in the next section.
Interestingly Hallback and Folkow (1973) noted that SHR's produced a 
larger and more sustained sympathetic response to stress than their 
normotensive counterparts. They also showed that the threshold for the 
“defence” response to stress was lower and less likely to be inhibited by 
vagal restraint. As these changes were particularly apparent in the pre­
hypertensive phase, they suggest that they may be a neuro-hormonal trigger 
for subsequent changes in structure, ionic transport and sympathetic 
activity, and thus be important in the initiation of hypertension. It is 
tempting to draw parallels between this and the involvement of stress in 
essential hypertension in man.
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1.5.3 An introduction to noradrenergic neurotransmission, and some of 
Its changes in hypertension.
The diagram on the following page is a simplified schematic 
representation of noradrenergic neurotransmission. While the detail of 
sympathetic neurotransmission is not all pertinent to this work, a brief 
description of some of the changes that have been shown to occur with 
hypertension will be discussed. This is especially relevant to this work 
as noradrenergic neurotransmission was examined using the in situ blood 
perfused mesentery model.
It is generally considered that a sympathetic action potential causes 
the release of noradrenaline into the synaptic cleft. This noradrenaline 
can then cross the cleft to interact with a,-adrenoceptors and cause 
contraction of the smooth muscle in the vessel wall. The interaction with 
the a,-adrenoceptors causes contraction via an increase in Ca"*""; this may 
be as a result of the operation of a receptor-operated Ca^-channel or the 
release of intracellular Ca^^ (Bulbring & Tomita 1987). This release of 
noradrenaline has been shown to be increased in vessels from the SHR 
(Yamamoto & Cline 1987). The noradrenaline is also able to interact with 
presynaptic a^-adrenoceptors which have an inhibitory effect on further 
transmitter release. It has been suggested that in the SHR this effect is 
reduced, and that noradrenaline acts almost exclusively on the 
postjunctional a!-adrenoceptors (Lefevre-Borg et al 1988).
FIGURE 2: A schematic diagram of noradrenergic neurotransmission.






ANG II = Angiotensin II
PG = Prostaglandin
PLC = Phospholipid-cholesterol complex
AC = Adenylate cyclase
ATP = Adenosine triphosphate
CAMP = Cyclic adenosine monophosphate
ROC = Receptor operated calcium channel
VOC = Voltage operated calcium channel
U1 = Uptake 1




Red arrow-head = Inhibitory effect.
Green arrow-head = Facilitatory effect.
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There are also prejunctional 3^-adrenoceptors which are acted on by 
adrenaline to facilitate the release of noradrenaline. As there is more 
circulating adrenaline in the SHR this action may contribute to the
development of hypertension (Rand et al 1983, Remie et al 1988). There is 
increasing evidence that activation of the prejunctional p^-adrenoceptors 
not only has a direct effect but also causes the release of locally
generated angiotensin II (Kawasaki et al 1984, Nakamaru et al 1986, 
Schlicker et al 1988).
Locally released angiotensin II has been shown to have a presynaptic 
effect increasing the release of noradrenaline. The exact mechanism of 
this action is not known, nor is the exact involvement with the presynaptic 
P^-adrenoceptor (Hughs & Roth 1971, Malik & Nasjletti 1975, Jackson & 
Campbell 1979, 1980a, 1980b, Dzau 1984, Kaufmann & Vollmer 1985, Costa &
Majewski 1988). The angiotensin II facilitation of noradrenaline release 
has been shown to be significantly larger in the SHR (Cline 1984, Zimmerman 
et al 1987).
There is also considerable evidence that prostaglandins are released 
as a result of the noradrenaline-induced activation of the vascular smooth 
muscle. These prostaglandins (most likely PG E2 and possibly PG I2 ) have a 
presynaptic inhibitory effect on noradrenaline release, either directly 
(Weeks 1972, Hedqvist 1973, Manku et al 1977, Bolton 1979, Langer 1981) or 
by inhibiting the angiotensin II facilitation (Jackson & Campbell 1980a, 
Mizuno et al 1988). The release of these inhibitory prostaglandins has 
been shown to be reduced in the SHR compared with its normotensive
counterpart (Pipilli et al 1988).
Besides these various interactions the neuronally released
noradrenaline can diffuse away from the synapse and be taken up by tissues 
and destroyed (uptake 2) or be taken back up into the nerve cells (uptake
18
1). There is evidence to suggest that there is reduced reuptake of
noradrenaline in the SHR (Yamamoto & Cline 1987) allowing it to remain in
the synaptic cleft longer.
In addition to these factors, other associated changes can occur in 
hypertension which affect noradrenergic neurotransmission. The changes in
Ca^-metabolism resulting in an increased Ca^-sensitivity in the SHR have
already been discussed. This can obviously have a great effect on the
action of noradrenaline on the smooth muscle.
It should also be considered that there is increasing evidence of
co-transmission in the sympathetic nervous system. There is evidence to 
suggest that both neuropeptide Y (NPY) and adenosine triphosphate (ATP) act 
as co-transmitters with noradrenaline (Campbell 1987). There is also 
evidence that circulating adrenaline can be taken up by the nerve and 
co-released with noradrenaline; and that this is more likely in the SHR 
(Rand et al 1983).
The previous section has shown that noradrenergic neurotransmission is 
a complicated interaction of a large number of influencing factors. Many 
of these factors are seen to be altered in hypertension such that they 
produce an increase in the effect of neurotransmission and result in
greater vasoconstriction. It is possible that these changes are very
important in the actual cause of essential hypertension. It is therefore 






2. 1. 1 Atenolol: A brief history.
Professor Sir James Black developed the hypothesis that drugs which 
improved myocardial energetics in the presence of a reduced oxygen supply 
would improve exercise tolerance in angina pectoris and reverse or prevent 
catecholamine dependent arrhythmias. This led to the discovery of 
propranolol, a drug which has a widely accepted efficacy in angina 
pectoris, arrhythmias and thyrotoxicosis (Fitzgerald 1972). Clinicians 
were, however, concerned about the unwanted effects of propranolol, 
particularly the effect on respiratory 0-adrenoceptors. Work on this 
problem led to the development of practolol, a 0-adrenoceptor antagonist 
which was different from propranolol in four ways:- It was less potent, it 
was a partial agonist, it had no membrane stabilising properties and was 
cardioselective (Dunlop & Shanks 1968). This raised the question of 
whether differences in the responses to these drugs were due to adrenergic 
or to non-specific, non-adrenergic effects. In order to resolve this 
question a series of 0-blockers with differing combinations of adrenergic 
and non-adrenergic properties was sought. One of the required
pharmacological profiles, specified: a potency equivalent to that of
propranolol; cardioselectivity; an absence of both partial agonism and 
membrane stabilising properties. The compound that most nearly met these 
criteria was atenolol (Tenormin, ICI 66082), The development of this 
cardioselective drug with high efficacy and low incidence of side effects 
has led to its present wide-spread clinical use.
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2. 1. 2 Structure of atenolol.
The structure of atenolol [ (4--21 -hydroxy-3' -isopropyl-aminopropoxy) 
phenylacetamide], has several features in common with other p-adrenoceptor 
antagonists, having an aromatic ring with a substituted ethanolamine side 
chain linked to it by an -OCH2 group. The P,-adrenoceptor selectivity is 
partly due to the acidic nature of the proton in the parasubstituted CH2- 
CO-NH* group, although structure activity analysis shows that this is not 
the only determinant of cardioselectivity. The structure of atenolol is 
shown below.
OCH2CHOHCH2NHCH(CH3 )2
2.1.3 Pharmacodynamic properties of atenolol.
p-adrenoceptor blocking drugs are competitive inhibitors of 
catecholamine binding at p-adrenoceptor sites. Studies in vitro using 
guinea pig and human atrial tissue (Harms 1976) and in vivo using 
anaesthetised cats (Carlsson 1972) show that atenolol displays a 
differential blockade of the chronotropic actions of isoprenaline and 
noradrenaline. Richardson and Witherington (1976) compared the effects of
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propranolol and atenolol on isoprenaline-induced increases in hepatic blood 
flow in anaesthetised dogs. They found that atenolol antagonised the 
chronotropic actions of isoprenaline but did not affect the increases in 
hepatic blood flow. Atenolol is a 3i-selective blocking agent when used in 
low doses; it inhibits cardiac 3,-receptors but has less influence on 
bronchial and vascular p2-receptors. In high doses, however, 3 y-selective 
blockers will also block 3:2~receptors (Frishman 1982).
In addition to its cardioselective effects there is some evidence of 
atenolol's action on other adrenoceptors. Renin release from the kidney is 
3-mediated and is antagonised by propranolol. Some work suggests that 
atenolol may affect stimulated renin release, although the effect and 
potency of atenolol seems to vary with species and experimental conditions. 
Atenolol does not significantly alter lypolysis in either human or rat 
adipocytes; its anti-lipolytic potency being a 50th of that of propranolol 
(Harms & Van der Meer 1975). Simon and Kather (1977) investigated 
adenylate cyclase activity in isolated human adipocytes and found that 
atenolol was a third as potent as propranolol in antagonising both 
adrenaline and isoprenaline stimulated adenylate cyclase activity.
In high concentrations certain 8“blockers have a “local anaesthetic", 
membrane stabilising effect on the cardiac action potential. This property 
is exhibited equally by the two stereoisomers of a drug and is unrelated to 
3~blockade. Atenolol has been shown to possess no significant membrane 
stabilising effects; it has no significant effects on desheathed frog nerve 
(Fitzgerald 1977) and its (+) dextrorotatory stereoisomer has no recognised 
clinical value (Frishman 1979).
Certain 8-adrenoceptor blockers possess partial agonist activity, 
these drugs cause some activation of the 3~receptor in addition to their 
prevention of agonist access. Quantitative assessment of partial agonist
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activity of atenolol made in animals whose resting sympathetic tone has 
been abolished by adrenalectomy and reserpine pretreatment has shown that 
atenolol did not have any positive intrinsic activity (Frishman 1984).
The p-adrenoceptor blockers vary in their lipid solubility, atenolol 
is one of the least lipid soluble p-blockers. As such it does not easily 
cross the blood/brain barrier and is much less concentrated in the brain 
than more lipid soluble drugs (Cruickshank 1980). The concentration of a 
drug in the brain is not necessarily important, as, in the brain fat it may 
not be “available” to act at central receptors. The concentration of the 
drug in the cerebrospinal fluid (CSF) may be more important. The 
concentration of atenolol in the CSF was recently measured in terms of 
CSF/plasma ratio and found to be low with a value of 0*25 (Taylor et al
1981). Lipid solubility is also important in the metabolism of atenolol; 
being more water soluble it is not metabolised by the liver but excreted 
via the kidneys, (see section 2.1.5)
2. 1. 4 Toxicology of atenolol.
Acute toxicological studies have shown that atenolol is well tolerated 
in all species and that there is no major difference between its oral and 
intravenous administration. The acute toxicity of atenolol following oral 
administration to rats, expressed as LDSo is 3*0gm/kg. No abnormalities 
were observed 14 days after acute single dose administration in surviving 
animals. Prolonged toxicological studies using an atenolol dose of 
300mg/kg/day over six months in rats showed that there was no evidence of
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any tumorigenic potential. Similar studies showed that atenolol has no 
mutagenic or teratogenic potential (Fitzgerald 1979).
2. 1.5 Pharmacokinetics and metabolism of atenolol.
Atenolol absorption from the gut varies between species but the plasma 
level achieved is proportional to the dose administered. In the dog 
absorption is almost complete, while in the rat it is about 60%. The 
plasma level following oral administration is proportional to the dose 
administered. Peak plasma levels are observed after two hours in dogs and 
after two to four hours in rats. The elimination half-life (T%> is 6*5 
hours in dogs and 24-35 hours in rats. Autoradiographic studies show that 
,4C labelled atenolol is widely distributed throughout the body, with the 
exception of the brain and spinal cord. This is true in both rats and 
dogs. In the blood, atenolol is evenly distributed between red cells and 
the plasma (Fitzgerald 1979). In both the dog and the rat, the major route 
for the excretion of atenolol is in the urine. When ,4C labelled atenolol 
is given i. v. , over 80% is excreted in the urine within 24 hours. The 
major component in the urine is unchanged ,4C labelled atenolol, 10-12% of 
the radiolabel being- in the form of urinary metabolites. Less than 10% of 
the ,4C labelled material is recovered from the bile, suggesting only a 
minor role for biliary excretion (Reeves et al 1978a).
Atenolol is absorbed rapidly from the gut in man, peak plasma levels 
being attained 2-3 hours after oral administration. The bioavailability is 
between 45-55% of the dose and is not improved by its administration as a 
solution. Plasma proteins bind less than 30% of a dose of atenolol and 
there is relatively little variation between individuals given the same
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oral dose. The elimination half life (Tte) in man is about 6 hours, 
although this is increased by impaired renal function. As in animals, 
atenolol is widely distributed throughout the body with the exception of 
the brain and spinal cord. In common with rats and dogs atenolol is almost 
completely excreted in the urine and undergoes less than 10% 
biotransformation (Reeves et al 1978b).
2.1.6 Cardiovascular and hypotensive effects of atenolol.
The (3,-adrenoceptor specificity and potency of atenolol (discussed in 
section 2.1.3) provide a theoretical basis for its safe and therapeutically 
effective use for a variety of cardiovascular disorders.
The cardiovascular effects of atenolol depend on the dose used and the 
degree of autonomic activity present prior to its administration. The 
haemodynamic effect of i. v. administered atenolol in anaesthetised dogs is 
typically a fall in heart rate, and a reduction in both contractile force 
and aortic blood flow (Fitzgerald 1979). These effects may be explained by 
assuming that conduction of impulses through the atrioventricular node is 
modulated by autonomic activity, and that catecholamines facilitate this 
conduction. (3-adrenoceptor blockers delay conduction by antagonising this 
catecholamine mediated facilitation (Frishman & Silverman 1984). 
Fitzgerald (1979) showed that atenolol reduced atrioventricular 
conductivity in anaesthetised dogs in a dose dependent manner up to a dose 
of lmg/kg i,v. , but had no further significant effects at higher doses. 
This reduction in cardiac output does not, however result in an immediate 
reduction in systemic blood pressure due to increased baroreceptor reflex 
activity and subsequent increase in peripheral resistance (Scott 1981).
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The reduction in cardiac output occurs acutely after p-blockade (Gibson 
1974, Fitzgerald et al 1978) but the fall in blood pressure is delayed 
(Tarazari & Dustan 1972, Antonaccio et al 1986). The ability of p.o. 
administration of single doses of various p-adrenoceptor blockers to reduce 
blood pressure in spontaneously hypertensive rats is controversial. Some 
authors found that such administration reduced blood pressure (Levy 1976, 
Sybertz et al 1982, Roba et al 1972, Smits et al 1980, Garvy & Ram 1975), 
while others found that it had no effect or raised blood pressure (Davy 
et al 1977, Levy 1976, Nakao et al 1975, Tabei et al 1970, Sybertz et al
1982). Similar contradictions in the antihypertensive effects of p- 
blockers exist in work using other experimental forms of hypertension. 
While some of these differences may be explained by variation in the 
methods and the pharmacology of the various p-adrenoceptor blockers used, 
it is obvious that the hypotensive action of atenolol (& other p-blockers) 
is more complicated than is suggested by the theoretical considerations 
explained earlier.
The hypotensive action of atenolol and other p-adrenoceptor blockers 
following chronic administration is less controversial. Antonaccio et al 
(1986) showed that administration of atenolol (30mg/kg p. o. ) to conscious 
spontaneously hypertensive rats over four days produced a reduction in mean 
blood pressure. The onset of this reduction in blood pressure was, 
however, slower than the onset of p-blockade and became greater with 
duration of treatment. Other workers have also shown a similar delay in 
the hypotensive action of p-adrenoceptor blockers (Smits et al 1980, Scott 
1981, Frishman & Silverman 1984). Esler and co-workers (1977) examined the 
antihypertensive effect of propranolol over a wide range of doses. They 
found that propranolol in plasma concentrations between 10-30ng/ml produced 
a modest hypotensive effect that was well correlated with a decreased 
cardiac output. However, when the dose was increased, a further decrease
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in blood pressure was noted despite no further change in cardiac output. 
This and other work has suggested that the hypotensive action of atenolol 
<& other p-blockers) is unrelated to acute p-blockade and changes in heart 
rate (Antonaccio et al 1986). Although acute (3-adrenoceptor blockade is 
important in the prevention of the pressor response to catecholamines with 
exercise and stress (Frishman & Silverman 1984). This alone does not 
sufficiently explain the widely accepted view that p-adrenoceptor blockers 
are effective antihypertensive agents in humans. The clinical efficacy of 
atenolol (& other (3-blockers) as a antihypertensive has been well 
established and it is widely used for this purpose (Robertson 1983, Kaplan 
1983, Btlhler et al 1983). There is, however, no consensus of opinion as to 
the mechanism(s) of atenolol's antihypertensive action.
2.1.7 Possible mechanisms of the hypotensive action of atenolol.
A number of proposed mechanisms to explain the antihypertensive action 
of p-adrenoceptor blockers are discussed by Frishman and Silverman (1984). 
They suggest that the following may play a part in the hypotensive effect 
of p-blockade:
1. Reduction in cardiac output.
2. Central nervous system effects.
3. Reduction in plasma volume.
4. Reduction in venomotor tone.
5. Resetting of baroreceptor levels.
6. Inhibition of renin.
7. Prejunctional effects - reducing noradrenaline release.
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The reduction in cardiac output has already been discussed, and while 
it is undoubtedly important in preventing the pressor responses to stress 
and exercise it does not seem to be directly related to an antihypertensive 
effect. The initial reduction in cardiac output may. however, be important 
in the subsequent development of an antihypertensive effect, although this 
may not be correlated to {3-adrenoceptor blockade.
Although some {3-adrenoceptor blockers may exert a central hypotensive 
effect, atenolol is not lipid soluble and as such does not reach the brain, 
spinal cord or CSF in sufficient quantities to produce such an effect 
(Frishman 1982).
Studies have demonstrated that {3-adrenoceptor blockers reduced both 
plasma volume and venomotor tone after both acute and chronic 
administration (Frishman & Silverman 1984). These studies are not yet 
fully substantiated, and while they are of interest they are somewhat 
contradictory as one would expect a reduced cardiac output to produce a 
reflex increase in plasma volume.
Pickering and co-workers (1972) suggest that in hypertension 
baroreceptors exhibit a reduced sensitivity which may be increased by {3- 
blockade. The lack of an initial hypotensive effect with {3-blockers is 
caused by an increase in baroreflex activity as a result of a fall in 
cardiac output. Subsequently the peripheral resistance falls below 
previous control values and blood pressure is decreased (Smits et al 1979) 
this may be as a result of a change in baroreceptor reflex. After chronic 
administration of propranolol Angell-James & Bobik (1978) demonstrated a 
reduced threshold pressure and an increased gain of individual baroreceptor 
fibres in hypertensive rabbits.
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The relationship between the hypotensive action of p-adrenoceptor 
blockers and their ability to reduce plasma renin is a controversial area 
in hypertension research. There is no doubt that some p-blocking drugs can 
antagonise sympathetically-mediated renin release (Laragh 1973) but this is 
not the only mechanism of mediating renin release. It has been suggested 
that p-adrenoceptor blockers may have a hypotensive effect by decreasing 
plasma renin activity (BUhler et al 1975). Work by Antonaccio and co­
workers (1986) with a number of p-adrenoceptor blocking drugs shows that 
while some do decrease plasma renin activity there is no correlation 
between this and their ability to reduce blood pressure. Furthermore they 
found that atenolol did not significantly alter plasma renin activity but 
did reduce blood pressure. This lack of correlation between p-blockade and 
plasma renin activity has also been noted in clinical studies (Langer et al 
1980). It seems unlikely therefore that the hypotensive action of p- 
adrenoceptor blockers can be explained by simple reductions in plasma renin 
activity. Interestingly Kawasaki, Kline & Su (1984) suggest that a 
vascular renin-angiotensin system may be involved in the hypotensive 
effects of some p-adrenoceptor blockers.
There have been several suggestions that p-adrenoceptor blockers may 
act at some presynaptic site on peripheral noradrenergic neurons. Some 
blockers may act on presynaptic p-adrenoceptors decreasing a p-mediated 
facilitation of noradrenaline release (Frishman & Silverman 1984). The 
effects of such an interaction depends on the specificity and dose of the 
p-blocker used and the degree of intrinsic activity it possesses. Studies 
have shown that the presynaptic p-receptor resembles the p2-subtype and 
stimulation causes an increase in noradrenaline release (Rand, Majewski and 
Tung 1983). This presynaptic p-receptor would be activated either by
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circulating adrenaline, which has been shown to be raised (three fold) in
hypertension (Pak 1981) or from adrenaline co-released at the synapse.
There is evidence that adrenaline derived from neuronal uptake from the 
circulation can be co-released from sympathetic nerves (Kawasaki et al 
1984). Atenolol, being P,-selective and having no significant partial 
agonistic properties (see section 2.1.3) would not be likely to interact
with presynaptic p-receptors. Additionally the time course of the
antihypertensive action of p-blockers does not seem to be correlated with 
p-blockade.
Some workers have suggested that p-blockade can affect the turnover of 
noradrenaline (Alexandre & Chevillard 1980) or inhibit its uptake (Street & 
Walsh 1984). These effects seem to depend on lipid solubility and membrane 
stabilising effects and are therefore not likely to be the main mode of 
atenolol's hypotensive action.
Scott (1981) discovered that atenolol reduced sympathetic efferent 
discharge, and attenuated the reflex responses of the sympathetic nerves to 
changes in blood flow in her work with anaesthetised cats. This suggested 
that atenolol acted on sympathetic nerves outside the CNS possibly either 
as a result of changes in the baroreceptor reflex arc or some influence at 
transmission at sympathetic ganglia.
Jackson and Campbell (1979, 1980a 1980b) have shown that angiotensin
II in sub-pressor doses inhibited neuronal noradrenaline uptake and 
facilitated its release (Campbell & Jackson 1979). Some workers have 
suggested that p-adrenoceptor blockers may act by increasing the vascular 
production of prostaglandins, which in turn act to inhibit the angiotensin 
II potentiation of adrenergic transmission (Jackson & Campbell 1980a, 1981,
Daniell et al 1988). This is an attractive proposition as the effect 
appears to be independent of p-blockade and has been shown in a number of
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species and preparations. This theory is supported by the clinical 
observations that treatment with drugs such as indomethacin which inhibit 
the production of prostaglandins can attenuate the effect of {3-blockade on 
blood pressure (Durao et al 1977a, 1977b, Watkins et al 1980, Salvetti et
al 1984).
The effect of {3-adrenoceptor blockers on the sympathetic nervous 
system is complex. There is a great deal of evidence suggesting that {3- 
blockers interact with the system after chronic administration, and that 
the time course of this interaction may be important in their hypotensive 
effects. The exact interactions and the significance of acute p-blockade 
has yet to be determined.
In addition to the possible hypotensive mechanisms of atenolol 
previously discussed, there is also an argument as to its involvement in 
changing the structural abnormalities involved in hypertension. 
Hypertensive animals (& man) have long been recognised as having 
ventricular and atrial hypertrophy &/or hyperplasia. There is argument as 
to whether this is as a direct result of the hypertension (Laplace1s Law) 
or if it contributes to the cause and development of the hypertension. 
There is also some controversy as to whether {3-blockade can prevent &/or 
reduce the structural abnormalities by reducing the cardiac output and so 
removing the stimulus for its development (Mulvany 1984, Folkow et al 1984, 
Richer et al 1978). The importance of this effect depends on whether the 
structural abnormalities cause, or arise from, hypertension.
The therapeutic efficacy and safety of atenolol has been well 
established in patients with a variety of cardiovascular disorders. It is 
recognised as being effective in reducing the blood pressure of many 
patients with systemic hypertension and is widely used clinically for this 
purpose. There is, however, no consensus as to the mechanism(s) of action 
whereby atenolol has a hypotensive effect. While there is agreement on the 
reduction in cardiac output obtained with acute p-blockade, this does not 
adequately explain the hypotensive effect observed chronically. The 
mechanism(s) of action involved in this long-term reduction in blood 
pressure was investigated in this work.
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2.2 METHODS.
2.2. 1 Investigation of blood pressure in the conscious rat.
The first study of blood pressure was undertaken with normotensive 
male Wistar rats (University of Bath strain) weighing approximately 200g. 
Systolic blood pressure was measured using a non-invasive “tail-cuff” 
procedure.
Animals were maintained in a warming chamber at 3 9 *C for 10 minutes to 
dilate the caudal arteries. A pneumatic cuff was placed around the base of 
the tail and a sensitive pressure transducer was placed immediately distal 
to this. An electrosphygmomanometer (type 8002, W+W Ltd) was used to 
inflate and deflate the pressure cuff at a constant rate and to record the 
tail pulse measured by the pressure sensor. This was used to record three 
measurements of blood pressure, the mean of which was noted. Animals were 
minimally restrained throughout the procedure and extraneous activity in 
the laboratory was minimised to reduce stress.
Blood pressure was measured before and two hours after the daily dose 
of either atenolol or polyethylene glycol (PEG). During the first week of 
dosing all animals were treated with 5% PEG alone; this allowed them to 
become accustomed to the procedures involved. In the subsequent three 
weeks the treated group received 50mg/kg atenolol in a 5% PEG vehicle, 
while the control group received the PEG vehicle alone. Drugs were orally 
administered (lml/lOOg) daily; blood pressure was not, however, measured 
over weekend periods. Care was taken to ensure the correct fitting and 
placement of both the pneumatic cuff and the pressure sensor. The
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temperature and duration of pre-warming was consistent throughout the 
experiment. The warming chamber was thermostatically maintained at 39*C 
and water was available ad libitum enabling animals to drink and also 
providing a reasonable level of humidity.
This protocol was repeated using spontaneously hypertensive Japanese 
Okamoto rats (University of Bath strain) weighing approximately 200g.
2,2.2 Investigation of heart rate in the conscious rat.
Heart rate was calculated by counting the pulse pressure waves 
recorded by the pressure sensor on the proximal portion of the tail during 
the measurement of blood pressure described previously. These were counted 
over a 10 second period and multiplied by 6 to give heart rate in beats per 
minute. In each instance pulse pressure waves recorded before the tail 
cuff was sufficiently inflated to impede blood flow were used in the 
calculation. This was carried out on five traces for each animal and the 
mean value recorded.
This protocol was repeated using both normotensive Wistar rats and 
spontaneously hypertensive Japanese Okamoto rats (university of Bath 
strains) weighing approximately 200g.
35
2.2.3 Assessment of B-adrenoceptor blockade.
p-adrenoceptor blockade was assessed using an anaesthetised rat 
preparation to establish a dose response curve to bolus i. v. injections of 
isoprenaline.
Male Wistar rats (University of Bath strain), weighing 275-300g were 
anaesthetised with sodium thiobutobarbitone (Inactin; BYK) at a dose of 
120mg/kg administered i. p.. The trachea was exposed and cannulated with 
polythene tubing (200/300/060, Portex Ltd) to facilitate ventilation.
The left carotid artery was catheterised with a polythene tube (ref: 
200/300/030, Portex Ltd) which was connected to a pressure transducer (Type 
PD CR 75, Druck), the whole unit being filled with heparinised saline (100 
units/ml 0*9% w/v NaCl). The transducer was coupled to a blood pressure 
pre-amplifier (type 7179, NarcoBio-Systems), the output of which was fed to 
a heart rate coupler (type 7302, NarcoBio-Systems) which derived heart rate 
from the blood pressure pulse. The pressure and heart rate output was 
recorded on a Physiograph pen recorder (Mk III-S, Narco).
The left jugular vein was catheterised with a saline-filled polythene 
tube (ref: 200/300/020, Portex Ltd) to allow intravenous injection of
isoprenaline.
Body temperature was maintained at 37‘C using a thermostatically 
controlled heated table (type 50-1247, SRI Ltd). Following a 5 minute 
stabilisation period bolus i. v. doses of isoprenaline (25-200ng in 0*9% w/v 
NaCl) were administered via the venous cannula. Responses were measured in 
terms of increase in heart rate, which was allowed to return to control 
levels between doses of isoprenaline.
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This protocol was used to assess p-adrenoceptor blockade following 7 
and 21 days pretreatment with either atenolol (50mg/kg p. o. in 5% PEG, 
lml/lOOg) or 5% PEG (lml/lOOg). The procedure was followed 24 hours after 
the last dose of either atenolol or PEG.
2.2.4 The in-situ blood perfused rat mesentery.
The effect of chronic p-adrenoceptor blockade on adrenergic 
neurotransmission was investigated using the in-situ blood perfused 
mesentery method of Jackson and Campbell (1980a).
Animals were anaesthetised with a single bolus i. p. injection of 
sodium thiobutobarbitone (120mg/kg, Inactin, BYK). The trachea was exposed 
and cannulated with polythene tubing (200/300/060, Portex Ltd). The 
mesentery was exposed by a midline incision, the intestines were 
exteriorised and wrapped in saline moistened gauze. The abdominal aorta and 
superior mesenteric artery were carefully exposed and cleared ready for 
ligation. The wound was covered with saline moistened gauze and the 
preparation was left for 10 minutes to allow haemostasis.
Heparin (1500 units) was administered via the tail vein. The lower 
abdominal aorta was then catheterised distal to the left renal artery 
permitting connection to an extracorporeal circuit. The circuit was 
allowed to fill with blood and the free end used to cannulate the superior 
mesenteric artery. (details of the extracorporeal circuit are shown 
diagrammatically in figure 3) A peristaltic pump (type P3, Pharmacia) was 
used to perfuse the mesentery at a constant 2ml/min and physiological 
saline (0*9% w/v NaCl) was infused into the circuit at 0 * lml/min (Infusion
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FIGURE 3
Diagram showing the details of the extracorporeal circuit used in 
the in-sltu blood perfused mesentery method.
200m m  Polythene tubing ( i /d  0 .6m m ).
25mm T h ick -w alled  silicon tubing  
( i /d  0 .75m m ).
220m m  Peristaltic pum p tubing ( i /d  2 .0m m ).
100m m  P olythene tubing ( i /d  0 .6m m ).
30mm Thick-w alled  silicon tu b in g  ( i /d  0 .75m m ).
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pump 5200, SRI Ltd). During the cannulation procedure the mesenteric 
vascular bed was subjected to a brief ischaemic period of less than 2 
minutes. Bipolar platinum electrodes were placed around the superior 
mesenteric artery about 3mm distal to the cannulation point. Finally the 
abdomen was covered in saline-moistened gauze and the preparation was 
allowed to stabilise. Throughout the whole procedure the animal's body 
temperature was maintained at 37*C using a thermostatically controlled 
heated table (type 50-1247 SRI Ltd).
Pressure was recorded in the circuit before the perfusion pump, to 
give a measure of aortic blood pressure, and after the pump to give a 
measure of mesenteric pressure. Pressure transducers (type PD CR 75,
Druck) coupled to pressure pre-amplifiers (type 7179, Narco) recorded
pressure changes on a pen recorder (Physiograph mk III-S, Narco). Changes
in pressure were indicative of changes in mesenteric vascular resistance in 
this constant flow system.
Figure 4 shows a diagrammatic representation of the in-situ blood perfused 
mesentery method.
This protocol was used to investigate mesenteric response to exogenous 
noradrenaline (20-2000ng in 0*9% w/v NaCl) and periarterial electrical 
stimulation (15v rectangular pulses of 1ms duration for 20s, 2-35Hz). This 
was undertaken 24 hours after the last dose of either atenolol (50mg/kg in 
5% PEG, lml/lOOg) or 5% PEG (lml/lOOg) after both 7 and 21 days
pretreatment. The work was carried out with both normotensive male Wistar 




A diagrammatic representation of the in-situ blood perfused 
mesentery method.
oM esen te r ic  P re s su re .
(mmHg)
H e a t in g  L am p .
In jec tion  P o r t .
S u p e r io r  M esen te r ic  
A r te ry .
P e r fu s io n  P u m p .  (2 m l /m in )
A b d o m in a l  A o r ta .
P e r ia r t e r ia l  E lec tr ica l  S t im u la t io n .  
(15v pulses  o f 1ms fo r  20sec) A o rtic  P ressu re .
(mmHg) N o rm a l  S a line  In fu s io n .  (O .lm l/m in )
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2.2.4(1) Adaptation of the in-situ blood perfused mesentery method to 
allow a blood-Krebs comparison.
The method described in section 2.2.4 was modified to allow a 
comparison between blood- and Krebs-perfused in-situ mesentery methods. 
The extracorporeal circuit shown in figure 4 was modified such that the 
saline infusion line could be used for the infusion of Krebs. This 
adaptation is illustrated in figure 5.
The protocol was carried out as previously described (section 2.2.4) 
using normotensive male Wistar rats (Alderly park strain, 300g). Responses 
were obtained to exogenous calcium chloride (10-100mg) or periarterial 
electrical stimulation during blood perfusion. The supply of blood from 
the abdominal aorta was then stopped by clamping the silicon tubing 
proximal to the saline infusion line. Krebs at 37*C gassed with 95% 02 and 
5% C02 was supplied via the saline infusion line. The hepatic portal vein 
was ligatured and cut to allow the drainage of the Krebs from the 
mesenteric vascular bed. The system was allowed to stabilise for 10 
minutes and the responses to exogenous calcium chloride (10-lOOmg) or 
periarterial electrical stimulation were re-examined.
Appropriate time controls (n=4) revealed that there was no significant 
difference in blood perfused responses to calcium chloride or periarterial 
electrical stimulation over the 30-45 minutes required to obtain the 
results during perfusion with Krebs. Further blood and Krebs comparisons 
were made in the same animals; a group of three animals was used to compare 
response to calcium chloride and a group of eight animals used to compare 
response to electrical stimulation.
FIGURE 5
A diagrammatic representation 
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Table 1 shows that there is no significant difference in response to 
exogenous calcium chloride in blood- and Krebs-perfused systems.
Table 1: Response to exogenous calcium chloride. (mmHg)
BLOOD PERFUSED KREBS PERFUSED
C CaCl2] meantSE meantSE
lOmg 5*0 10*0 10*0 8* 3±1•4 5*0 20*0 0*0 8* 3t4* 9
20 mg 10*0 20*0 5*0 11 • 7±3* 6 10*0 30*0 2*0 14* 0t6* 8
40 mg 15*0 20*0 15*0 16* 7±1•4 15*0 20*0 7*0 14* 0i3*1
lOOmg 10-0 ----  15*0 12•5± 1 • 8 15*0 35*0 10*0 20* 0t6* 2
Figure 6 is a graphical representation of the result s of the
comparison in response to electrical stimulation. This indicates there is 
a highly significant (p<0*001) reduction in response in the Krebs perfused 
system. The decrease in base-line perfusion pressure (approx. 70mmHg) 
experienced during Krebs perfusion may partly explain this result, although 
it did not appear to influence the response to calcium chloride.
The results of this work supported the decision to use the blood 
perfused system for all further work.
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FIGURE 6
Graph showing the mesenteric response to periarterial electrical 
stimulation in normotensive male Wistar rat during perfusion with 
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St imula t ion  F requency  (Hz)
O---- O Blood perfused mesentery (n=8)
X---- X Krebs perfused mesentery (n=8)
Difference from corresponding value in Krebs perfused preparation : 
* p<0•05 ** p<0-01 *** p<0-001
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2.2.5 Investigation of stimulus-induced 3H-noradrenaline overflow.
The in-situ blood perfused mesentery method was also further modified 
in some later experiments to allow serial blood sampling from the hepatic 
portal vein. A fine polythene tube (200/300/020, Portex) was used to 
catheterise a side-branch of the hepatic portal vein such that the end was 
positioned in the main flow of the mesenteric venous drainage. This 
modified technique is illustrated in figure 7.
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FIGURE 7
A diagrammatic representation of the in-situ blood perfused 
mesentery method, showing its adaptation to allow the 
investigation of 3H-noradrenaline overflow.
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2.2.5(1) Construction of a quench curve for tritium.
Previous studies had shown that whole blood was likely to produce the 
greatest amount of quenching because of the strong colour effect exhibited 
at the red end of the spectrum. To compensate for this, a standard quench 
curve was calculated and stored to be used in the automatic correction of 
subsequent readings. Calculation and storage of the quench curve was 
carried out automatically in the Rackbeta scintillation counter using the 
following method:-
Ten vials were prepared, a standard amount of tritium ( 1210-120, LKB 
Wallac) was added to each vial. The multipurpose liquid scintillation 
cocktail, Optiphase 'Safe', which is suitable for use with both aqueous and 
non-aqueous samples (LKB Scintillation Products), was added to each vial 
(10ml). The first vial was then capped without the addition of any 
quenching agent. Increasing amounts of untreated whole blood was then 
added to the other nine tubes. Each tube contains the standard tritium, 
lOmls of scintillation cocktail and the following volumes of whole blood: 
Opl, 5jil, 10pl, 15pl, 20pl, 30p.l, 50pl, 75pl, lOOpl and 150j j.1. Following
the addition of the blood, the vials were capped and the samples loaded 
into the scintillation counter for quench calibration. The counts in each 
vial were measured and the quench calibration was calculated and stored in 
the counter's memory.
The tritium quench curve is shown in figure 8 on the following page.





Before each experiment clean vials were prepared each containing 2ml 
of Optiphase 'Safe*. As each 20j j.1 blood sample was taken it was placed 
into a vial which was capped and mixed well. At the end of each experiment 
all the vials were whirli-mixed for 30 seconds, placed into a rack and 
loaded into the liquid scintillation counter (Rackbeta 1215, LKB Wallac) 
for counting. Each sample was counted for 5 minutes against the internal 
control using the quench calibration previously calculated.
2.2.5(lii) Investigation of the time course of stimulus Induced tritlated 
noradrenaline overflow.
Throughout the investigation of tritiated noradrenaline overflow the 
radioisotope L-(7,8) noradrenaline hydrochloride (Amersham International 
PLC) was used. This isotope was supplied with an activity of 9-25 MBq at a 
concentration of 1*0 mCi/ml.
The in-situ blood-perfused mesentery was prepared as previously 
described (2.2.4) with the additional cannulation of the side branch of the 
hepatic portal vein. The venous cannula was filled with heparinised saline 
(100 u/ml 0*9% w/v NaCl) and connected to a lOOpl microsyringe (Hamilton). 
The mesentery was loaded with 2*5pci 3H-noradrenaline in 5ml of saline in a 
25 minute infusion. Desmethylimipramine (DMI, 2 f5mg/kg in 0-9% w/v NaCl)
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was added through the infusion line and the tritiated noradrenaline 
infusion replaced with a saline (0*9% w/v NaCl) infusion (0•lml/min).
After 5 minutes a 20pl blood sample was taken from the hepatic portal 
vein and placed in a vial. Three minutes later the superior mesenteric 
artery was stimulated at 16Hz (15v rectangular pulses of 1ms duration for 
20s) via the periarterial platinum electrodes. Blood samples (20pl) were 
then taken 30 seconds, 1 minute, 2 minutes, 3 minutes, 6 minutes and 10 
minutes after the start of stimulation. Three minutes after the last blood 
sample the periarterial electrical stimulation was repeated and blood 
samples were taken 30 seconds, 1 and 2 minutes after stimulation. The time 
course of the sampling procedure is summarised in the following table:-
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TIME ACTION
-33 min ............ Start 3H-noradrenaline infusion.
-8 min ............. Stop 3H-noradrenaline infusion
Add DMI (2-5mg/kg)
Start saline infusion.
-3 m i n ............. Sample 1.
0 ................... Stimulation 16Hz - ON.
+20 s ..............  Stimulation - OFF.
+30 s ..............  Sample 2.
+ 1 m i n .............  Sample 3.
+2 m i n ............. Sample 4.
+3 m i n ............. Sample 5.
+6 m i n .............  Sample 6.
+ 10 m i n ............ Sample 7.
+ 13 m i n ............ Stimulation 16Hz - ON.
+ 13m 2 0 s ..........  Stimulation - OFF.
+ 13m 3 0 s ..........  Sample 8.
+ 14 m i n ............ Sample 9.
+ 15 m i n ............ Sample 10.
These samples were then prepared and measured as previously explained 
in section (ii).
This work was undertaken using a group of 4 normotensive male Wistar 
rats (University of Bath strain) weighing approximately 300g. The 
following table shows the mean of the results obtained:-
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SAMPLE MEAN DPM SAMPLE MEAN DPM
sample 1 2277-6 sample 7 2457-3
sample 2 4047*5 sample 8 3004*8
sample 3 2926-5 sample 9 1944-7
sample 4 2564-8 sample 10 1889-1
sample 5 2430-0
sample 6 2924-3
These results show that the highest level of radiolabel was observed 
in samples collected 30 seconds after electrical stimulation. The release 
of tritiated label was apparent after a second stimulation but at a reduced 
level. These results led to the conclusion that in all further work blood 
samples should be taken 30 seconds, 1, 2 and 3 minutes after stimulation in 
order to observe the stimulus induced overflow.
2.2.5(iv) Investigation of the effect of chronic atenolol pretreatment on 
stimulus-induced 3H-noradrenaline overflow.
The in-situ blood perfused mesentery, with the additional cannulation, 
was set up as described previously. The mesentery was loaded with 2-5pci 
3H-noradrenaline as described in section (iii); DMI (2-5mg/kg) was added 
and the tritium infusion replaced with a saline (0*9% w/v NaCl) infusion.
After 5 minutes a 20pl blood sample was removed from the hepatic 
portal catheter and placed in a vial. After a further 3 minutes the 
superior mesenteric artery was stimulated at a frequency of 16Hz (15v 
rectangular pulses of 1ms duration for 20s). Further blood samples were
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taken 30 seconds, 1 and 3 minutes after stimulation. The time course of 
the sampling procedure is shown in the table below.
TIME ACTION
-33 min ............ Start 3H-noradrenaline infusion.
-8 min ............. Stop 3H-noradrenaline infusion
Add DMI (2'5mg/kg)
Start saline infusion.
-3 m i n ............. Sample 1.
0 ................... Stimulation 16Hz - ON.
+20 s ..............  Stimulation - OFF.
+30 s ..............  Sample 2.
+ 1 m i n ............. Sample 3.
+2 m i n ............. Sample 4.
+3 m i n ............. Sample 5.
The samples were prepared and measured as previously described. 
Stimulus-induced radio-label release was shown by the difference in DPM 
measured before stimulation (sample 1) and the maximum levels recorded 
after stimulation (sample 2). This difference was compared between animals 
pretreated for 21 days with either atenolol (50mg/kg in 5% PEG) or 5% PEG 
(lml/lOOg). This work was undertaken in male normotensive Wistar rats 
(University of Bath strain, 300g); 24 hours after pretreatment.
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2.2.6 Investigation of the effect of chronic atenolol pretreatment on 
mesenteric vascular responses in normotensive Beagles.
Normotensive male Beagles (Alderly park strain, 17-20kg) were 
anaesthetised with sodium pentobarbitone <30mg/kg, i.v.). The right 
femoral vein was catheterised <500/100/260, ID=l*5mm, 0D=2'5mm; Portex Ltd) 
and used to administer an infusion of sodium pentobarbitone (lmg/min in 
0-9% w/v NaCl) to sustain anaesthesia. An endotracheal tube was inserted 
and the animals ventilated with room air. The right femoral artery was 
exposed, catheterised (Portex polythene tube ref 500/100/260) and used to 
measure systemic blood pressure. This was achieved by attaching the 
cannula to a pressure transducer (PD CR 75, Druck) coupled to a Devices 
pressure pre-amplifier. Heart rate was derived from a lead II
electrocardiogram (ECG) using a cardiotachometer (Devices). The left 
femoral artery was catheterised (Portex Ltd, ref 500/100/260) to facilitate 
the intermittent sampling of arterial blood. This was used for the 
determination of blood pH, p02 and pCCL* which were adjusted to normal 
values as required. Blood gasses were measured using a blood gas analyser 
(Corning 165) using freshly drawn arterial blood sealed against the 
atmosphere.
A laparotomy was performed and the superior mesenteric artery was 
located and carefully cleared to allow the location of a flow probe. The 
flow probe was located as near the base of the vessel at the junction with 
the abdominal aorta as possible. This section of vessel was well cleared 
of connective tissue to allow the correct fitting of the probe. The 
diameter of the probe used was selected so as to provide a ’snug’ fit 
without occluding the vessel. Bipolar platinum electrodes were placed 
around the vessel distal to the probe. The electrodes were located on a
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section of vessel that was minimally cleared to allow access without 
disturbing the periarterial nerves. A suitable side-branch of the superior 
mesenteric artery was located and cleared to permit cannulation. This was 
then catheterised with polythene tubing (200/300/030, Portex Ltd) to allow 
the administration of drugs and the measurement of mesenteric blood 
pressure. Mesenteric blood pressure was recorded using a pressure
transducer (PD CR 75 Druck) coupled to a pre-amplifier (Devices). Figure 9 
(page 58) shows the location of the probe, electrodes and the cannula on 
the superior mesenteric artery. The abdominal wound was then closed with 
clamps and covered with saline moistened gauze. Throughout the whole 
experimental procedure the animal’s body temperature was maintained at 37*C 
using a thermostatically controlled heating blanket. Temperature was 
monitored and the heating blanket controlled via a rectal temperature 
probe. Following a 30 minute stabilisation period mesenteric
vasoconstrictor responses to exogenous noradrenaline (l-400ng in 0*9% w/v 
NaCl) and periarterial electrical stimulation (15v rectangular pulses of 
lms duration for 1 min, 2-35Hz) were obtained. Systemic blood pressure, 
heart rate, ECG, mesenteric blood pressure and mesenteric flow were 
displayed on a Devices (M19) pen recorder. Mesenteric resistance was 
calculated from this data using the following formula:
Rm (dyns/sec/cm5 ) = [ mean BPM (mmHg) * 1330 ] -5- FM (mls/sec)
Where : RM = mesenteric resistance, BPM = mesenteric blood pressure and
Fm = mesenteric flow.
This investigation was undertaken with dogs pretreated for 21 days 
with atenolol at a dose of 7*5mg/kg. The atenolol was administered daily 
as a solid in a gelatin capsule. The surgical procedure was carried out 24 
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Rats at the University of Bath were all housed under similar 
conditions. A 12 hour light and dark cycle was used and both housing and
experimental rooms were kept at 20-22*C with a relative humidity of 40-60%.
Animals were provided with 'Labsure' CRM diet and tap water ad libitum. 
Rats were housed in groups, so that the stress either of overcrowding or of 
solitude was avoided (groups of between 4 and 8).
Stock rats at Alderly park are housed under similar conditions with a 
12 hour light and dark cycle, a temperature of 21 ±2*C and a relative 
humidity of 55±10%. Animals were provided with PCD %ths SQC from 'Special 
Diet Services' and tap water ad libitum, and were housed in groups.
Dogs at Alderly park are kennelled with a 12 hour light and dark cycle
at a temperature of 19 ±2*C, and a relative humidity of 55 ±10%. Dogs were 
supplied with water ad libitum and fed with 400g Lab A diet (Special Diet 
Services) per day.
When animals had to be moved from a breeding or holding colony they 
were kept for a week before they were used in any experimental procedures 
to allow them to become accustomed to the new quarters.
Surgical procedures undertaken in both rats and dogs were carried out 
under a general anaesthetic. The depth of anaesthesia was assessed by 
observing respiration, systemic blood pressure, heart rate and muscle tone.
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The “pinch" reflex, the "blink" reflex and the "leg withdraw" reflex were 
also used to gauge the depth of anaesthesia.
All surgical procedures undertaken in both rats and dogs were non­
recovery. At the end of each procedure rats were killed by the injection 
of a 2-3ml bolus of air i.v., followed by cervical dislocation. Dogs were 
killed with an overdose of barbiturate (Euthatal) administered i.v. . In 
both cases death was confirmed by monitoring heart rate, systemic blood 
pressure and respiration.
2.2.7(ii) Data Transformation.
The blood pressure pulse does not take the form of a sinusoidal wave 
as systole and diastole are not of equal length. As a consequence, mean 
arterial blood pressure cannot be derived by calculating the arithmetical 
mean of the systolic and diastolic blood pressure. A routinely used
approximate of mean blood pressure is given by the following formula:
Mean BP = [(Systolic BP - Diastolic BP) t  3] + Diastolic BP 
This approximation of mean blood pressure was used in the present study.
Vascular resistance was calculated from blood flow and pressure which 
were measured directly. Resistance was calculated using the following 
formula:
Resistance (dyne/s/cm3 ) = [mean BP * 1333] t flow (ml/s)
Change in minute flow and resistance was calculated using a Basic program 
shown in appendix (1).
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2.2.7(ili) Statistical Analysis.
The Kolmogorov-Smirnov test was used to ascertain whether data was 
distributed in a “Normal” manner. This test compares the cumulative 
distribution function for a variable with a normal distribution. The 
Kolmogorov-Smirnov Z value is computed from the largest difference between 
the observed and theoretical distribution functions. A significantly large 
difference indicates that observed distribution function was not normally 
distributed.
When the sample size was large enough cumulative frequency was calculated 
and bar graphs plotted, normal curves were superimposed and the two 
compared. This was used in conjunction with the Kolmogorov-Smirnov test to 
investigate the normality of data.
An analysis of variance (ANOVA) was used to investigate the difference 
between treatment groups. This test indicates any significant variance 
between groups; follow-up tests were used to show where any differences 
lay. Tukey's honestly significant difference (HSD), Fisher's least 
significant difference (LSD) and Scheffe*s test were used for this purpose. 
These tests all involve multiple comparisons between group means; the three 
tests were used to compensate for the type I and II errors associated with 
these procedures.
Blood pressure and heart rate data recorded from conscious 
normotensive and hypertensive rats was analysed by the Kolmogorov-Smirnov 
test and was plotted as a frequency histogram with a normal curve 
superimposed to ascertain the deviation from a normal distribution. An 
ANOVA with LSD, HSD and Scheffe's follow-up tests were performed on data 
from week I, when all animals received PEG alone. This was performed to
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discover any differences between groups before atenolol treatment. The 
ANOVA and follow-ups were repeated using data from week IV, after 3 weeks 
atenolol administration to examine the differences following chronic 
treatment.
An unpaired t-test was used to compare two sample means by calculating 
Student's t and testing the significance of the difference between the 
means. This procedure was used if the data followed the normal 
distribution; if the data was non-parametric the Mann-Whitney U test was 
used.
In all experiments animals were randomly assigned to groups and drug 
treatments were randomly allotted to these groups. This procedure is a 
prerequisite for any meaningful statistical analysis.
All statistical analysis was carried out using the computer package 
SPSS-X version 2-1 on a Prime 9750 main-frame computer. Values of p>0*05 
were taken as indicating no significant difference between the parameters 
under comparison.
63
2.2.7(iv) Drugs and general chemicals.
Noradrenaline bitartrate Sigma Chemical Co. Inc.
Isoprenaline hydrochloride Sigma Chemical Co. Inc.
Atenolol t ICI Pharmaceuticals PLC
Sodium heparin Duncan, Flockhart & Co
Sodium thiobutobarbitone (Inactin) t BYK Gulden Lomberg Chem.
Sodium pentobarbitone (Sagatal) May & Baker Ltd.
Sodium pentobarbitone (Euthatal) May & Baker Ltd.
Desmethylimipramine hydrochloride. Geigy Pharmaceuticals Ltd
L-(7,6) noradrenaline hydrochloride t Amersham Int. PLC.
Polyethylene glycol (400 grade) Fisons PLC.
Optiphase 'safe' LKB Wallac Ltd.
t These drugs were kindly donated by ICI Pharmaceuticals PLC.
All doses of drugs given in the text are expressed as the weight of the 
salts. Drugs were prepared immediately before use, or were stored as 
frozen aliquots which were thawed as required. All drugs administered to 
conscious animals were given at room temperature.
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2.3 RESULTS.
2.3. 1 Results of the investigation of blood pressure.
2.3. l(i) Results from conscious normotensive Wistar rats.
During week I of the study, when all animals were dosed with
Polyethylene glycol (PEG) alone, there was no significant difference 
between the two groups of animals. In both groups blood pressure was high 
on the first day of the treatment; this then stabilised at a lower level 
(around 152 mmHg).
“Active” drug treatment commenced at the beginning of week II and was 
continued for three weeks. At the start of week II, before treatment, the 
atenolol treated group had a mean systolic blood pressure of 153 (±l*3)mmHg 
while the control group had a mean blood pressure of 155 (1*7)mmHg. During
the first week of atenolol treatment the mean systolic blood pressure of
the treated group fell to a minimum of 131 (±3*2)mmHg while that of the
control group remained relatively constant (approx 150mmHg). During this 
first week of dosing, a large difference between blood pressure recorded 
before and two hours after dosing was apparent in the treated group. Over 
the subsequent two weeks of dosing this difference was reduced. The blood 
pressure of the treated group stabilised at a reduced level over the second 
and third week of dosing. The mean blood pressure of the control group 
remained fairly constant over this period. Statistical analysis of the 
results obtained during week IV, the third week of dosing, showed a very 
highly significant difference between the treatment groups (p<0‘0001). The
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group treated with atenolol had a mean blood pressure over week IV of 140*6 
(±1.5)mmHg while that of the control group was 153 (±1. 6)mmHg.
These results are expressed graphically in figure 10 on page 75.
2.3.l(ii) Results from conscious spontaneously hypertensive rats.
There was no significant difference between the groups during week I 
when all animals received PEG alone. The systolic blood pressure of 
spontaneously hypertensive rats was found to be higher than that measured 
in normotensive animals. During control treatment with PEG hypertensive 
rats had a mean systolic blood pressures of 207*5 (±2*5) mmHg; while their 
normotensive Wistar counterparts had a mean sytolic blood pressure of 153*7 
(±1*3) mmHg.
Dosing with atenolol commenced during week II, during this week the 
blood pressure of treated animals was dramatically reduced while that of 
the control group remained at its previous level. The variation in blood 
pressure measured before and after dosing was large during week I and 
diminished over time. This variation was negligible in control animals. 
Blood pressure remained reduced in treated animals over the whole dosing 
period. During week IV the mean systolic blood pressure in treated animals 
was 194 (±1.0)mmHg while that of control animals was 227 (±1.3)mmHg. This 
reduction in blood pressure was found to be very highly statistically 
significant (p<0*0001). The blood pressure was not not, however, reduced 
to levels found in normotensive rats. Figure 11 shows a graphical 
representation of these blood pressure results.
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2.3.2 Results of the investigation of heart rate.
2.3. 2 (i) Results from conscious normotensive rats.
The graph of heart rate (figure 12) demonstrates that heart rate was 
variable during week I when both groups received PEG alone; there was no 
significant difference between groups. In general, heart rate was reduced 
during atenolol treatment from around 460 b/min to about 350 b/min over the 
first ten days of atenolol treatment. Heart rate is also reduced in the 
control group over the experimental period from around 460 b/min to around 
400 b/min. Despite this, and the tendency for the heart rate of the 
treated animals to increase slightly, there was a significant difference 
between the groups (p<0*05) during the final week of treatment.
2.3.2(ii) Results from conscious spontaneously hypertensive rats.
In the hypertensive rat, heart rate was seen to decrease in both 
groups over the entire experimental period. However, animals treated with 
atenolol exhibited a reduced heart rate compared with control animals. 
There was no statistically significant difference between groups during 
week I but after three weeks atenolol treatment the treated group exhibited 
a significantly reduced heart rate (p<0*0001).
Figure 13 on page 78 is a graph of heart rate over the experimental 
period.
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2. 3. 3 Results of the assessment of B-adrenoceptor blockade.
The dose response curve to isoprenaline was shifted to the right after 
7 days pretreatment with atenolol indicating p-adrenoceptor blockade. The 
shift in the dose response curve was not, however, parallel. The 
displacement occurred in the upper portion of the curve and the maximum 
response appeared to be reduced. Figure 14 shows the dose response curves, 
it is apparent that there is no difference in the lower portion of the 
curves while there is a significant (p<0*01) displacement in the upper 
portion.
A similar series of changes in dose response curves was observed after 
21 days atenolol pretreatment (figure 15). The p-adrenoceptor blockade 
observed after 7 days pretreatment was still apparent after 21 days. The 
shift in the curves was limited to the upper portion of the curve as 
previously described. There was found to be a significant attenuation of 
the responses to the upper half of the isoprenaline dose response curve 
(p<0*01) while no such difference was apparent in the lower portion of the 
curve.
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2.3.4 Results from the in-situ blood perfused mesentery model.
2.3. 4(1) Results from normotensive Wistar rats.
Pretreatment with atenolol for 7 days resulted in a tendency for an 
increase in response to higher doses of exogenous noradrenaline. This was 
not, however, very pronounced with the only significant increase occurring 
in response to a dose of lOOOng noradrenaline (p<0*05). The dose response 
curves to exogenous noradrenaline following 7 days pretreatment are shown 
in figure 16.
Figure 17 shows the frequency response curves to periarterial 
electrical stimulation following 7 days atenolol pretreatment. The graph 
clearly shows that there is no difference in response between the control 
and the treated groups.
The dose response curves to exogenous noradrenaline following 21 days 
atenolol pretreatment are shown in figure 18. The dose response curves 
follow the same pattern as that previously described following 7 days 
pretreatment. There is some evidence of an increased mesenteric response 
to higher doses of noradrenaline. Although this is only statistically 
significant at a dose of 640ng (p<0-05).
The mesenteric response to periarterial electrical stimulation 
following 21 days pretreatment with atenolol is significantly (p<0*05) 
reduced at higher frequencies (16 & 35Hz). The graph of the frequency 
response curves is shown in figure 19.
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The mean systemic blood pressure, mean mesenteric blood pressure and 
mesenteric resistance measured in the anaesthetised animals before 
responses to noradrenaline and electrical stimulation were ascertained are 
shown in appendix 2. There were no apparent differences in any of these 
parameters between animals pretreated with PEG or atenolol.
2. 3. 4(ii) Results from spontaneously hypertensive rats.
The dose response curves to exogenous noradrenaline shown in figure 20 
are similar in shape to those obtained from normotensive animals. There 
was, however, an increased response to doses of exogenous noradrenaline in 
the spontaneously hypertensive animals.
There was a tendency for an increased response to higher doses of 
exogenous noradrenaline following 7 days atenolol pretreatment. The 
observed increase did not, however, reach statistical significance. This 
is a similar pattern of results to that observed in normotensive animals.
The frequency response curves shown in figure 21 are of a similar 
shape to those obtained from Wistar rats. A large increase in response 
compared with that of normotensive animals was, however, apparent over the 
whole stimulation frequency range.
There was no apparent change in response to periarterial electrical 
stimulation following 7 days atenolol pretreatment in the hypertensive rat, 
the two curves being almost superimposed; this was also true after 7 days 
treatment in normotensive animals.
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The noradrenaline dose response curves obtained after 21 days 
pretreatment are shown in figure 22. The curve obtained from the treated 
animals was more sigmoidal in shape than the control curve. There was a
significant (p<0-001) attenuation of the middle portion of the curve while 
the lower and upper portions remain unchanged.
Figure 23 shows the stimulation frequency response curves after 21 
days atenolol pretreatment. The curves are of a similar shape to the 
frequency response curves previously described. There is a very large 
parallel displacement of the curve obtained from the atenolol treated 
animals to the right. This attenuation of response to periarterial 
electrical stimulation is highly statistically significant (p<0*001).
Data shown in appendix 2 shows that there was a tendency for an 
increase in “resting”: mean systemic blood pressure, mean mesenteric blood 
pressure and mesenteric resistance following 7 days atenolol pretreatment 
in the anaesthetised rat. These parameters were, however, all reduced 
after 21 days atenolol pretreatment.
2.3.4(iii) Results from the investigation of 3H~noradrenaline overflow.
The results from the investigation of tritiated noradrenaline overflow 
in the mesentery of anaesthetised Wistar rats are shown in the following 
tables.
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mean 3051-5 4256-9 1205-4
SE ±188-2 ±121-3 ±142-8






























There are no significant differences in the DPM values of samples 
taken before or after stimulation between control and treated animals. 
There is, however, a statistically significant (p<0-05) reduction in the 
overflow levels (difference between pre and post stimulation values) 
following pretreatment.
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2.3.5 Results from the Investigation of the effect of treatment on the 
mesenteric vascular responses of normotensive male Beagles.
2.3.5(i) Mesenteric blood pressure responses.
Figure 24 shows the mesenteric pressure dose response curve to 
exogenous noradrenaline. The dose response curves from the control and the 
treated animals are parallel and no significant difference was found 
between these curves.
The mesenteric pressure response to periarterial electrical 
stimulation is shown in figure 25. The curves from both treated and 
untreated animals are parallel. The responses obtained from the atenolol 
pretreated dogs are somewhat smaller than the control responses; this 
attenuation did not, however, reach statistical significance.
2.3.5(ii) Mesenteric blood flow responses.
The mesenteric flow response to exogenous noradrenaline illustrated in 
figure 26 shows the distribution of the flow responses to doses of 
noradrenaline. The computer generated regression lines show that the % 
decrease in flow is directly proportional to the dose of noradrenaline. 
This is true of both the control and treated responses; the two regression
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lines were found to be not significantly different. Responses to 
individual doses of exogenous noradrenaline were also found to exhibit no 
significant differences between treated and control groups.
There was also no statistically significant differences between the 
treated and control groups in respect to the mesenteric flow response to 
electrical stimulation. This is shown in the graph on page 92 (figure 27).
2.3.5(iii) Mesenteric resistance response.
Figure 28 shows the mesenteric response to exogenous noradrenaline in 
terms of resistance. There is no significant difference between the curve 
obtained from the untreated control animals and that obtained from dogs 
pretreated with atenolol.
The graph on page 94, figure 29, shows the mesenteric resistance 
response to periarterial electrical stimulation. There is a marked 
attenuation of the mesenteric resistance response to periarterial 
electrical stimulation. This reduction is statistically significant 
(p<0*05) at every stimulation frequency except 16Hz.
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In the following graphs (figures 10-29), statistical difference was 
calculated between the values from control animals (treated with PEG) 
and the corresponding values from atenolol treated animals. This 
difference is shown by the following notation :
* p<0•05 ** p<0'01 *** p<0-001
FIGURE 10
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Graph showing the effect of atenolol (50mg/kg) p. o. on systolic
blood pressure in the conscious normotensive male Wistar rat.
Systo lic  Blood Pressure {mmHy)









Atenolol (50mg/kg in 5% PEG lml/lOOg) p. o. ; mean ±SE, n=8.
Polyethylene glycol (5%, lml/lOOg) p.o. ; mean ±SE, n=6.
FIGURE 11
76
Graph showing the effect of atenolol (50mg/kg> p. o. on systolic
blood pressure in the conscious spontaneously hypertensive male
Japanese Okamoto rat.
lystolic Blood Pressure (mmHg)
260 W eek I 
(control)







T i m e  ( d a y t )
Atenolol (50mg/kg in 5% PEG lml/lOOg) p. o. ; mean ±SE, n=4.
Polyethylene glycol (5%, lml/lOOg) p.o.; mean ±SE, n=4.
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FIGURE 12
Graph showing the effect of atenolol (50mg/kg) p. o. on heart rate
in the conscious normotensive male Wistar rat.
Heart  Rate (b/min)
W eek IVWes.< IIIWeek I(control) W eek II
Atenolol (50mg/kg in 5% PEG lml/lOOg) p. o. ; mean ±SE, n=8.
Polyethylene glycol (5%, lml/lOOg) p. o. ; mean ±SE, n=6.
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FIGURE 13
Graph showing the effect of atenolol (50mg/kg) p. o. on heart rate
in the conscious spontaneously hypertensive male Japanese Okamoto
rat.
Heart Rate (b/min)
W e e k  IVW e e k  II W e e k  III
(OcomrcJII)
T i m  ■ ( d a y s )
Atenolol (50mg/kg in 5% PEG lml/lOOg) p. o.; mean ±SE, n=4.
Polyethylene glycol (5%, lml/lOOg) p. o. ; mean ±SE, n=4.
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FIGURE 14
Graph showing the effect of 7 days pretreatment with atenolol
(50mg/kg) p. o. on the heart rate response to exogenous
isoprenaline in the anaesthetised Wistar rat.
Heart Rate Change (b/min)
Log D o s e  Isoprenal ine  (ng)
0---- □ Atenolol (50mg/kg) p. o. (n=4) mean ±SE.
® ® PEG (5% lml/lOOg) p. o. (n=8) mean ±SE.
* p<0*05 ** p<0-01 *** p<0.001
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FIGURE 15
Graph showing the effect of 21 days pretreatment with atenolol
(50mg/kg) p. o. on the heart rate response to exogenous
isoprenaline in the anaesthetised Wistar rat.
Heart Rate Change (b/min)
Log D o s e  Isoprenal ine  (ng)
O------o Atenolol (50mg/kg) p. o. (n=4) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=8) mean ±SE.
* p<0•05 ** p<0-01 *** p<0. 001
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FIGURE 16
Graph showing the effect of 7 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to exogenous




1.5 2 2.5 3
Log D o s e  Noradrenaline (ng)
3.5
□----□ Atenolol (50mg/kg) p. o. (n=10) mean ±SE.
■----* PEG (5% lml/lOOg) p. o. (n=6> mean ±SE.
* p<0-05 ** p<0-01 *** p<0. 001
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FIGURE 17
Graph showing the effect of 7 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Wistar rat.
Pressure Change (mmHg)
150
1 0 0  -i
50 n
0 5 10 15 20 25 30 35
Stimulation F req uency  (Hz)
□---- □ Atenolol (50mg/kg) p. o. (n=10) mean ±SE.
■----1 PEG (5% lml/lOOg) p. o. (n=6> mean ±SE.
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FIGURE 18
Graph showing the effect of 21 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to exogenous






4 0  -i
20 n
T1-------------i------------  I------------ 1 I
1 1.5 2 2.5 3 3.5
Log D o s e  Noradrenaline  (ng)
O---- O Atenolol (50mg/kg) p. o. (n=7) mean + SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=7) mean ±SE.
* p<0•05 ** p<0-01 *** p<0. 001
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FIGURE 19
Graph showing the effect of 21 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Wistar rat.
Pressure Change (mmHg)
TTT TT1----------- 1-------- 1--------- 1 I I I I
0 5 10 15 20 25 30 35
Stim ulation  F requency  (Hz)
O----O Atenolol (50mg/kg) p. o. (n=7) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=7) mean ±SE.
* p<0•05 ** p<0*01 *** p<0.001
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FIGURE 20
Graph showing the effect of 7 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to exogenous
noradrenaline in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
2 0 0  -i
150 n
1 0 0  -i
50 n
I i1 1 I T I I
1 1.5 2 2.5 3 3.5
Log D o s e  N oradrena line  (ng)
D---- □ Atenolol (50mg/kg) p. o. (n=6) mean + SE.
■----■ PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
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FIGURE 21
Graph showing the effect of 7 days pretreatment with atenolol
(50mg/kg) p.o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
TTTI I I I I i I I
0 5 10 15 20 25 30 35
Stim ula t ion  F re q u e n c y  (Hz)
□---- □ Atenolol (50mg/kg) p. o. (n=6) mean ±SE.
■----« PEG (5% lml/lOOg) p. o. (n=5> mean ±SE.
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FIGURE 22
Graph showing the effect of 21 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to exogenous






1.5 2 2.5 3
Log D o s e  Noradrenaline  (ng)
3.5
O----O Atenolol (50mg/kg) p. o. (n=7) mean ±SE.
 •----• PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
* p<0•05 ** p<0-01 * * * p<0.001
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FIGURE 23
Graph showing the effect of 21 days pretreatment with atenolol
(50mg/kg) p.o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
i  ^  i r -  t  t
0 5 10 15 20 25 30 35
Stimulation F req u en cy  (Hz)
O---- O Atenolol (50mg/kg) p. o. (n=7) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
* p<0•05 ** p<0-01 *** p<0.001
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FIGURE 24
Graph showing the effect of 21 days pretreatment with atenolol
(7'5mg/kg) p. o. on the mesenteric blood pressure response to
exogenous noradrenaline in the anaesthetised Alderly Park Beagle.









o 0.5 1 1.5 2 2.5
Log D o s e  Noradrenaline  (ng)
i
3
O---- O Atenolol (7’5mg/kg) p. o. (n=5) mean ±SE.
•----• Untreated control. (n=7) mean ±SE.
FIGURE 25
Graph showing the effect of 21 days pretreatment with atenolol 
(7-5mg/kg) p. o. on the mesenteric blood pressure response to 
periarterial electrical stimulation in the anaesthetised Alderly 
Park Beagle.
Pressure Change (mmHg)
I I I T i l  I
0 5 10 15 20 25 30 35
Stimulation F requ en cy  (Hz)
O-----O Atenolol (7‘5mg/kg) p. o. (n=5) mean ±SE.
•-----• Untreated control. (n=7) mean ±SE.
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FIGURE 26
Graph showing the effect of 21 days pretreatment with atenolol
(7’5mg/kg) p. o. on the mesenteric blood flow response to




4 0  n
2 0  -i
i I I i I i i
0 0.5 1 1.5 2 2.5 3
Log D o s e  Noradrenaline (ng)
Decrease in Flow
O-----O Atenolol (7-5mg/kg) p. o. (n=5) mean ±SE.
•----• Untreated control. (n=7) mean ±SE.
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FIGURE 27
Graph showing the effect of 21 days pretreatment with atenolol 
(7*5mg/kg) p. o. on the mesenteric blood flow response to 
periarterial electrical stimulation in the anaesthetised Alderly 
Park Beagle.





0 5 10 15 20 25 30
Stimulation F req u e n cy  (Hz)
35
O-----O Atenolol (7-5mg/kg) p. o. (n=5) mean ±SE.
•----• Untreated control. (n=7) mean ±SE.
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FIGURE 28
Graph showing the effect of 21 days pretreatment with atenolol
(7*5mg/kg) p. o. on the mesenteric vascular resistance response to
exogenous noradrenaline in the anaesthetised Alderly Park Beagle.
Resistance Change (Kdvns/sec/cmS)
Log D o s e  Noradrenaline (ng)
O-----O Atenolol (7’5mg/kg) p. o. (n=5) mean tSE.
•----• Untreated control. (n=7) mean ±SE.
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FIGURE 29
Graph showing the effect of 21 days pretreatment with atenolol 
(7*5mg/kg) p. o. on the mesenteric vascular resistance response to 
periarterial electrical stimulation in the anaesthetised Alderly 
Park Beagle.
Resistance Change (Kdyns/sec/cm6)
T T TT T
0 5 10 15 20 25 30 35
Stimulation F re q u e n c y  (Hz)
O---- O Atenolol <7-5mg/kg) p. o. (n=5) mean ±SE.
 •---- • Untreated control. (n=7) mean ±SE.
* p<0*05 ** p<0-01 *** p<0.001
2.4 CONCLUSIONS.
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2,4. 1 Conclusions from the conscious rat studies.
Treatment of conscious normotensive and spontaneously hypertensive 
rats with atenolol (50mg/kg p. o. ) reduced both heart rate and systolic 
blood pressure. This can clearly be seen in figures 10-13 inclusive (pages 
75-78).
Results are consistent with the theory that hypertension is a result 
of raised peripheral resistance rather than an increase in cardiac output. 
It was apparent during treatment with the control that the systolic blood 
pressure of the conscious hypertensive rats was significantly higher 
(around 35%) thatn that of their normotensive counterparts. There was, 
however, no significant difference in heart rate between normotensive and 
hypertensive animals.
Atenolol given orally in the manner previously described (section 
2.2.1) reduced both the heart rate and blood pressure of rats. The whole 
time course of the decrease in blood pressure was interesting. Pressure 
fell to a minimum over the first week of atenolol treatment and then 
reached a plateau at a slightly higher level over the subsequent two weeks 
of dosing. This was apparent in both normotensive and hypertensive animals 
but was clearer in the normotensive group. This raised the possibility of 
change in the hypotensive mechanism(s) of action of atenolol over the 
dosing period. Also the variation in blood pressure recorded 2 and 24 
hours after each dose of atenolol decreased over the experimental period. 
This variation was especially noticeable in hypertensive animals. The
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daily troughs in blood pressure (2 hours after dosing) coincide closely 
with expected daily peak plasma levels of the drug (see section 2.1.5). 
The reduction in this variation may suggest, that with chronic 
administration, atenolol possibly reached concentrations that produced a 
more constant hypotensive action.
The decrease in blood pressure observed in hypertensive animals was 
greater than that in normotensives, although it was not reduced to 
normotensive levels. This larger reduction may be as a result of the 
higher initial pressure, which provided more scope for reduction. 
Alternatively it is possible that atenolol acted by “correcting” a 
pathophysiologically abnormal blood pressure control system and thus helped 
to normalise blood pressure. As the same system could be expected to be 
“normal” in normotensive animals there would be less of a reduction in 
blood pressure.
While the changes in heart rate, shown by both normotensive and 
hypertensive animals, over the treatment period follow a similar pattern to 
that of blood pressure, there are some important differences. The blood 
pressure of the normotensive Wistar rats did not fall significantly until 
the second day of dosing, while the heart rate was reduced immediately. 
Also, in general, changes in blood pressure did not “mirror” changes in 
heart rate, that is, the peaks and troughs of blood pressure did not match 
those in heart rate. This evidence supports the hypothesis that atenolol's 
hypotensive action is distinct from the acute decrease in cardiac output.
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2.4.2 Conclusions from the assessment of B-adrenoceptor blockade.
The dose response curve obtained in response to isoprenaline was 
shifted to the right after both 7 and 21 days pretreatment with atenolol 
(figures 14 and 15). This shift in dose response curve is indicative of p- 
adrenoceptor blockade and suggests that blockade is present after both 7 
and 21 days atenolol pretreatment. The shift in the dose response curve 
was not parallel; displacement occurred in the upper portion and the 
maximum appeared to be reduced. The shift and shape of the curves was 
similar after both 7 and 21 days pretreatment. The shape of the 
isoprenaline curves following atenolol pretreatment were not as would be 
expected for competitive p-adrenoceptor antagonism. This is probably 
largely due to the experimental method used to investigate it. The 
response to isoprenaline was measured by the p,-mediated increase in heart 
rate, which is antagonised by atenolol. Heart rate in the anaesthetised 
animal can, however, be influenced by other systems which may be affected 
by isoprenaline's P2-mediated actions which are not antagonised by 
atenolol. The change in the balance of isoprenaline's P, and p2- 
adrenoceptor mediated action may thus explain the shape of the dose 
response curve following atenolol pretreatment.
The situation is further complicated by methodological difficulties 
encountered with this technique. The range of heart rate changes was such 
that differences in the changes produced by low doses of isoprenaline may 
not have been apparent due to the scale employed in recording. This would 
make the lower portions of the dose response curves appear closer than was 
actually the case. Also, high doses of isoprenaline caused death in 
anaesthetised animals due to the combined effect of its p2-mediated 
vasculature vasodilation which results in a reduction in cardiac return and
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its tendency to cause arrhythmias. This resulted in difficulty in 
obtaining a maximal heart rate response to isoprenaline. Additionally it 
is harder to obtain the maximal increase in rate in pretreated animals, as 
death, due to isoprenaline's “unblocked" 32-mediated actions, occurs before 
the dose is high enough to produce a maximum response in terms of its 
attenuated 0,-mediated effects. This effect may result in distortion of 
the dose response curve and the combined effect of these methodological 
problems may explain the shape of the dose response curves obtained.
These methodological difficulties could have been avoided by using a 
Langendorff heart preparation to assess 0-blockade. This, or other 
isolated preparations would have produced results that were more 
straightforward and easier to analyse. They would, however, contravene the 
initial aim of undertaking the work in-situ as far as possible.
2.4.3 Conclusions from the in-sltu blood perfused mesentery model.
The results from the investigation of adrenergic neurotransmission 
using this in-situ blood perfused model were interesting (see section 2.3.4 
and figures 16-23).
The results show that the spontaneously hypertensive rats treated with 
the PEG control were more sensitive to both exogenous noradrenaline and 
periarterial electrical stimulation than their normotensive counterparts. 
This supports the numerous studies that suggest that there is an increase 
in noradrenergic neurotransmission in the spontaneously hypertensive rat 
(Lefevre-Borg et al 1988, Yamamoto & Cline 1987, Westfall & Meldrum 1985).
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Pretreatment of normotensive rats with atenolol for 7 days produced 
little change in response apart from a tendency for an increased response 
to higher doses of noradrenaline. This tendency was still apparent after 
21 days pretreatment and more importantly was combined with a significant 
reduction in response to periarterial electrical stimulation. This 
suggests that, after 21 days pretreatment with atenolol, changes in 
adrenergic neurotransmission have occurred which result in a reduced 
response to stimulation. As the response to exogenous noradrenaline has 
not been greatly altered it is possible that this is the result of some 
presynaptic effect of atenolol.
The effect of 7 days pretreatment in spontaneously hypertensive rats 
is similar to that in normotensives. After 21 days, however, there is a 
reduction in response to exogenous noradrenaline in the mid part of the 
dose response curve and a very large reduction in response to electrical 
stimulation. The response to electrical stimulation following 21 days 
atenolol pretreatment in the hypertensive has been reduced to the control 
level found in normotensive animals. This is clearly shown in the graph on 
the following page (Figure 58). Once again this strongly suggests that 
after 21 days atenolol is exerting some presynaptic effect to reduce 
adrenergic neurotransmission. The size of this effect is interesting, as 
it seems that noradrenergic neurotransmission, which has been shown to be 
increased in hypertension (Lefevre-Borg et al 1988) has been reduced to 
normotensive levels (see figure 58). The time course of the effect is also 
interesting since it is unrelated to p-blockade, which has been shown to be 
present after 7 days; suggesting it may be involved in the plateau effect 
of blood pressure reduction observed in the conscious animals. The size 
and time course of this effect also suggests that it may be important in 
the antihypertensive effect of atenolol observed clinically.
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FIGURE 58
Graph showing the effect of 21 days pretreatment with atenolol
(50mg/kg) p. o. on the mesenteric response to periarterial





1 0 0  n
50
0 5 10 15 20 25 30 35
Stimulation F req uency  (Hz)
O O Atenolol (50mg/kg) p. o. Hypertensive rat (n=7) mean ±SE.
•---- • PEG p. o. Hypertensive rat (n=6) mean ±SE.
X-**-X PEG p. o. Normotensive rat (n=7) mean ±SE.
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Results of experiments pre-loading the mesentery with 3H-noradrenaline 
supported the theory that atenolol was having some chronic presynaptic 
effect independent of its (5-blockade. There was evidence that 21 days 
pretreatraent with atenolol in normotensive rats caused a significant 
reduction in 3H-noradrenaline overflow. This suggests that the chronic 
effect of atenolol on adrenergic neurotransmission involves a reduction in 
transmitter release. Lack of time precluded extending this work to include 
other pretreatment times and hypertensive animals. It is interesting to 
speculate that this effect may not be present after 7 days atenolol 
pretreatment and may be larger in hypertensive animals. Although there is 
no evidence to support this, it would fit with the pattern of previous work
with the in-situ blood perfused mesentery.
2.4.4 Conclusions from the investigation of mesenteric vascular responses 
In normotensive male Beagles.
The lack of an atenolol effect on the mesenteric response to exogenous 
noradrenaline combined with a reduced response to periarterial electrical 
stimulation suggests that chronic atenolol may have a presynaptic effect in 
the dog. This would support and complement the work previously described 
in the rat.
The mesenteric response recorded in the normotensive dog is 
interesting (Figures 24-29). The method of investigation was different 
from that used in the rat (section 2.2.6) and allowed the mesenteric blood 
pressure, flow and resistance to vary (unlike in the rat where flow was
kept constant). While there was no obvious change in response to
noradrenaline, the change observed to electrical stimulation was more
clearly apparent when resistance was calculated. As in this preparation 
the animals were able to vary both flow and pressure in response to 
stimulation, changes were more apparent when both these parameters were 
used to calculate resistance. This raises the possibility that a similar 
method involving variable flow and pressure in the rat may have been both 
more physiological and more sensitive. Unfortunately limitations in the 




Atenolol (50mg/kg p. o. ) has been shown to reduce both blood pressure 
and heart rate in normotensive and hypertensive rats. The hypotensive 
effect was bigger in hypertensive animals and appeared to be separate from 
acute p-blockade. The antihypertensive effect of atenolol appeared to
change over time, with a minimum value after 7 days treatment and a
subsequent slight increase to a plateau.
Investigation of the effects of atenolol on adrenergic neuro­
transmission has shown that atenolol has a presynaptic effect reducing 
transmitter release. This effect has been demonstrated in both
normotensive and hypertensive rats and in dogs. The putative presynaptic 
effect is not apparent after 7 days atenolol treatment but is clearly seen 
after 21 days. This presynaptic effect is distinct from acute f3-
adrenoceptor blockade; and its size and time course suggest that it may be 
important in atenolol's clinically observed antihypertensive effect.
These conclusions are more fully discussed and compared with those 





3. 1. 1 Nitrendipine: a historical overview.
Tanshinone, a naturally occurring calcium antagonist, has featured in 
Chinese cardiovascular medicine for three thousand years (Nayler & Dillon 
1986). Current interest in this group of drugs does not stem from this, 
but from work undertaken by Fleckenstein in the mid 1960's. Fleckenstein 
was using electro-physiological techniques to investigate the properties of 
two newly synthesized compounds, prenylamine and verapamil. Fleckenstein 
and colleagues found that these drugs were able to uncouple excitation- 
contraction coupling in the heart, and that this could be reversed by the 
addition of Ca-""'. He later found that they produced a selective 
inhibition of the slow channel component of cardiac action potentials 
similar to that of Mn^^. It was decided that these properties were 
distinct enough to warrant the formation of a new class of drugs, the 
“calcium antagonists" (Fleckenstein et al 1969). By early in the 1970's 
the dihydropyridines had been discovered and were being developed (Vater 
et al 1972). By the mid 70's work was increasing; new drugs, including 
nitrendipine, were discovered and their pharmacology and potential uses are 
currently being widely investigated.
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3.1.2 Structure of nitrendipine.
Calcium antagonists are a very heterogeneous group of compounds. 
Nitrendipine is a dialkyl4-aryl-l, 4-dihydropyridine-3,5-di-carboxylate 
(dihydropyridine). The dihydropyridines are devoid of any basic activity 
due to the resonance of the lone pair electron on the nitrogen atom with 







One important characteristic of nitrendipine, distinct from some other 
dihydropyridines is the presence of non-identical ester groups. This has 
been shown in the examination of structure activity relationships to 
account for the higher vasodilatory, or antihypertensive, activity compared 
with symmetrically substituted dihydropyridines (Meyer 1984).
3. 1. 3 Pharmacodynamics of nitrendipine.
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The electrophysiological activity of calcium entry blockers (also
known as calcium antagonists & slow channel blockers) in cardiac tissue has
been thoroughly investigated (Cohen et al 1984, Katz 1986, Nayler 1980,
Nayler et al 1984, 1986, 1988), but less is known about their
electrophysiological effects in smooth muscle.
Two types of channels (slow & fast) can be identified in the heart and 
vasculature, based on differences in their action potential. The rapid 
initiation of the action potential characteristic of fast channels is 
mediated by the movement of sodium ions. Calcium crosses the cell membrane 
through voltage-dependent, Ca++ selective, “slow” channels and so initiates 
the “slow” response and provokes excitation-contraction coupling. In 
vascular smooth muscle, Ca""^ ions enter the cell through “receptor-
operated” channels and mediate the excitation-contraction coupling (Hofmann
1985, Godfraind et al 1986). Rogart et al (1985) have proposed that there 
are “high affinity” binding sites related to “slow” channels in vascular 
smooth muscle and “low affinity” binding sites associated with cardiac
muscle. Recent research using rat mesentery has suggested that the slow 
channel in vascular smooth muscle is more sensitive to nitrendipine 
blockade than the slow channels in cardiac muscle (Bean et al 1986, Triggle
1986, Ross & Monis 1988). This suggests that the slow channels in vascular 
smooth muscle may be different from those in cardiac muscle (Fleckenstein 
1977, Van Breemen et al 1980). In clinical trials in patients with 
coronary heart disease, angina pectoris and borderline hypertension,
nitrendipine did not alter conduction through sinus or atrioventricular 
nodes (Van Zwieten & Timmermans 1983, Rutsch & Schmutzler 1984). Similarly 
nitrendipine given to patients with essential hypertension had no
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significant effect on resting PR, QRS, QT intervals or on AV conduction 
(Maltz et al 1986).
Total peripheral resistance has been shown to be reduced in both
normotensive and spontaneously hypertensive rats following a single dose of 
nitrendipine (Pegram et al 1984). The reduction in peripheral resistance 
is greater in spontaneously hypertensive rats after chronic treatment; 
however, there is evidence that it is reduced or absent following chronic
treatment in normotensive animals (Pegram et al 1984, Dunn et al 1984).
Single doses of nitrendipine have also been shown to produce a reduction in 
mean, systolic and diastolic blood pressure via a reduction in total 
peripheral resistance in hypertensive patients. These levels remain
depressed from 8-24 hours after the dose (Andren et al 1982, Burris et al 
1982, Hanson et al 1983). Acute dosing with nitrendipine in normotensive 
subjects also produced similar effects, but somewhat less pronounced 
(Pedersen 1983, Wallia et al 1985). The antihypertensive effect of 
nitrendipine is sustained during long term administration in hypertensive 
patients (Nannan et al 1984, Fouad et al 1982, 1984, Pedrinelli et al
1986). The reflex increase in heart rate following acute oral 
administration of nitrendipine in both hypertensive patients and normal
volunteers is around 6-32% (Nannan et al 1984, Debbas et al 1984, Frohlich
1985). This increase is reduced or absent following long term treatment in 
man (Fouad et al 1982, 1984, Nannan et al 1984). The reflex tachycardia
associated with a decrease in total peripheral resistance following
nitrendipine administration is observed in normotensive but not 
hypertensive rats (Pegram et al 1984). Nitrendipine exhibited a similar 
hypotensive action during exercise (Nannan et al 1984) although the reflex 
increase in heart rate that accompanied the reduction in blood pressure was 
less pronounced. Overall the evidence suggests that nitrendipine reduces
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total peripheral resistance preferentially in the presence of an abnormally 
raised tone.
In normotensive and spontaneously hypertensive rats, acute and chronic 
oral nitrendipine treatment decreased renal vascular resistance (Dunn et al 
1984, Pegram et al 1984). The effects of nitrendipine on renal 
haemodynamics in human subjects has been shown to be minimal following both 
acute and chronic administration (Fouad et al 1982, 1984, Wallia et al
1985). Chronic nitrendipine treatment has been shown to increase plasma 
renin activity (Fouad et al 1982) although there is some controversy over 
this effect. Increases that were observed have been shown to decline over
time and be normalised at the end of 12 months therapy (Weber & Drayer
1984, Leonetti & Zanchetti 1985). Further it has been suggested that this
putative effect is not related to the antihypertensive effect of 
nitrendipine, as the magnitude of hypotensive effect is positively 
correlated with low initial plasma renin activity (Kiowski et al 1985, 
McMahon 1986). Acute administration of nitrendipine has been shown to 
produce modest natriuresis and diuresis without increased potassium loss 
(Wallia et al 1985, Hall & Hungerford 1984). The evidence of these actions 
continuing over the long term, however, is less conclusive. Since 
nitrendipine does not appear to have a large effect on renal blood flow or 
glomerular filtration rate its acute natriuretic and diuretic effects may 
be mediated by other than haemodynamic changes. Wallia (1985) postulates 
that nitrendipine may block the reabsorption of sodium by a direct action 
on the proximal tubule of the kidney.
The location of the 3H-nitrendipine binding is separate from 
a,-adrenoceptors (Ross & Monis 1988, Triggle 1986, Dompert & Traber 1984, 
Nayler et al 1984, Motulsky et al 1983). Studies in vivo have shown that
nitrendipine blocks pressor responses to both exogenous and endogenous
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noradrenaline (Pedrinelli & Tarazi 1984), and to vasopressin and
angiotensin II (Pedrinelli & Tarazi 1985a). While other work has suggested
that nitrendipine reduces pressor responses to noradrenaline but not to
angiotensin II (Simon & Snyder 1984, Lefevre-Borg et al 1988), the exact 
involvement of Ca^-blockers and the sympathetic nervous system is 
contentious. There is evidence that nitrendipine both does and does not 
alter transmitter release. The results vary between species, vascular beds 
and methods used. In general it seems that concentrations of nitrendipine 
that are required to produce alterations in neurotransmitter release are 
considerably higher than those required to effect the response to
noradrenaline. It is questionable whether the concentrations required to 
alter transmitter release have any therapeutic relevance. The only effect 
nitrendipine has on sympathetic transmission at doses achieved during 
clinical usage appear to be via postjunctional effects. These can vary 
between vascular beds depending on the relative populations of 
postjunctional a,- and ot2-adrenoceptors. This is because noradrenaline is 
more potent at a,-receptors while nitrendipine appears to be more potent at 
Oz-receptors, although increasing evidence suggests that the difference in 
Ca^-antagonist potency at a-adrenoceptors may be due to variation in 
receptor reserve (Pedrinelli & Tarazi 1985a, 1985b). For a more detailed
discussion of the effects of C a ^ - a n t  agonists on sympathetic neuroeffector 
function the reader is directed to a review of the subject by Eikenburg 
and Lokhandwala (1986).
When given in therapeutic doses, nitrendipine does not alter serum 
glucose or lipid concentrations, although it was shown to inhibit glucose 
transport in adipocytes (Christensen & McDonald 1985). Similarly in 
chronic studies nitrendipine was shown to have no effects on cholesterol, 
total triglycerides or high density lipoproteins (Ferrara et al 1985).
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In some animal models nitrendipine has been shown to have other 
effects; there is evidence that it dilates cerebral blood vessels and 
reduces pulmonary artery vasoconstriction with a subsequent decrease in 
pressure. A single clinical study in patients with pulmonary hypertension 
demonstrated similar effects. In addition to its ability to relax vascular 
smooth muscle, nitrendipine also inhibits tracheobronchial and uterine 
contractions in animals. The clinical implications of these effects are, 
however, uncertain (Goa & Sorkin 1987). Interestingly nitrendipine has 
been shown to decrease free cellular Ca++ in platelets and this decrease is 
highly correlated with its hypotensive action. It has been suggested that 
the decrease in platelet Ca^"^ may reflect a decrease in the overall free 
C a s t a t u s  of patients, which has been shown to be raised in hypertension 
(Erne et al 1984).
3.1.4 Selectivity of nitrendipine.
Calcium channels are present in a wide variety of tissues including 
the heart and smooth muscle, and Ca-*"" flux is vital to many physiological 
processes (Godfraind et al 1986). 3H-nitrendipine binding sites have been 
demonstrated to be associated with Ca'*"*' channels in a wide -variety of 
tissues including vascular and other smooth muscle, brain and heart. These 
binding sites are generally considered to be of a single class which 
reversibly bind dihydropyridines with a high affinity (Kd O 1-1*0 nm); 
binding sites present in skeletal muscle are, however different with a much 
lower affinity (Kd 5nm) (Nayler et al 1984, Dompert & Traber 1984, 
Godfraind et al 1986, Ross & Monis 1988). Despite the variety of potential 
binding sites nitrendipine has been shown to exhibit a very high degree of
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vasoselectivity (Taira 1987). The explanation of this selectivity is 
unclear, but Bean (1983) has suggested the following theory:- Calcium 
channels can exist in one of three states; resting (closed), activated 
(open) and inactivated (closed) (Tsein 1983, Triggle 1986). The channels 
are able to cycle between these three states. When a cell is polarised, 
these channels exist dominantly, or exclusively in a resting state. The 
channels are voltage operated, that is their state is dependent on the 
membrane potential. When the cell is depolarised they shift to the open 
state; if they remain depolarised at a high enough level for long enough 
they change to the inactivated state. Nitrendipine has the option of 
binding to any of these states but its affinity for the inactivated state 
is a thousand times higher than for the other states (Taira 1987). On 
binding to the channel nitrendipine stabilises it in that configuration and 
thus prevents the entry of Ca^.
In working cardiac muscle cells the channels become inactivated during 
the plateau of the action potential. However the time the channels remain 
in this state (<1 s) is much less than the time required for nitrendipine 
binding. Even if the nitrendipine does bind it dissociates promptly during 
electrical diastole. Thus, it is “difficult" for nitrendipine to bind to 
working cardiac muscle. In contrast, in vascular smooth muscle the 
membrane potential is less than the diastolic membrane potential in cardiac 
cells. The vascular muscle is partially depolarised all the time, 
therefore the Ca^-channels are more likely to be in the inactivated state, 
and to remain there for long enough to allow nitrendipine to bind. This 
same principle may explain the “finer” specificity such as the preference 
for particular vascular beds, but there are, however, questions still to be 
answered. Why are other Ca^^-antagonists (eg verapamil) which are able to 
bind to the Ca^-channel in its inactivated state (McDonald et al 1980) not 
more vasoactive? Why does nitrendipine exhibit inactivity or low activity
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in neural systems when binding sites are present (Triggle & Janis 1984, 
Spedding & Middlemasm 1985)? These inconsistencies may be explained by 
differences in the relationship between the 3H-nitrendipine binding site 
and the Ca^-channel, or possibly by the relative importance of “activator” 
Ca-*"*" from internal sources. More work is required to explain fully the 
basis of Ca^^-antagonist selectivity.
3.1.5 Pharmacokinetics and metabolism of nitrendipine.
Investigation of the absorption of nitrendipine in man has shown that 
about 80% of an oral 20mg dose was absorbed in healthy volunteers, and peak 
plasma concentrations of between 4*7 and 41*6 pg/L were achieved within 1 
to 2 hours. Linear increases in area under the plasma concentrat ion-time 
curves were observed after oral doses of up to 40mg/kg indicating that 
liver enzyme saturation had not occurred (Johnson et al 1986, Hanson et al
1983). Studies have shown that nitrendipine has a relatively low and
variable bioavailability of 16 ±6%, and that the bioavailability of tablets 
relative to solution was 75% (Kann et al 1984) A study in healthy
volunteers has shown that following a single i.v. nitrendipine dose of 2mg 
the volume of distribution of the central compartment obtained at steady 
state (VD»„) was 2-04 L/kg. The study also showed that nitrendipine is 
about 98% bound to plasma proteins (Raemsch & Sommer 1984).
Nitrendipine is very extensively metabolised in the liver to one of
five major metabolites, each one of them around a thousand times less
pharmacologically potent than nitrendipine. The major routes of metabolism
are dehydrogenation to the pyridine analogue, cleavage of the ester groups 
by hydrolysis to carboxylic acids and hydroxylation of the methyl groups
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with subsequent glucuronide conjugation in the bile. About 45% of a dose 
of nitrendipine is excreted in the urine in the form of inactive 
metabolites during the first 24 hours. Around 8% is excreted in a similar
form in the faeces and the rest is eliminated in the bile. Less than 0*1%
of an oral dose appears as unchanged drug in the urine. This high first 
pass effect explains the relatively low bioavailability of the drug
(Raemsch & Sommer 1984, Kann et al 1984). In healthy volunteers and 
hypertensive patients the half life of nitrendipine varied from 2 to 24 
hours, with a mean value of about 12 hours (Raemsch & Sommer 1984, Kann 
et al 1984, Hanson et al 1983).
The hypotensive effect of nitrendipine is evident at concentrations 
that are undetectable in the plasma. It has been postulated that the
antihypertensive effect of nitrendipine may correlate with its activity at 
the calcium channel rather than with its plasma concentration (Aronoff
1984).
It should be noted that some of the variation in the pharmacokinetics 
of nitrendipine may be due to the methods of detection employed. In 
earlier studies high performance liquid chromatography (HPLC) and 
radiolabelled receptor methods were used to measure plasma and urine 
nitrendipine concentrations. In more recent studies mass spectrometric or 
capillary gas chromatography with electron capture were used. These later 
methods are both more specific and more sensitive.
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3. 1. 6 Toxicology of nitrendipine.
Results from acute toxicity studies have shown that nitrendipine is 
only weakly toxic when given orally with an LDso value of greater than 
10000 rag/kg in the rat. When administered by an intravenous route it was, 
however, considerably more toxic with an LDso value of 12*6 mg/kg in rats. 
The major symptoms of toxicity were central and included reduced motility, 
cyanosis, vomiting and convulsions. The intensity and time course of these 
symptoms depended on the route of nitrendipine administration. After oral 
administration symptoms persisted for between 1 and 8 days and were 
followed by death; however, after i. v. administration death was immediate.
Chronic toxicity studies with doses of nitrendipine of up to 
30 mg/kg/day for 2 years produced no signs of toxic effects in rats. At 
doses of 147 mg/kg/day the growth rate of rats was retarded and signs of 
liver damage were apparent; some individuals also showed signs of 
myocardial scarring which was thought to be due to hypoxic damage that 
occurred as a result of the initial high degree of hypotension and 
tachycardia. The chronic investigations also showed that nitrendipine 
possessed no apparent adverse effects on the fertility of rats and no 
teratogenic or mutagenic effects (Hoffmann 1984).
3. 1. 7 Mechanisms of the antihypertensive action of nitrendipine.
The primary action of nitrendipine is to inhibit the movement of Ca'*"*’ 
through the voltage-dependent “slow” channels in plasma membranes (see 
sections 3.1.3 & 3.1.4). Elevated levels of free Ca*"1' in the cytosol are
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known to enhance vascular tone (Rosendorff 1984), and it has been suggested 
that levels of Ca-’"1' in the vascular smooth muscle are raised in 
hypertension (Aoki et al 1982, Erne et al 1984). The main antihypertensive 
action of nitrendipine is a result of its blockade of Ca^-dependent 
contractile activity in vascular smooth muscle. This results in a
relaxation of peripheral vascular tone, a subsequent decrease in systemic 
vascular resistance, resulting in a reduction of blood pressure. In
addition to this main effect, nitrendipine possesses some other properties 
which may contribute to its hypotensive mode of action.
The natriuretic effect of nitrendipine (section 3.1.3) seems to play a
part, in that it relieves sodium build up that is often present in 
hypertension and so reduces water retention. The reduction in volume load 
this causes may play a significant part in its antihypertensive effect 
(Garthoff et al 1983, Hall & Hungerford 1984). Nitrendipine has also been 
shown to normalise renal blood flow and glomerular filtration rate in 
angiotensin II induced hypertension in rats (Sterzel et al 1984).
Chronic nitrendipine treatment has been shown to reduce generalized 
vasculopathy and cardiac hypertrophy and these effects may also contribute 
to maintaining its antihypertensive action. There is also evidence that 
nitrendipine treatment preserves tissue integrity and has been shown to 
increase life span in malignant hypertension and in stroke-prone 
hypertensive rats. It has been postulated that these effects are a result 




3.2.1 Investigation of blood pressure in the conscious rat.
The initial study of blood pressure was undertaken with normotensive 
male Wistar rats (University of Bath strain) weighing approximately 200g. 
Systolic blood pressure was measured using a non-invasive “tail-cuff" 
technique. The methodological details of the procedure are described in 
section 2. 2. 1.
Blood pressure was measured before and two hours after the daily dose 
of either nitrendipine or polyethylene glycol (PEG). During the first week 
of dosing all animals were dosed with 5% PEG alone; in order that they 
became accustomed to the procedures involved. In the subsequent three 
weeks the treated group received 3mg/Kg nitrendipine in a 5% PEG vehicle, 
while the control group received the 5% PEG vehicle alone. In both cases 
drugs were orally administered (lml/lOOg) daily, blood pressure was not, 
however, measured over weekend periods.
This work was repeated with spontaneously hypertensive Japanese 
Okamoto rats (University of Bath strain) weighing approximately 200g.
The investigation of the effects of nitrendipine on blood pressure in 
both conscious normotensive and hypertensive rats was undertaken in 
parallel with the study investigating the effects of atenolol (section 
2 . 2 . 1 ) .
118
3.2.2 Investigation of heart rate in the conscious rat.
Heart rate was calculated from the pulse pressure waves recorded 
during the measurement of blood pressure. This was undertaken with both 
normotensive Wistar and spontaneously hypertensive Japanese Okamoto rats.
The details of how this was calculated is given in section 2.2.2; the 
effects of nitrendipine on heart rate was was examined in the same study as 
the examination of the effects of atenolol.
3. 2. 3 Assessment of isoprenaline challenge.
(3-adrenoceptor blockade was assessed using an anaesthetised rat 
preparation to investigate the dose response response curve to bolus i. v. 
injections of isoprenaline.
The protocol, described in detail in section 2.2.3, was used to assess 
(3-adrenoceptor blockade following 7 and 21 days pretreatment with either 
nitrendipine (3mg/kg p. o. in 5% PEG, lml/lOOg) or 5% PEG (lml/lOOg). The 
procedure was followed 24 hours after the last dose of either nitrendipine 
or PEG.
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3.2.4 The in-sltu blood perfused mesentery method.
The effect of chronic calcium channel antagonism by nitrendipine on 
adrenergic neurotransmission was investigated using the in-sltu blood 
perfused mesentery method of Jackson and Campbell (1980a). Details of the 
method used is given in section 2.2.4., the method is shown 
diagrammatically in figure 3.
The protocol was used to investigate mesenteric responses to exogenous 
noradrenaline (20-2000ng in 0*9% w/v NaCl) and periarterial electrical 
stimulation (15v rectangular pulses of 1ms duration for 20s, 2-35Hz). This 
work was undertaken 24 hours after the last dose of either nitrendipine 
(3mg/kg in 5%, lml/lOOg) or 5% PEG (lml/lOOg) after both 7 and 21 days 
pretreatment. This work was carried out with both normotensive male Wistar 




Normotensive Wistar and spontaneously hypertensive Japanese Okamoto 
rats were used in the investigation of the chronic effects of nitrendipine. 
These rats were housed at the University of Bath with a 12 hour light/dark
120
cycle at a temperature of 20-22*C and a relative humidity of 40-60%. The 
animals were provided with ' Labsure' CRM diet and tap water ad libitum, and 
were housed in groups.
Details of animal husbandry are described in greater detail in section 
2.2.7(i) on page 59.
3. 2.5(ii) Statistical analysis.
The blood pressure and heart rate data recorded from conscious animals 
was analysed using the values obtained before daily dosing. The normality 
of the data was tested with the Kolmogorov-Smirnov procedure and was 
checked by plotting a frequency histogram with a normal curve superimposed. 
Analysis of variance (ANOVA) with Fisher's LSD, Tukey's HSD and Scheffe's 
test follow-ups were performed on the week I data to discover any 
differences between groups before “active” treatment. The ANOVA and 
follow-ups were repeated with the week IV data to examine the differences 
following chronic treatment with nitrendipine. The ANOVA's examined not 
only the differences between animals treated with nitrendipine and the 
controls but differences between the other treatment groups as well. 
Unpaired Student's t-tests or Mann-Whitney U tests were used to compare two 
sample means depending on whether the data was normal or non-parametric.
In all experiments animals were randomly assigned to groups and 
treatments randomly allotted to these groups. The statistical analysis was 
carried out by computer using the SPSS-X package. Full details are given 
in section 2.2.7(iii) on page 61.
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3.2.5(111) Drugs and general chemicals.
In addition to the list of drugs and chemicals given in section 
2.2.7(iv) on page 63 the 1,4-dihydropyridine nitrendipine was used. This 
was kindly provided by Bayer Pharmaceuticals PLC.
The light sensitivity of nitrendipine dictated that great care was 
taken to avoid its exposure to light, both in its storage in solid form and 
during the daily preparation of solutions. Nitrendipine was solubilised in 




3.3. 1 Results of the investigation of blood pressure.
3. 3. 1(1) Results from conscious normotensive Wistar rats.
Throughout the control period (week I), when all animals were dosed 
with 5% polyethylene glycol (PEG) alone, there was no significant 
difference between the two groups of animals. In both groups blood 
pressure was elevated on the first day of the procedure; this then 
normalised at around 151 mmHg.
Both groups had a mean blood pressure of around 154 (max SE 2*9) mmHg 
at the start of "active" treatment in week II, During the first week of 
dosing with nitrendipine the blood pressure of the treated group fell to 
132 (±4-2) mmHg while that of the control group remained around 153 (±1*5) 
mmHg. The diurnal variation in blood pressure (pre and post dosing) 
followed a similar pattern to that described for the atenolol treated 
animals. The variation was initially large and diminished over the dosing 
period. The attenuation of blood pressure observed; was maintained 
throughout the subsequent period of nitrendipine treatment. The blood 
pressure of the control group remained fairly constant throughout this 
treatment period with the group having a mean systolic blood pressure of 
153 (±1*6) mmHg during the final week of dosing. The animals treated with 
nitrendipine had a mean systolic blood pressure of 143 (±2*1) mmHg during 
the same period. This difference was found to be statistically highly 
significantly different (p<0*0001) using an ANOVA procedure. Fisher's LSD 
follow-up to ANOVA indicated that there was a significant (p<0*05)
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difference between the group treated with nitrendipine and the group 
treated with atenolol. That is animals treated with nitrendipine had a 
higher blood pressure during week IV than animals treated with atenolol; 
although it was still reduced from the level of the control group. This 
difference was not apparent when the data was examined using either the 
Tukey HSD or Scheffe procedure follow-ups. The graph of these results 
(figure 30, page 131) shows that the blood pressure of the nitrendipine 
group follows a similar pattern to that described for animals treated with 
atenolol (figure 10, page 75). The reduction of blood pressure is, 
however, slower in onset and less pronounced; although there is no clear 
statistical evidence to support this.
3. 3. l(ii) Results from conscious spontaneously hypertensive rats.
During the first week (control) of the investigation there was no 
significant difference between the two groups. As previously described 
(section 2.3. 1 (ii)) the systolic blood pressure of the hypertensive rats 
was found to be around 50 mmHg higher than their normotensive counterparts 
during control PEG treatment.
On the initiation of “active" treatment with nitrendipine the blood 
pressure of the treated animals was reduced compared with that of the PEG 
treated control animals. This reduction occurred during the first week of 
nitrendipine treatment and was maintained throughout the dosing period. 
The blood pressure of the spontaneously hypertensive animals was at no time 
reduced to normotensive levels. The reduction was, however, found to be 
highly statistically significant (p<0*0001) using an ANOVA. Mean systolic 
blood pressure of the treated group had been reduced to 196 (±2*7) mmHg
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from the control level of 226 (±0*6) mmHg during the final week of dosing. 
Unlike the situation described for the normotensive groups in the previous 
section there was no evidence of any difference between reductions observed 
with nitrendipine and atenolol. The daily variation in blood pressure 
measured before and after dosing was as previously described with the 
difference becoming smaller over time.
The graph of conscious systolic blood pressure over the treatment 
period for control and nitrendipine treated hypertensives is shown in 
figure 31 on page 132.
3.3.2 Results of the Investigation of heart rate.
3.3.2(1) Results from conscious normotensive rats.
There was found to be no significant difference between treatment 
groups during week I when all animals received PEG alone. In the initial 
part of the first week heart rate was around 460 b/min; this decreased over 
the control week.
During the “active” dosing period (weeks II-IV) the heart rate of the 
control group varied around 400 b/min. In general heart rate in the 
animals treated with nitrendipine was higher than that recorded in control 
animals; there was, however, some variation. Data from the last week of 
dosing was analysed and the nitrendipine treated group was found to have a 
significantly (p<0*05) raised heart rate compared with that of the control 
group. The nitrendipine treated animals also had significantly (p<0*05)
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increased heart rates compared with those measured in atenolol treated 
animals. These results are shown as a graph in figure 32 on page 133.
3.3.2(11) Results from conscious spontaneously hypertensive rats.
The results of the changes in heart rate measured in hypertensive 
animals is similar to that described in normotensives in that there is an 
overall tendency for heart rate to decrease over the experimental period 
irrespective of treatment. Also, there was no significant difference 
between the groups before “active” treatment commenced. However, 
Nitrendipine treatment did not produce any significant difference in heart 
rate between the treated and control groups in the hypertensive animals. A 
significant (p<0*05) difference between hypertensive animals treated with 
nitrendipine and those treated with atenolol was, however, observed.
Figure 33 on page 134 is a graph of heart rate over the experimental 
period.
3.3.3 Results of the assessment of isoprenaline challenge.
Pretreatment with nitrendipine for 7 days resulted in an increase in 
response to low doses of isoprenaline. The lower portion of the dose 
response curve measured after 7 days nitrendipine was shifted up the x-axis 
compared to the control curve. This shift in response was found to be
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statistically significant (p<0-05) at isoprenaline doses up to 0-02ng. 
This is clearly illustrated in the graph shown in figure 34.
A similar pattern of changes to the isoprenaline dose response curves 
was apparent following 21 days nitrendipine treatment. Again the responses 
observed to doses of isoprenaline at doses up to 0*02ng were raised 
compared to control responses. This increase was found to be statistically 
significant (at between p<0*05 and p<0'01). The increase in response to 
isoprenaline did not result in a parallel shift in the dose response curves 
after 7 or 21 days pretreatment.
3.3.4 Results from the in-situ blood perfused mesentery model.
3.3. 4(1) Results from normotensive Wistar rats.
The noradrenaline dose response curves obtained after 7 days 
pretreatment with either PEG or nitrendipine are shown in figure 36. 
Nitrendipine pretreatment did not produce any significant changes in the 
dose response curve to exogenous noradrenaline compared with the PEG 
treated control group.
Figure 37 shows the frequency response curve to periarterial 
electrical stimulation following 7 days nitrendipine pretreatment. The 
curve obtained from the nitrendipine pretreated animals shows that there is
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no evidence of any significant change in response to periarterial
electrical stimulation.
The dose response curves to exogenous noradrenaline obtained after 21 
days pretreatment with either PEG or nitrendipine are shown in figure 38. 
The response curve from the nitrendipine treated animals is almost 
superimposed on the curve obtained from the control animals. There is no 
statistically significant difference between the two groups.
The mesenteric response to periarterial electrical stimulation 
following 21 days pretreatment is shown in figure 39. The responses 
obtained from animals pretreated with nitrendipine are reduced in 
comparison with control responses. This attenuation is significant, with a 
p<0*01 at frequencies up to 8Hz and with a p<0*05 at higher frequencies. 
The two response curves are of a similar shape and are parallel.
The mean systemic blood pressure, mean mesenteric blood pressure and 
mesenteric resistance measured in the anaesthetised animals before 
responses to noradrenaline and electrical stimulation were ascertained are 
shown in appendix 2. There was no over-all differences in any of these 
parameters between animals pretreated with PEG or nitrendipine. There was 
a slight reduction in mean systemic and mesenteric blood pressures 
following 7 days pretreatment, this was no longer apparent after 21 days.
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3.3.2(11) Results obtained from hypertensive rats.
The noradrenaline dose response curves and the stimulation response 
curves obtained in spontaneously hypertensive animals following 7 and 21 
days pretreatment with PEG (control) are similar to the control curves 
obtained from normotensive animals, There is, however, a greater response 
to both exogenous noradrenaline and periarterial electrical stimulation in 
the hypertensive animals.
The dose response curve to noradrenaline following 7 days pretreatment 
with either nitrendipine or PEG is shown in figure 40. The graph shows 
that following 7 days nitrendipine pretreatment there is a reduced response 
to noradrenalin resulting in a parallel shift of the dose response curve. 
This attenuation in noradrenaline response was found to be statistically 
significant (p<0*05 - p<0*01).
Figure 41 shows the stimulation response curves following 7 days 
pretreatment in spontaneously hypertensive animals. This graph also shows 
a reduced response; in this case a significant (p<0-01) attenuation of 
mesenteric response to periarterial electrical stimulation.
The dose response curves to exogenous noradrenaline after 21 days 
pretreatment is shown in figure 42. There is a reduction in mesenteric 
response to all doses of exogenous noradrenaline. This reduction was found 
to be statistically significantly different (p<0*01).
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The mesenteric response to periarterial electrical stimulation was 
also reduced following 21 days pretreatment with nitrendipine. This 
reduction was statistically significant (p<0*05> at all frequencies 
examined greater than 2Hz. Figure 43 shows the stimulation response curves 
obtained after 21 days pretreatment with either PEG or nitrendipine.
The stimulation response and noradrenaline dose-response curves 
following 21 days nitrendipine pretreatment both show a reduction compared 
to control curves. This parallel shift in the curves is similar to that 
seen in spontaneously hypertensive animals after 7 days nitrendipine 
pretreatment. Although there is some evidence to suggest that the 
attenuation is greater following 21 days pretreatment.
The data in appendix 2 shows that there was a tendency for an increase 
in “resting”: mean systemic blood pressure, mean mesenteric blood pressure 
and mesenteric resistance following 7 days nitrendipine pretreatment in the 
anaesthetised rat. These parameters are, however, all reduced after 21 
days nitrendipine pretreatment.
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In the following graphs (figures 30-43), statistical difference was 
calculated between the values from control animals (treated with PEG) 
and the corresponding values from nitrendipine treated animals. This 
difference is shown by the following notation :
* p<0*05 ** p<0-01 *** pCO-OOl
FIGURE 30
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Graph showing the effect of nitrendipine (3mg/kg> p. o. on
systolic blood pressure in the conscious normotensive male Wistar
rat.
S y sto lic  Blood Pressure (mmHg)180 Week I 






Time ( d e y j )
Nitrendipine (3mg/kg in 5% PEG lml/lOOg) p. o. ; mean ±SE, n=8.
Polyethylene glycol (5%, lml/lOOg) p. o. ; mean ±SE, n=6.
132
FIGURE 31
Graph showing the effect of nitrendipine (3mg/kg) p. o. on
systolic blood pressure in the conscious spontaneously
hypertensive male Japanese Okamoto rat.
Systolic Blood Pressure (mmHg)
Week I 
(control) Week IVWeek II Week
/i
Nitrendipine (3mg/kg in 5% PEG lml/lOOg) p. o.; mean ±SE, n=4.
Polyethylene glycol (5%, lml/lOOg) p.o.; mean ±SE, n=4.
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FIGURE 32
Graph showing the effect of nitrendipine (3mg/kg) p. o. on heart
rate in the conscious normotensive male Wistar rat.
Heart Rate (b/min)
Week IVWeek IIIWeek I 
(control)
Week
T i m e  (dayil
Nitrendipine (3mg/kg in 5% PEG lml/lOOg) p. o. ; mean ±SE, n=8.
Polyethylene glycol (5%, lml/lOOg) p. o. ; mean ±SE, n=6.
FIGURE 33
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Graph showing the effect of nitrendipine (3mg/kg) p. o. on heart
rate in the conscious spontaneously hypertensive male Japanese
Okamoto rat.
Week III
Ti m  e (day s )
Heart Rate (b/min)
Weak I
(UcorrtroK)) W eek II W eek IV
Nitrendipine (3mg/kg in 5% PEG lml/lOOg) p. o. ; mean ±SE, n=4. 
Polyethylene glycol (5%, lml/lOOg) p.o.; mean ±SE, n=4.
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FIGURE 34
Graph showing the effect of 7 days pretreatment with nitrendipine
(3mg/kg) p. o. on the heart rate response to exogenous
isoprenaline in the anaesthetised Wistar rat.
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-6 -5.5 -5 -4.5 -4
Log D o s e  Isoprenaline  (ng)
-3.5
X---- X Nitrendipine (3mg/kg) p. o. (n=4) mean +SE.
B---- B PEG (5% lml/lOOg) p. o. (n=8) mean ±SE.
* p<0•05 ** p<0-01 *** p<0.001
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FIGURE 35
Graph showing the effect of 21 days pretreatment with
nitrendipine (3mg/kg) p. o. on the heart rate response to 
exogenous isoprenaline in the anaesthetised Wistar rat.
Heart Rate Change (b/min)
Log D o s e  Isoprenaline  (ng)
+---- + Nitrendipine (3mg/kg) p. o. (n=4) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=8> mean ±SE.
* p<0•05 * * p<0-01 *** p<0.001
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FIGURE 36
Graph showing the effect of 7 days pretreatment with nitrendipine
(3mg/kg) p. o. on the mesenteric response to exogenous
noradrenaline in the anaesthetised Wistar rat.
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Graph showing the effect of 7 days pretreatment with nitrendipine
(3mg/kg) p. o. - on the mesenteric response to periarterial
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X---- X Nitrendipine (3mg/kg) p. o. (n=7) mean ±SE.
■----■ PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
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FIGURE 38
Graph showing the effect of 21 days pretreatment with
nitrendipine (3mg/kg) p. o. on the mesenteric response to
exogenous noradrenaline in the anaesthetised Wistar rat.
Pressure Change (mmHg)
1 20  -] 
100 -  
80 -  
60 -  
40 -  
20 -
0  i i i i i r
1 1.5 2 2.5 3 3.5
Log D o s e  Noradrenaline  (ng)
+-----+ Nitrendipine (3mg/kg) p. o. (n=8) mean ±SE.
•----• PEG (5% lml/lOOg) p. o. (n=7) mean ±SE.
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FIGURE 39
Graph showing the effect of 21 days pretreatment with 
nitrendipine (3mg/kg) p. o. on the mesenteric response to 
periarterial electrical stimulation in the anaesthetised Wistar 
rat.
Pressure Change (mmHg)
1 5 0 -,
1 0 0  H
50 -i
T  I----------1 I I I I I
0 5 10 15 20 25 30 35
Stimulation F re q u e n c y  (Hz)
+---- + Nitrendipine (3mg/kg) p. o. (n=8) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=7) mean ±SE.
* p<0•05 ** p<0-01 *** p<0.001
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FIGURE 40
Graph showing the effect of 7 days pretreatment with nitrendipine
(3mg/kg) p. o. on the mesenteric response to exogenous
noradrenaline in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
T Ti i i i r  i
1 1.5 2 2.5 3 3.5
Log D o s e  Noradrenaline (ng)
X---- X Nitrendipine (3mg/kg) p. o. (n=8) mean ±SE.
■---- 1 PEG (5% lml/lOOg) p. o. (n=6> mean ±SE.
* p<0•05 ** p<0-01 * * * p<0.001
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FIGURE 41
Graph showing the effect cf 7 days prel.reatment with nitrendipine
<3mg/kg) p. o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
Tl
0 5 10 15 20 25 30 35
Stimulation F requency  (Hz)
X---- X Nitrendipine (3mg/kg) p. o. (n=7) mean ±SE.
■---- ■ PEG (5% Iml/lOOg) p.o. (n=6) mean ±SE.
* p<0*05 * * p<0-01 *** p<0.001
143
FIGURE 42
Graph showing the effect of 21 days pretreatment with
nitrendipine (3mg/kg) p. o. on the mesenteric response to 
exogenous noradrenaline in the anaesthetised Japanese Okamoto 
SHR.
Pressure Change (mmHg)
i i i i i r
1 1.5 2 2.5 3 3.5
Log D o s e  Noradrenaline (ng)
+---- + Nitrendipine (3mg/kg) p. o. (n=6) mean ±SE.
 •---- • PEG (5% Iml/lOOg) p. o. (n=6) mean ±SE.
* p<0-05 ** p<0-01 * * *  p<0.001
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FIGURE 43
Graph showing the effect of 21 days pretreatment with
nitrendipine (3mg/kg) p. o. on the mesenteric response to




20 0  -i
150 -|
1 0 0  n
50 n
Ti r i i i i i i
0 5 10 15 20 25 30 35
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+---- + Nitrendipine (3mg/kg) p. o. (n=6) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. <n=6) mean ±SE.
* p<0•05 ** p<0-01 *** p<0.001
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3.4 CONCLUSIONS.
3.4.1 Conclusions from the conscious rat studies.
Treatment with nitrendipine (3 mg/kg) reduced the blood pressure in 
both normotensive and hypertensive rats. This hypotensive effect was 
accompanied by a reflex tachycardia in normotensive but not hypertensive 
animals. These results are shown in the graphs (figures 30-33) on pages 
131-134.
The reduction of blood pressure followed a similar pattern in both 
normotensive and hypertensive animals, that is, pressure was reduced over 
the first 2-3 days of dosing. The blood pressure remained at this reduced 
level throughout the whole of the rest of the dosing period. There was no 
tendency for pressure to plateau at a higher level, as it did during 
atenolol treatment (section 2.4, 1). There was, then, no evidence of any 
change in the antihypertensive effect of nitrendipine over the experimental 
period. The variation in blood pressure measured 2 and 24 hours after 
doses of nitrendipine decreased with time. The values were lowest 2 hours 
after dosing, a time that corresponds well to the expected peak plasma 
concentration of the drug (see section 3. 1.5). The fact that this daily 
variation decreased with time suggests that nitrendipine reached more 
stable plasma concentrations with chronic dosing. It was interesting that 
nitrendipine treatment caused a reduction in blood pressure in normotensive 
animals. Previous work (Pegram et al 1984, Dunn et al 1984) has suggested 
that chronic nitrendipine administration does not produce a hypotensive 
effect in normotensive animals. The hypotensive effect of nitrendipine 
observed in the normotensive rats was only 30% of that obtained in
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hypertensives, and significantly smaller than that observed in 
normotensi ves treated with atenolol (section 2.3.1(D). This suggests 
that, as previously reported, the hypotensive effect of nitrendipine is 
much greater when the peripheral resistance is initially raised. The fact 
that a small hypotensive effect was observed in the normotensive animals 
may have been partly due to the fact that the physiological stress reaction 
to the measuring procedure may have raised the blood pressure. This
“raised” blood pressure may have been reduced by nitrendipine.
The reflex tachycardia present on treating the normotensive rats was 
not apparent in the hypertensive animals; this has been described by other
workers (Pegram et al 1984, Dunn et al 1984). This effect may be due to an
abnormality in the baroreceptor activity in spontaneously hypertensive 
animals (Sapru & Wang 1976, Pfeffer & Frohlich 1973) preventing the reflex 
increase in heart rate. Alternatively, the physiological adaptation to 
both the stress of blood pressure measurement and to the warming involved 
may “swamp” any drug-induced tachycardia. Physiological responses to 
warming involve peripheral vasodilation and an associated tachycardia,
while that to stress involves tachycardia as a direct sympathetic response. 
As animals become accustomed to the procedures, these effects would be 
expected to be reduced resulting in a reduction in tachycardia due directly 
to the measuring procedure. This would explain the reduction in heart rate 
over time observed in both control and treated SHRs (figure 33). The fact 
that this effect is not present in normotensive rats may be explained by 
the relative importance of the stress-induced tachycardia; SHRs are known 
to be especially susceptible to the effects of stress.
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3.4.2 Conclusions from the assessment of B-adrenoceptor blockade.
The dose-response curves obtained to isoprenaline after both 7 and 21 
days pretreatment with nitrendipine show that there is no sign of any p- 
adrenoceptor blockade, (figures 34 & 35)
The response to isoprenaline in the anaesthetised rats seems to have 
been increased following nitrendipine pretreatment. Low doses of 
isoprenaline have produced significantly greater increases in heart rate 
following pretreatment. There is no evidence that nitrendipine has any 
effect on cardiac p-adrenoceptors (section 3.1,3 & 4) so this response is 
somewhat unexpected. The explanation of this increased response lies with 
the preparation used for the investigation. Isoprenaline is a p- 
adrenoceptor agonist which acts at P 7-adrenoceptors in the heart to 
produce an increase in rate and at peripheral p2-adrenoceptors producing 
vasodilation. In the whole animal preparation used to investigate p- 
adrenoceptor blockade both these systems were intact. The vasodilation 
produced by isoprenaline's P2-adrenoceptor effect may be expected to 
contribute to the increase in heart rate via baroreceptor reflex activity. 
It would seem possible that in the presence of nitrendipine-induced 
vasodilation the vasodilatory effects of isoprenaline would be of a 
sufficient magnitude and duration to initiate the reflex tachycardia at 
lower doses. Higher doses of the p-adrenoceptor agonist would “swamp" this 
“additive” effect. This is a potential explanation for the increased 
response to isoprenaline at the lower end of the dose response curve. If 
this explanation is correct, an investigation of p-blockade using an 
Langendorff preparation would not show an increase in isoprenaline 
response.
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3.4.3 Conclusions from the in situ blood perfused mesentery model.
The results from the investigation of adrenergic neurotransmission 
using the in situ blood perfused mesentery are shown in figures 36-43. 
There was no change in the responses of normotensive rats after 7 days 
nitrendipine pretreatment and only small changes after 21 days. After the 
longer nitrendipine treatment there was some evidence of a slightly reduced 
response to periarterial electrical stimulation. In the hypertensive 
animals nitrendipine pretreatment reduced responses to both noradrenaline 
and electrical stimulation after both 7 and 21 days.
The absence of any large change in mesenteric response in normotensive 
animals was consistent with the relatively small hypotensive effect 
obtained in the conscious animal. This supports the theory that 
nitrendipine only has an antihypertensive effect when the peripheral 
resistance is initially raised. In the hypertensive animals nitrendipine 
pretreatment reduced the response to both noradrenaline and electrical 
stimulation suggesting that its effect was postjunctional. This
attenuation in response was large enough to account for the 
antihypertensive effect observed in the conscious animal. This is
consistent with the work of Pedrinelli and Tarazi (1984) who showed that 
nitrendipine blocked the effects of both endogenous and exogenous 
noradrenaline. It also supports the idea that at concentrations achieved 
during clinical usage there is no indication of any presynaptic effect 
(Eikenburg & Lochandwala 1986). The results suggest that nitrendipine 
exerts its antihypertensive effect by blocking Ca""" flux associated with 
noradrenaline’s interaction with postjunctional a-adrenoceptors. Eikenburg 
(1984) has demonstrated that both endogenous and exogenous noradrenaline 
cause vasoconstriction via postsynaptic interactions with predominantly a,-
adrenoceptors in the in situ blood perfused mesentery. As nitrendipine 
pretreatment reduced these responses and had no apparent presynaptic 
effects it would seem that nitrendipine is able to inhibit the Ca-*"*- flux 
associated with the a,-adrenoceptor. This is consistent with the idea that 
nitrendipine can inhibit the Ca_,"+‘ flux associated with both a!- and a2- 
adrenoceptors (Eikenburg & Lochandwala 1986, Pedrinelli and Tarazi 1985a, 
1985b) and so inhibit the Ca^-dependent contraction of vascular smooth 
muscle. By doing this it reduces vascular tone and thus reduces blood 
pressure by reducing peripheral resistance. The reduced noradrenaline 
response observed in the mesentery suggests that nitrendipine reduces 
mesenteric vascular tone and thus resistance. This supports the findings 
of Pegram and co workers (1984); and, as the mesentery is a large and 
important vascular bed, suggests that it is an important site for the 
reduction in systemic blood pressure.
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3. 4. 4 Overall conclusions.
Nitrendipine treatment has been shown to reduce systemic blood 
pressure at the dose used, in both normotensive and hypertensive rats. The 
reduction in normotensive animals was smaller and associated with a reflex 
tachycardia. No apparent fJ-adrenoceptor blockade was produced by 
nitrendipine; and its hypotensive action appeared to be adequately 
explained by its antagonism of Ca^ "'’ flux associated with postjunctional a- 
adrenocept ors.
These findings are consistent with the theory that nitrendipine’s main 
antihypertensive action is a blockade of Ca"’"’' induced contraction in 
vascular smooth muscle and thus a reduction of peripheral resistance. They 
also support the idea that this effect is greater when peripheral 
resistance is initially high, such as in the spontaneously hypertensive 
rat.
These conclusions are more fully discussed and compared with those 





4. 1. 1 Historical context of combination treatment of hypertension.
During the past two decades, encouraging strides have been made in the 
recognition and treatment of high blood pressure and in the development of 
antihypertensive therapy. Despite increasing education about the risk- 
factors involved in cardiovascular disease and changing attitudes to 
health, there are still concerns surrounding hypertension and its control. 
As many as two thirds of the hypertensive patients in the USA remain 
inadequately controlled (Tarazi & Fouad-Tarazi 1986). The p-adrenoceptor 
blockers were heralded as the antihypertensive drugs of the sixties and 
early seventies. These drugs, used alone or in combination with thiazide 
diuretics, have led the assault on hypertension. Recently, the use of 
thiazide diuretics and p-blockade has been questioned. There is evidence 
that thiazide-induced hypokalaemia may lead to ventricular extrasystoles 
and so may increase the risk of myocardial infarction (Moser 1986). With 
the reduction in the use of thiazide diuretics there is room for increasing 
the use of calcium antagonists, both alone and in combination. Calcium 
antagonists are now rapidly establishing themselves as the antihypertenBive 
drugs of the eighties.
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4.1.2 Theoretical considerations for the use of combination treatment.
Before the possible benefits of the combined use of p-adrenoceptor 
blockers and calcium antagonists can be evaluated, their modes of action 
should be considered. The pharmacology of these two entirely different 
groups of drugs has been discussed in some detail in the introductions to 
chapters 2 and 3. The pharmacological basis of the antihypertensive action 
of atenolol and nitrendipine are discussed in sections 2.1.7 and 3.1.7
respectively.
On referring to the previous sections concerning the modes of action
of atenolol and nitrendipine it can be seen that, although the exact
mechanism of atenolol's hypotensive action is unknown, there is no evidence 
of it having any effect on voltage operated Ca^-channels. Similarly there 
is no evidence of nitrendipine possessing any ability to blockade p- 
adrenoceptors. It is theoretically possible, therefore, that, as both 
these drugs produce a reduction in blood pressure via different mechanisms 
of action, their use in combination may prove additive.
The pharmacological profiles of nitrendipine and atenolol make them
appear particularly well suited for combination therapy. While some
calcium antagonists, such as verapamil, reduce AV conduction producing a 
potentially dangerous situation in the presence of p-blockade; nitrendipine 
has no effects on cardiac nodal tissue or conduction in the heart (Van 
Zweiten & Timmermans 1983, Rutsch & Schmutzler 1984, Maltz et al 1984). 
Indeed the presence of p-adrenoceptor blockade would have the advantage of 
reducing the reflex tachycardia observed with nitrendipine treatment 
(Warltier et al 1984). Nitrendipine would also counteract the reduction in 
coronary blood flow associated with the “unmasking" of a-adrenoceptors
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during p-adrenoceptor blockade (Nayler 1988).
Nitrendipine's reduction of free Ca'*"1' has been shown to inhibit 
atherosclerotic plaque formation and reduce platelet aggregation (Erne 
et al 1984). This is particularly beneficial as p-blockade has been shown 
to increase the low/high-density lipoprotein cholesterol ratio and so 
create conditions which favour plaque formation (Weinstein & Heider 1987, 
Mac Carthy 1988).
As nitrendipine undergoes rapid metabolism in the liver (section 3.1.5), 
interactions with a lipid soluble p-blocker, such as propranolol, which is 
similarly handled are possible. However, they are unlikely with atenolol 
which is not lipid soluble and is excreted by the kidneys after only 
minimal metabolism (section 3.1.5).
In the treatment of hypertension, patients who do not respond to p- 
blockers alone are often treated with the addition of a diuretic. From a 
theoretical standpoint, however, treatment with a combination of a p- 
adrenoceptor blocker and a calcium antagonist offers a better therapeutic 
rationale. Atenolol and nitrendipine seem particularly suitable for such a 
regime as they lack deleterious pharmacological and metabolic interactions 
and have positive interactions resulting in a reduced incidence of side- 
effects. These theoretical considerations have led to this combination of 
drugs being widely clinically investigated.
4.1.3 Clinical basis for the use of the combination therapy.
The combination of atenolol and nitrendipine was studied in a large 
multicenter trial in patients with mild to moderate hypertension 
(Kirkendall et al 1987). After an initial placebo period patients were
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treated with two of the following three drugs: atenolol (50mg),
nitrendipine (20mg) and hydrochlorothiazide (50mg). While all three 
regimes were effective at reducing blood pressure, the mean fall in 
systolic blood pressure was significantly greater in patients receiving the 
combination of atenolol and nitrendipine. This regime also resulted in a 
greater number of patients achieving their target blood pressure and fewer 
failures to respond.
The study of De Divitiis et al (1985) also used the combination of atenolol 
and nitrendipine and permitted the assessment of the hypotensive 
contribution of the individual agents to the overall effect. Significant 
additional blood pressure reduction was observed when atenolol (lOOmg/day) 
was added to treatment with nitrendipine (20mg/day). Further decreases in 
blood pressure were also obtained when patients with moderate hypertension, 
which persisted despite atenolol treatment, received additional 
nitrendipine. Also, as blood pressure was measured between 21 and 24 hours 
after the daily administration of drugs in this study, it suggests that the 
combination is effective when administered only once a day.
A study by De Kock et al (1985) showed that the combination of nitrendipine 
and atenolol was effective at improving early diastolic dysfunction in 
patients with essential hypertension. In all of these three studies using 
atenolol and nitrendipine in combination the incidence and severity of 
side-effects was found to be no greater, or less, than those experienced 
using the drugs individually. The incidence of tachycardia reported early 
in nitrendipine treatment was reduced in combination treatment and patients 
complained less of cold extremities during treatment with the combination 
than they did during treatment with atenolol alone.
Nitrendipine has also been investigated in combination with other p- 
adrenoceptor blockers. Me Mahon (1986) reported on a multicentre trial 
with nitrendipine and propranolol involving 329 patients for over a year.
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He concluded that the combination was safe, well tolerated and produced an 
additive effect on the reduction of blood pressure without a development of 
tolerance over the year. Maltz et al (1986) found that nitrendipine used 
in combination with propranolol did not affect atrioventricular 
conductivity and was a safe and potentially useful combination. The 
combination of nitrendipine and the {3-blocker metoprolol also produced an 
additive hypotensive effect and reduced incidence of side-effects (Orb & 
Ryman 1984).
Similarly atenolol has been studied in combination with other 
dihydropyridine calcium antagonists. The combination of atenolol and 
nifedipine has been found to augment symptom benefit compared to either 
drug alone when used in treating both hypertension and chronic stable 
angina pectoris (Rowland et al 1983, Leon et al 1985). In general, 
clinical investigations involving the combined use of p-blockade and 
calcium antagonism have led to the conclusion that the drugs provide a more 
effective treatment in combination than either drug given alone (Blihler 
et al 1983, Me Innes et al 1985, Mac Carthy 1988, Nayler 1988).
The high degree of antihypertensive action of the combination of 
atenolol and nitrendipine combined with the relatively low incidence of 
side-effects make it particularly useful in combatting severe hypertension. 
The pharmacokinetics of the drugs are such that effective therapy is 
provided by a single daily dose, a factor which increases patient 
compliance. These considerations suggest that the combination would 
provide better blood pressure control and improved quality of life.
The effect of the combination of atenolol and nitrendipine on blood 
pressure, heart rate and sympathetic neurotransmission together with their 
possible interactions was investigated in this work.
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4.2 METHODS.
4.2. 1 Investigation of blood pressure in the conscious rat.
Normotensive male Wistar rats and spontaneously hypertensive male 
Japanese Okamoto rats (approx. 200g, University of Bath strain) were used 
in this study. Systolic blood pressure was measured using a non-invasive 
"tail-cuff” technique. Full details of the protocol used are described in 
section 2.2. 1 on page 33.
Blood pressure was measured before and two hours after the daily 
administration of drug. The treated animals received a combination of
atenolol (50mg/kg) and nitrendipine (3mg/kg) in a 5% polyethylene glycol 
(PEG) vehicle. Control animals were dosed with the 5% PEG vehicle alone. 
During the first week of dosing all animals were dosed with PEG alone to 
allow the animals to become accustomed to the procedures involved. In the 
subsequent three weeks the treated animals were dosed with the combination 
and the control animals with PEG. Drugs were administered orally 
(lml/lOOg) every day; blood pressure was not, however, measured during the 
weekend periods.
The investigation of the effects of chronic treatment with the 
combination of atenolol and nitrendipine and with the two drugs in 
isolation was carried out in a concomitant study.
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4.2.2 Investigation of heart rate in the conscious rat.
The pulse pressure waves recorded during the measurement of systolic 
blood pressure were used to calculate heart rate. This was carried out 
with the data from both the normotensive and hypertensive rats.
Full details of this calculation procedure is shown in section 2.2.2 
on page 34, As with the investigation of blood pressure this study was 
carried out in conjunction with the investigation of the two drugs in 
isolation.
4. 2. 3 Assessment of B-adrenoceptor blockade.
An anaesthetised rat preparation was used to assess the degree of £- 
adrenoceptor blockade. This was achieved by examining the effects of 
pretreatment on a dose-response curve obtained to bolus i. v. doses of 
isoprenaline.
The precise method used is explained in section 2.2.3 on page 35. 
This was carried out following 7 and 21 days pretreatment with either the 
combination of atenolol (50mg/kg) and nitrendipine (3mg/kg) or PEG control; 
in both cases drugs were administered orally (lml/lOOg). The procedure was 
undertaken 24 hours after the final dose of either the combination or PEG.
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4.2.4 The in-situ blood perfused mesentery method.
The effects of the combination of chronic g-adrenoceptor blockade and 
chronic calcium channel antagonism on adrenergic neurotransmission was 
investigated using the in-sltu blood perfused mesentery method described by 
Jackson and Campbell (1980a). Details of the methodology is described in 
section 2.2.4 and shown as a diagram on page 39 (figure 3).
The protocol shown in section 2.2.4 was used to investigate mesenteric
responses to both exogenous noradrenaline (20-2000ng in 0*9% w/v NaCl) and 
to periarterial electrical stimulation (15v rectangular pulses of 1ms 
duration for 20s, 2-35Hz). This was undertaken 24 hours after the last
dose of either 5% PEG (lml/lOOg) or the combination of atenolol (50mg/kg) 
and nitrendipine (3mg/kg) after 7 and 21 days pretreatment. This work was 
carried out using both normotensive male Wistar and spontaneously
hypertensive male Japanese Okamoto rats. (University of Bath strain, approx
300-330g).
4.2.5 General considerations.
4. 2. 5(i) Animal husbandry.
The rats used in this study were housed at the University of Bath with 
a 12 hour light/dark cycle at an ambient temperature of 20-22*C and a 
relative humidity of 40-50%. Normotensive Wistar rats and spontaneously 
hypertensive Japanese Okamoto rats were used and were provided with
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1labsure's‘ CRM diet and tap water ad libitum and were housed in groups so 
as to avoid both overcrowding and solitude.
Details of animal husbandry are described in more detail in section
2.2. 7 (i) on page 59.
4.2.5(ii) Statistical analysis.
As previously described blood pressure and heart rate data was 
analysed using the measurements recorded before the daily dose of either
the combination or PEG. The distribution of the data was compared with the
normal distribution using the Kolmogorov-Smirnov procedure and was checked 
by overlaying a normal distribution curve over a frequency histogram 
plotted from the data. An ANOVA with LSD, HSD and Scheffe's test follow-
ups were carried out on the data collected during week I when all animals
were treated with PEG alone. This was used to compare groups before any 
administration of ‘‘active” drug. The ANOVA and follow-up procedures were 
repeated on the data collected during week IV after three weeks treatment 
with the combinations. The ANOVA was used to examine the differences 
between all the groups, control, and atenolol and nitrendipine both alone 
and in combination. Unpaired Student's t-tests or Mann-Whitney U tests
were used to compare two samples means depending on whether the data was 
non-parametric or normal.
In all experiments animals were assigned to groups in a random manner 
and treatment was randomly allotted to these groups. The statistical
analysis was undertaken on a main-frame computer using the SPSS-X package.
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Full details of the statistical analysis are described in section 
2.2.7(iii) on page 62.
4.2.5(iii) Drugs and general chemicals.
The drugs and chemicals used are given in sections 2.2.7(iv) and 
3. 2. 5 (iii).
Atenolol was made up in a 5% PEG solution at a concentration of 
lOmg/ml and nitrendipine in PEG at 6 0 ’C and diluted to a 5% solution with 
the nitrendipine at a concentration of 0*6mg/ml. These two solutions were 
then mixed to give a solution of atenolol and nitrendipine at 
concentrations equal to those used during their individual dosing regimes. 
Animals all received the same relative volume of drug (lml/lOOg) 




4.3.1 Results of the investigation of blood pressure.
4.3. 1(1) Results from conscious normotensive Wistar rats.
Throughout week I of the study when all the animals were dosed with 5% 
polyethylene glycol (PEG) alone, there was no significant difference in 
blood pressure between the two groups of animals. The mean systolic blood 
pressure of both groups of animals was elevated during the first day of the
procedure; this then stabilised at a lower level (around 152mmHg) by the
middle of the week.
Both groups of animals had a mean systolic blood pressure of 155mmHg 
(±l-7mmHg control, ±2*ImmHg combination) immediately prior to dosing with 
the “active” treatment in week II. During the first week of treatment with 
atenolol and nitrendipine in combination the mean systolic blood pressure 
of the treated group fell to a minimum of 122mmHg (± 5*1) while that of the 
PEG treated control group remained around 153mmHg (1*5). This large 
reduction in blood pressure observed in animals treated with the
combination was of a similar magnitude and pattern as that described for 
atenolol-treated animals. A large and significant reduction in blood 
pressure became established during the first three days of treatment with 
the combination, falling to a minimum at the end of the week. The blood 
pressure of the group treated with the combination remained reduced 
compared with the control group but stabilised at the slightly higher level 
of around 143mmHg over the subsequent two weeks of treatment. The blood 
pressure of the control group remained fairly constant over the whole
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experimental period; during week IV this was 153 (±l-6)mmHg. The mean
systolic blood pressure of the group treated with the combination was 142 
(±2’0)mmHg over the same period. Statistical analysis of the results
obtained during the final week of dosing (week IV) showed a very highly
significant difference between treatment groups (p<0‘0001). Further 
analysis showed there was no difference between groups treated with
atenolol and combination, while there was some evidence to suggest
(Fisher's LSD, p<0*05) that these two groups were different from the group 
treated with nitrendipine alone. There was a very clear and large 
difference between all the treated groups and the control group.
The variation in blood pressure measured before and after dosing with 
the combination followed a similar pattern to that observed with atenolol
treatment alone. The value measured two hours post-dosing was reduced;
this reduction became less pronounced over time.
The graph on page 171 shows the effect of treatment with the
combination on the systolic blood pressure of the normotensive male Wistar 
rat (Figure 44).
4.3. 1 (ii) Results from conscious spontaneously hypertensive rats.
During week I (all animals treated with PEG control) of the 
investigation there was no significant difference between the blood
pressure of the two groups. The groups had mean systolic blood pressures 
of 214 (±5*7)mmHg and 211 (±3*0). As previously described (section
2.3. l(ii)) the systolic blood pressure of the hypertensive rats was found
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to be higher than that of their normotensive counterparts during control 
PEG treatment.
Dosing with the combination of atenolol and nitrendipine began at the 
start of week II. The blood pressure of animals treated with the 
combination was greatly reduced compared with the control group over the 
first week of dosing. This reduction was large and maintained over the 
whole period of dosing. Blood pressure was not, however, reduced to 
normotensive levels. The blood pressure of the control group remained 
fairly constant over the whole period and was 227 (±l*3)mmHg over the final 
week of dosing. The blood pressure of the group treated with the 
combination was reduced to 199 (±2*l)mmHg over the same period. An ANOVA 
found this to be a highly significant reduction (p<0-0001) and follow-up 
procedures found no difference between groups treated with atenolol, 
nitrendipine or the combination. These groups were, however significantly 
different from the control group. As with the reduction in blood pressure 
observed with atenolol and nitrendipine alone, treatment with the 
combination produced a larger attenuation in the hypertensive rat than in 
its normotensive counterpart.
The variation in blood pressure measured pre- and post-dosing followed 
a similar pattern to that previously described. The variation was 
initially large but decreased over time; as before, this variation was 
larger in hypertensive animals.
Figure 45 on page 172 is a graph of the systolic blood pressure 
response of conscious hypertensive rats to the combined atenolol and 
nitrendipine treatment.
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4.3.2 Results of the Investigation of heart rate.
4.3.2(1) Results from conscious normotensive rats.
The graph on page 173 (Figure 46) shows the heart rate response of 
normotensive rats to treatment with the combination of atenolol and
nitrendipine. There was found to be no significant difference between 
treatment groups during week I when all animals received PEG alone. The 
mean heart rate of the two groups over the first week was 446 (±12*0)b/min 
and 461 (±4*3)b/min respectively.
During the period of dosing with the combination (weeks II-IV) the
heart rate of the control group slowly declined from 461 b/min to stabilise 
at around 400 b/min. The heart rate of the group treated with the 
combination decreased from 446 b/min to a minimum of 325 b/min after ten 
days dosing. This then increased slightly to around 367 (±2-2)b/min in the 
final week. This reduction was found to be statistically significant
(p<0-05) using an ANOVA. Follow-up procedures show that there is no 
difference between the groups treated with atenolol alone or in
combination, but that these groups are significantly different from both 
control and nitrendipine treated groups (which are themselves significantly 
dif ferent).
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4.3.2(11) Results from conscious hypertensive rats.
The results obtained from hypertensive rats treated with the
combination of atenolol and nitrendipine are similar to those of rats 
treated with atenolol alone. Figure 47 on page 174 is a graphical
representation of these results.
During week I (control) there was no significant difference between 
the heart rate of the two groups, both exhibited a gradual decline which
continues throughout the whole treatment period. On commencing “active”
treatment with the combination in week II the mean heart rate of the
treated group was reduced compared to the control group. During the final 
week of dosing (week IV) the mean heart rate for the group treated with the
combination was 331 (ib'Slb/min while that of the control group was 372
(±6*9)b/min, this difference was significant (p<0*001). There was found to 
be no statistical difference in heart rate between groups treated with 
atenolol alone or in combination.
4.3.3 Results of the assessment of B-adrenoceptor blockade.
Pretreatment with the combination of atenolol and nitrendipine for 7 
days resulted in a displacement of the isoprenaline dose response curve to
the right. This displacement is similar to that observed after
pretreatment with atenolol alone. The lower portion of the curve is 
unchanged while there is a slight shift in the upper portion with a reduced
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maximal response. Figure 48 on page 175 shows the two dose response 
curves.
A similar series of changes in isoprenaline dose-response curve was 
observed after 21 days pretreatment with the combination (Figure 49). The 
shift appeared to be more parallel after 21 days pretreatment with a 
significant (p<0‘001) attenuation of the upper half of the dose response 
curve. The 0-adrenoceptor blockade observed after 7 days pretreatment with 
the combination appeared to be still present after 21 days.
4.3.4 Results from the in-situ blood perfused mesentery model.
4.3.4(i) Results from normotensive Wlstar rats.
The dose-response curves obtained to exogenous noradrenaline following 
7 days pretreatment with either the combination of atenolol and 
nitrendipine or 5% PEG are shown in figure 50 on page 177. There is 
clearly no difference in mesenteric response to exogenous noradrenaline 
following 7 days pretreatment with the combination.
Figure 51 (page 178) shows the frequency-response curve to 
periarterial electrical stimulation following 7 days pretreatment with the 
combination. There is evidence of a reduced response to low frequency 
stimulation (4 and 8Hz) following pretreatment with the combination.
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However, there is no clear overall difference between the curve obtained 
from the animals treated with the combination and the control curve.
After 21 days pretreatment with the combination there is evidence of a 
reduced response to exogenous noradrenaline. The reduced response is only 
evident at either end of the curve, with an attenuated response to 20ng and 
40ng noradrenaline and a reduced maximum response. These curves are shown 
in figure 52 on page 179.
Pretreatment with the combination for 21 days resulted in large and 
significant changes in the frequency response curve. There is no change in 
response to low frequency stimulation (2-8Hz). The response to stimulation 
at 16Hz was increased by 61%, and that to 35Hz by 55%. This increase in 
response was found to be highly statistically significant (p<0*001). This 
is shown in figure 53 on page 180.
The mean systemic blood pressure, mean mesenteric blood pressure and 
mesenteric resistance was measured in anaesthetised animals before the 
mesenteric responses to exogenous noradrenaline and periarterial electrical 
stimulation. These are shown in appendix 2. There appears to be a slight 
reduction in all of these parameters following 7 days pretreatment with the 
combination. This reduction is, however, no longer apparent after 21 days 
pretreatment.
169
4.3.4(11) Results from spontaneously hypertensive rats.
The dose response curves to exogenous noradrenaline obtained after 7 
days pretreatment with either the combination or PEG are shown in figure 54 
on page 181. There is a large (40-50%) reduction in the responses to 
exogenous noradrenaline following pretreatment with the combination. This 
shift in the noradrenaline dose response curve was found to be highly 
statistically significant (p<0*001).
There was however, no significant change in the stimulation response 
curve obtained from animals pretreated with the combination for 7 days. 
This graph is shown in figure 55 on page 188 and there is clearly no 
difference in the curves obtained from “treated” and control animals.
The large and highly significant decrease in mesenteric response to 
exogenous noradrenaline observed after 7 days pretreatment with the 
combination is still present after 21 days pretreatment. This highly 
significant (p<0-001) shift in the noradrenaline dose response curve is 
shown in figure 56 on page 183.
There is no apparent change in response to periarterial electrical 
stimulation following 21 days pretreatment with the combination. This is 
similar to the situation after 7 days pretreatment, described above. The 
stimulation response curves are shown in figure 57 on page 184.
The mean systemic and mesenteric blood pressure and mesenteric 
resistance measured in the anaesthetised animal (appendix 2) were slightly 
reduced following 21 days pretreatment.
170
In the following graphs (figures 44-57), statistical difference was 
calculated between the values from control animals (treated with PEG) 
and the corresponding values from nitrendipine treated animals. This 
difference is shown by the following notation :
* p<0•05 ** pCO-Ol *** p<0-001
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FIGURE 44
Graph showing the effect of the combination (atenolol 50mg/kg,
nitrendipine 3mg/Kg) p. o. on systolic blood pressure in the
conscious normotensive male Wistar rat.
Systo lic  B lood Pressure (mmHg)
W e e k  I 
(con tro l)
W e e k  III W eek  IVWeek II
Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. ; mean ±SE, n=8.




Graph showing the effect of the combination (atenolol 50mg/kg,
nitrendipine 3mg/Kg) p.'o. on systolic blood pressure in the
conscious spontaneously hypertensive male Japanese Okamoto rat.
Systolic B lood  F ressure (mmHg)
Week I 
(control) Week IIIWeek W eek  IV
220 -
Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o.; mean ±SE, n=4.
Polyethylene glycol (5%, lml/lOOg) p. o. ; mean ±SE, n=4.
FIGURE 46
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Graph showing the effect of the combination (atenolol 50mg/kg,
nitrendipine 3mg/Kg) p. o. on heart rate in the conscious
normotensive male Wistar rat.
Heart Rate (b/min)
5 0 0 Week i
(control)





Ti ."n * ( days )
Combination (aten. 50mg/kg, nit. 3mg/Kg) p.o.; mean ±SE, n=8.
Polyethylene glycol (5%, lml/lOOg) p.o. ; mean ±SE, n=6.
FIGURE 47
Graph showing the effect of the combination (atenolol 50mg/kg,
nitrendipine 3mg/Kg) p. o. on heart rate in the conscious




W e e k  II W e e k  III
T i m  i (days)
Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. ; mean ±SE, n=4.
Polyethylene glycol (5%, lml/lOOg) p. o. ; mean +SE, n=4.
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FIGURE 48
Graph showing the effect of 7 days pretreatment with the
combination p.o. on the heart rate response to exogenous
isoprenaline in the anaesthetised Wistar rat.
200 -









Log D o s e  Isoprenal ine  (ng)
0--- 0 Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=4) mean ±SE.
■-----■ PEG (5% lml/lOOg) p. o. (n=8) mean +SE.
* p<0* 05 ** p<0-01 *** p<0.001
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FIGURE 49
Graph showing the effect of 21 days pretreatment with the
combination p. o. on the heart rate response to exogenous
isoprenaline in the anaesthetised Wistar rat.
Heart Rate Change (b/min)
-6 -5.5 -5 -4.5 -4 -3.5
Log D o s e  Isoprenal ine  (ng)
®---- ® Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=4) mean ±SE.
 •---- • PEG (5% lml/lOOg) p. o. (n=8) mean ±SE.
* p<0•05 ** p<0-01 *** p<0. 001
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FIGURE 50
Graph showing the effect of 7 days pretreatment with the
combination p.o. on the mesenteric response to exogenous




1.5 2 2.5 3
Log D o s e  Noradrenaline  (ng)
3.5
El-----0 Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=8) mean +SE.
■---- ■ PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
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FIGURE 51
Graph showing the effect of 7 days pretreatment with the
combination p. o. on the mesenteric response to periarterial







Stimulation F req uency  (Hz)
K)----0  Combination Caten. 50mg/*kg, nit. 3mg/Kg) p. o. (n=8) mean +SE.
■---- 1 PEG (5% lml/lOOg) p. o. (n=6> mean ±SE.
* p<0•05 ** p<0-01 *** p<0.001
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FIGURE 52
Graph showing the effect of 21 days pretreatment with the
combination p. o. on the mesenteric response to exogenous










1.5 2 2.5 3
Log D o s e  Noradrenaline  (ng)
3.5
©---- © Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=8) mean ±SE.
 •----• PEG (5% lml/lOOg) p. o. (n=7) mean ±SE.
* p<0•05 ** p<0-01 *** p<0. 001
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FIGURE 53
Graph showing the effect of 21 days pretreatment with the
combination p. o. on the mesenteric response to periarterial




1 0 0  -i
50 -
0 5 10 15 20 25 30 35
Stimulation F req u e n cy  (Hz)
®----® Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=8) mean +SE.
 •---- • PEG (5% lml/lOOg) p. o. <n=7> mean ±SE.
* p<0•05 ** p<0-01 *** p<0.001
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FIGURE 54
Graph showing the effect of 7 days pretreatment with the
combination p. o. on the mesenteric response to exogenous
noradrenaline in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
M
1 I I I I I
1 1.5 2 2.5 3 3.5
Log D o s e  Noradrenaline  (ng).
0----0  Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=8) mean + SE.
■---- ■ PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
* p<0•05 ** p<0-01 * * * p<0.001
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FIGURE 55
Graph showing the effect of 7 days pretreatment with the
combination p. o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
250 i
2 0 0  -i
150
1 0 0  -i
50 -i
T T T Tl I I I I I I I
0 5 10 15 20 25 30 35
Stim ula t ion  F requency  (Hz)
E)-----El Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=8) mean ±SE.
■---- 1 PEG (5% lml/lOOg) p. o. (n=6> mean ±SE.
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FIGURE 56
Graph showing the effect of 21 days pretreatment with the
combination p. o. on the mesenteric response to exogenous
noradrenaline in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
150-1
1.5 2 2.5 3 3.5
Log D o s e  N oradrena l ine  (ng)
 ® Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=9) mean ±SE.
 •---- • PEG (5% Iml/lOOg) p. o. (n=6) mean tSE.
* p<0•05 ** p<0-01 *** p<0.001
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FIGURE 57
Graph showing the effect of 21 days pretreatment with the
combination p. o. on the mesenteric response to periarterial
electrical stimulation in the anaesthetised Japanese Okamoto SHR.
Pressure Change (mmHg)
TTT T1----- 1----- 1----- 1 I I i I
0 5 10 15 20 25 30 35
Stimulation F req u en cy  (Hz)
®---- ® Combination (aten. 50mg/kg, nit. 3mg/Kg) p. o. (n=9) mean ±SE.
•----• PEG (5% lml/lOOg) p. o. (n=6) mean ±SE.
185
4.4 CONCLUSIONS,
4.4.1 Conclusions from the conscious rat studies.
The graphs depicting the blood pressure and heart rate responses of 
conscious animals (figures 44-47) are on pages 171-174.
Following treatment with the combination of atenolol and nitrendipine 
the blood pressure and heart rate of treated animals followed a similar 
pattern to that of similar animals treated with atenolol alone. There was 
no additive hypotensive effect observed with combination treatment. As the 
blood pressure of the spontaneously hypertensive rats was not reduced to 
normotensive levels it appears that the failure to observe an additive
effect was not due to the hypotensive effect being maximal. There was
evidence to suggest that, as previously described in atenolol-treated
animals, there was a change in hypotensive action over the treatment period 
in the normotensive rat:;. As this possible mechanistic change was not
apparent during treatment with nitrendipine alone, it is presumably due to 
a change in the tissue reponse to atenolol, although it is possible that 
this change is different from that observed with atenolol alone and due to 
some interaction between the two drugs.
The combination seemed to be reaching constant plasma levels in a
similar way to that observed for the two drugs individually as the daily 
pre-/post-dose variation in blood pressure decreased in a similar fashion. 
This would appear to support the theoretical consideration that there 
would be no significant pharmacokinetic interaction between the two drugs. 
In addition to this, peak hypotensive effect was observed at two hours
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after dosing, the same as with the two drugs given separately. This 
suggests that dosing with a combination did not significantly alter 
absorption times.
There was evidence to suggest that acute p-adrenoceptor blockade was 
not related to the hypotensive action of the combination, as p-mediated
changes in heart rate did not closely “mirror'* changes in blood pressure. 
Thus atenolol administered alone or in combination did not appear to be 
exerting its antihypertensive effect as a result of an acute p-blockade. 
The use of atenolol in combination with nitrendipine prevented the reflex 
tachycardia that was associated with nitrendipine given alone in 
normotensive animals. There was, however, no evidence of the combination 
interacting to produce any other effects on the heart rate.
4.4.2 Conclusions from the assessment of B-adrenoceptor blockade.
Following both 7 and 21 days pretreatment with the combination there
was clear evidence of p-adrenoceptor blockade. The isoprenaline dose-
response curves (figures 48 & 49) were shifted to the right after
pretreatment with the combination. The addition of nitrendipine had no 
significant effect on the p-blockade, as the shift in the dose-response 
curves was similar to that obtained with atenolol alone. Interestingly, 
after 21 days pretreatment the isoprenaline shift was more parallel than 
that observed after atenolol treatment alone. It is possible that this is 
due to the chronic hypotensive action of the combination. This may reduce 
the relative importance of the p2-mediated vascular component of the 
isoprenaline response, which may be, at least partly, responsible for the 
non-parallel shift. The increase in response to low doses of isoprenaline
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observed after pretreatment with nitrendipine were not apparent when it was 
administered in the presence of atenolol. As this increase was thought to 
be due to a heightened reflex response to the drop in blood pressure (see 
section 3.4.2), which would be mediated by the action of catecholamines on 
the heart, it would seem likely that this was blocked by the action of 
atenolol on cardiac P ,-adrenoceptors.
4.4.3 Conclusions from the in situ blood perfused mesentery model.
The results from the investigation of adrenergic neurotransmission 
using the in situ blood perfused mesentery model were very interesting, 
they are described in section 4.3.4 and shown in figures 50-57.
The results obtained from animals treated with the combination are 
very hard to explain. The response to exogenous noradrenaline is similar 
to that obtained with nitrendipine alone, and there may be evidence of an 
additive effect with the combination. While there was only a limited 
decrease in response in normotensives the hypertensive response was reduced 
to a greater extent than that observed with nitrendipine or atenolol alone. 
Thus the reduction in response to exogenous noradrenaline in the 
hypertensive animals was large enough to be due to an additive effect of 
the drugs used in combination.
The responses of the animals to electrical stimulation was, however, 
much more complicated. When the two drugs were administered in isolation 
the overall effect of both was to reduce the response to electrical 
stimulation, and this was greater over time and in hypertensive animals. 
When the two drugs were used in combination this situation was reversed;
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there was no change in response in hypertensive animals, a small decrease
in response after 7 days in normotensives and a large increase in response
after 21 days. Treatment with the combination appears to be producing some
interaction to change the effect of each of the drugs on noradrenergic
neurotransmission and this effect appears to change over time. When given
alone nitrendipine appeared to have a postsynaptic effect which reduced the
mesenteric response to both endogenous and exogenous noradrenaline.
Atenolol in isolation had some prejunctional effect reducing the response
primarily to endogenous noradrenaline. Despite this, when these two drugs
were used together the response to endogenous noradrenaline appears to
initially decrease and then increase greatly in normotensive animals, while
remaining unchanged in hypertensive animals. The reasons behind these
changes are not clear, but there are a number of possibilities. It seems 
that although the ability of the tissue to vasoconstrict in response to
exogenous noradrenaline is reduced, its ability to respond to sympathetic
stimulation is unchanged or increased. This suggests that the importance
of noradrenaline as a transmitter at the sympathetic junction has been
altered by the interaction of the combination. It is possible that the
reduction of noradrenaline-induced vasoconstriction by atenolol and
nitrendipine in combination is so profound that there is some physiological
compensation via a non-adrenergic system. This may take the form of a
change in one of the systems thought to regulate noradrenergic
neurotransmission or possibly by the increase in the relative importance of
a substance co-released with noradrenaline. The fact that the response to
electrical stimulation was increased may indicate that while changes led to
a "normalisation” of response in hypertensive animals it led to a "rebound”
in response in normotensive animals.
What ever the complex changes produced by the combination are it must 
be remembered that the combination produced a hypotensive effect. The
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changes observed may, however, be responsible for the fact that the 
combination did not have an additive hypotensive effect in the conscious 
animal.
4.4.5 Overall conclusions.
The combination reduced blood pressure in conscious rats this 
reduction was bigger in hypertensive animals. There was, however, no 
indication of any additive effect. The antihypertensive effect appeared to 
change over time, as blood pressure reached a minimum and then plateaued at 
a slightly higher level. Although this was not so apparent in hypertensive 
animals. The reflex tachycardia obtained in response to nitrendipine alone 
was antaganised by atenolol as it was not present whith the combination.
The combination had a larger effect on the response to noradrenaline
than either drug in isolation, this may have been addative. This was seen 
in the results from the hypertensive rats only. Despite the fact that both 
drugs given alone produced a reduction in response to periarterial 
electrical stimulation; after combination treatment, an increase in some 
responses was noted. This did not appear to increase blood pressure, but 
may explain the absence of an additive hypotensive effect.
These conclusions are more fully discussed and compared with those






This chapter discusses further the results and conclusions from all 
three treatment regimes. The discussion concentrates on the investigation 
of adrenergic neurotransmission, in an attempt to explain the drug effects 
on blood pressure, and to suggest possible mechanisms of drug action and 
interaction. This is followed by suggestions of further work that would be 
required to firmly establish these theories. To facilitate the comparison 
of the treatment groups the discussion is preceeded by a tabular summary of 
the results obtained.
















7 days 21 days 7 days 21 days 7 days 21 days
Conscious
Blood pressure 11 11 l 4- 11 n
Conscious
Heart rate 4- l  t  T 1  1
Isoprenaline
response 1 4 - 1 4 -  t t 11 11
Noradrenaline
response = = = = = =1
Electrical
stimulation = 1 =1 l =1 tt
Spontaneously Hypertensive Rats (SHR)
ATENOLOL NITRENDIPINE COMBINATION
7 days 21 days 7 days 21 days 7 days 21 days
Conscious
Blood pressure 111 111 111 ill 111 111
Conscious
Heart rate 1 4  1 1  =  =  1 1  1 1
Noradrenaline
response = i i n  m  m
Electrical
stimulation i l l i l l
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5. 3 Discussion of the conscious rat studies.
Overall, the results obtained from the investigation of blood pressure
and heart rate in conscious animals were interesting. They revealed, that
atenolol appeared to have an antihypertensive effect that was distinct from 
0-adrenoceptor blockade, and possibly that this changed with chronic 
administration.
Nitrendipine reduced blood pressure in conscious rats, but this was less 
than that observed with the other treatments and was associated with a 
reflex tachycardia in normotensive animals. This was consistent with the 
theory that the dihydropyridine calcium antagonists are only really 
effective when peripheral resistance is initially raised, such as in the 
SHR.
The expected additive effect of the combination treatment was not apparent, 
and there was evidence that there may also be mechanistic changes over time 
with this group. This may, or may not, be as a result of changes in the
mechanism of atenolol's antihypertensive action. Although the prevention
of the nitrendipine induced tachycardia did not cause a greater reduction 
in blood pressure, it is a positive interaction, as it would alleviate the 
clinically reported side effects that result from increased heart rate.
5.4 Discussion of the assessment of B-adrenoceptor blockade.
Atenolol produced 0-blockade when administered alone and in 
combination. This was present after 7 days pretreatment and was still 
apparent after 21 days. There was no evidence of nitrendipine causing any
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3-blockade; it appeared, however, to increase the response to isoprenaline, 
presumably as a reflex response to vasodilation.
One of the considerations to come from this work was, that although 
the anaesthetised rat preparation was able to show whether p-adrenoceptor 
blockade was present, the results were somewhat confused by the complexity 
of the situation. There is an argument for using an isolated tissue 
preparation to investigate p-blockade, as such a preparation would be
simpler to interpret. This is discussed further in the section on future 
work.
5.5 Discussion of the investigation of noradrenergic neurotransmission.
This section of the work has produced interesting results that have 
led to a number of conclusions.
Atenolol appears to be acting presynaptically, possibly to reduce the 
release of noradrenaline. This has been shown in normotensive and
hypertensive rats and in normotensive dogs. Interestingly, the size and
time-course of this effect suggest that it may be important in the
antihypertensive effect of atenolol observed clinically. As the
presynaptic effect of atenolol is not apparent after 7 days treatment, but 
is established by 21 days, this change may explain the “plateau” effect 
seen in the blood pressure study.
Nitrendipine appears to be inhibiting the effects of both endogenous 
and exogenous noradrenaline, presumably via the blockade of Ca^-channels 
associated with the excitation-contraction coupling of the vascular smooth 
muscle.
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The combination would, perhaps, be expected to display both these 
previously described properties; as a result of each drug acting
separately. On initial examination this appears not to be so.
The combination undoubtedly produced a marked inhibition of exogenous 
noradrenaline, but electrical stimulation produced some unexpected results. 
In order to try and explain these results, it is perhaps prudent to look at 
the mechanisms by which the two drugs are acting when given separately, in 
more detail.
The main antihypertensive effect of nitrendipine, is a result of its 
blockade of the Ca^-dependent excitation-contraction coupling of smooth 
muscle. As endogenous noradrenaline acts on predominantly post-junctional 
a!-adrenoceptors in the mesentery, it follows that nitrendipine can inhibit 
the Ca^-dependent vasoconstriction associated with these receptors. The 
oci -adrenoceptors are thought to cause either Ca-4"4" release from the 
sarcoplasmic reticulum, or Ca-4"4' entry through receptor-gated channels. 
Nitrendipine would not be expected to antagonise either of these 
ch-adrenoceptor induced Ca’4"4’ fluxes. It would, however, antagonise the 
Ca-4"^  flux through the voltage-gated channels that these initial changes
would cause (Van Breemen et al 1980, 1986). This is how nitrendipine is
likely to inhibit the excitation-contraction coupling procedure in the
mesentery. The results obtained from the in situ mesentery model support 
this conclusion. They do not, however, eliminate other possible actions.
The investigation does not preclude nitrendipine having a diuretic 
and/or natriuretic hypotensive effect. Although some workers suggest that 
these aspects of nitrendipine's antihypertensive effect are important 
(Garthoff et al 1983, Hall & Hungerford 1984), they would not account for 
the changes observed in mesenteric noradrenergic neurotransmission. This 
does not, however, imply that they do not play a part in the overall
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antihypertensive action of nitrendipine. The well documented effects of 
nitrendipine on the structural abnormalities (eg. ventricular hypertrophy) 
of hypertension may also play a part in its overall hypotensive effect; but 
there was no histopathological study done in this investigation to confirm 
or refute this possibility.
The antihypertensive action of atenolol is a matter of some debate. 
This study would seem to confirm that the blockade of P^-adrenoceptors 
plays no direct role in its chronic effects, and suggests that it acts via 
some presynaptic interaction. The exact nature of this presynaptic effect 
is not certain. There is a possibility that some {3-blockers act by 
blocking the presynaptic P^-adrenoceptors, preventing the facilitation of 
noradrenaline release by adrenaline (Frishman & Silverman 1984). However, 
it would seem unlikely that this is the presynaptic mode by which atenolol 
acts, as it is P ,-adrenoceptor specific. Also, results suggest that the 
time course of its hypotensive effect is distinct from that of p- 
adrenoceptor blockade.
There is also the possibility that atenolol may cause depletion of 
noradrenaline at the sympathetic terminal via interactions with its 
turnover (Alexandre & Chevillard 1980) and/or uptake (Street & Walsh 1985). 
This would cause a reduction in the stimulus-induced release of 
noradrenaline as seen in the investigation. However, these actions appear 
to require a higher degree of lipid solubility and membrane stabilising 
properties than possessed by atenolol.
The theory that atenolol may act presynaptically to inhibit the 
facilitatory effect of locally released angiotensin II (Jackson & Campbell 
1980b) can not be discounted by this work. It seems likely that chronic
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atenolol may act via locally produced prostaglandins to achieve this 
inhibition. Prostaglandins E2 and I2 have been shown to be able to inhibit 
the angiotensin II facilitation of noradrenergic neurotransmission (Jackson 
& Campbell 1980a, Mizuno et al 1988) and it has been established that they 
may be produced locally (Westfall 1977, Gryglewski et al 1988). Recently 
it has been shown that after chronic administration 0-blockers may increase 
the prostaglandin (particularly PG E2 ) levels in vascular tissue and 
thereby inhibit the facilitatory role of angiotensin II (Jackson & Campbell 
1981, Daniell et al 1988). This theory is supported by the clinical 
observation that indomethacin, a prostaglandin synthesis inhibitor, can 
reduce the antihypertensive action of 0-blockade (Durao 1977, Salvetti 
et al 1984). Although this mechanism of action was not investigated, the 
time course of the presynaptic effect of atenolol observed in this work is 
similar to that described for the prostaglandin/angiotensin II interaction.
Other possible antihypertensive actions of atenolol cannot be 
discounted by this work. Plasma renin activity was not measured, and
some workers suggest that 0-adrenoceptor blockers may act by decreasing
this activity (Biihler et al 1975). While there is undoubtedly evidence 
that some 0-adrenoceptor blockers can reduce renin release via interactions 
with renal 02-adrenoceptors, this does not seem to be correlated with their 
antihypertensive ability. Additionally, 0,-bloking agents, such as 
atenolol, appear to have no effect on plasma renin activity (Antonaccio 
et al 1986), and the hypotensive effect observed in this work does not
appear to be related to blockade of 0-adrenoceptors. Also, the apparent
presynaptic effect of atenolol revealed in this study could not be easily
explained in terms of altered renin activity.
The idea that 0-blockers may produce their antihypertensive effect by 
interaction with the baroreceptor reflex (Pickering et al 1972, Scott 1981)
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can not be discounted by the present investigation. It would seem, 
however, that while such an effect may alter the sympathetic response to 
changes in blood pressure, it would not be expected to reduce stimulus 
induced transmitter release. Therefore, although it may play a part in the 
overall antihypertensive effect, it would appear not to be directly 
involved in the changes in neurotransmission observed in this work.
As no histopathological investigation was undertaken, the effect of 
atenolol on arterial hypertrophy and hyperplasia cannot be determined. 
While it is possible that these conditions were “reversed" by chronic 
atenolol treatment, it is unlikely that these effects would be entirely 
responsible for its hypotensive action. It is feasible that by changing 
the ratio between the vessel wall thickness and lumen size a drug may 
appear to be exerting a presynaptic effect. As the sympathetic nerve 
fibres are in the medial layer of the wall, and exogenously administered 
drugs have to diffuse through from the lumen, changing the wall thickness 
may alter the relative “efficiency" of these processes. If this was the 
case, response to sympathetic stimulation may be reduced because of a 
reduction in vessel wall “strength", while the effect of exogenous drugs 
may appear to be unchanged or increased, as drug diffusion across the 
thinner wall would be easier. This would fit with the observed results and 
the time course of the atenolol effect. It is, however, an unlikely 
explanation of the observed effects. Such structural changes occur because 
of a reduction in “load" on the vessel, in terms of pressure (Laplace's 
law); therefore all drugs which reduced pressure would be expected to have 
the same effect. As all three treatment regimes reduced pressure, and 
nitrendipine is known to reverse these structural changes, it would be 
expected that all the treatments would appear to have this same presynaptic 
effect. This was not the case, so it would seem likely that although
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structural changes may play a part, they are not responsible for the 
presynaptic effect observed with atenolol.
From this discussion, it would seem that nitrendipine is affecting 
noradrenergic excitation-contraction coupling via its action on voltage 
operated calcium channels, while atenolol appears to be having some 
presynaptic effect, which may reflect changes in uptake and storage of 
noradrenaline and/or alterations of the prostaglandin/angiotensin II 
regulation of noradrenaline release. These effects are shown in the 
diagram of noradrenergic neurotransmission on the following page (figure 
59).
FIGURE 59: A schematic diagram of noradrenergic neurotransmission





ANG II = Angiotensin II
PG = Prostaglandin
PLC = Phospholipid-cholesterol complex
AC = Adenylate cyclase
ATP = Adenosine triphosphate
CAMP = Cyclic adenosine monophosphate
ROC = Receptor operated calcium channel
VOC = Voltage operated calcium channel
U1 = Uptake 1
U2 = Uptake 2





Red arrow-head = Inhibitory effect.
Green arrow-head = Facilitatory effect.
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There appears to be no obvious interaction between atenolol and 
nitrendipine that could explain the effects of the combination treatment on 
neurotransmission. Further investigation revealed, that while there is no 
apparent link between prostaglandins and the action of nitrendipine, the 
actions of prostaglandins are Ca^-dependent. Therefore, it is possible 
that nitrendipine may interact with atenolol through its prostaglandin- 
mediated actions and that this may help to explain the confusing results 
obtained with the combination.
The phospholipase-dependent release of arachidonic acid from the membrane 
is the rate-limiting step for prostaglandin biosynthesis. The activity of 
these phospholipases is Ca^-dependent; Van de Velde and co-workers (1986) 
showed that the calcium antagonist nifedipine could suppress this synthesis 
by around 50%. Calcium antagonists are not able to inhibit this 
biosynthesis fully as intracellular Ca*"+‘ accounts for about half of the 
phospholipase activation. It would seem that although nitrendipine may 
reduce the atenolol mediated prostaglandin action, it would be unable to 
prevent it.
Interestingly, it has been shown that the inhibitory effect of
prostaglandins on noradrenergic neurotransmission may be reversed by
increasing the availability of Ca*"*- (Hedqvist 1970). It has been suggested
that prostaglandins may act by indirectly inhibiting the Ca"'* flux in the
nerve, which is responsible .for the focal extrusion of noradrenaline into 
the synaptic cleft, and so reduce transmitter release (Stjfirne 1973,
Hedqvist 1976). If this is the case, it is possible that nitrendipine may
also inhibit this flux and add to the inhibitory effect of the
prostaglandins. Should this occur, both atenolol and nitrendipine would
act to reduce noradrenaline release drastically.
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This possible interaction between atenolol and nitrendipine would 
undoubtedly result in a drastic reduction in the release of noradrenaline, 
but this alone does not explain the results obtained with the combination 
treatment.
As long ago as the mid 1960's it was recognised that the effects of 
sympathetic neurotransmission in the mesentery were not completely 
reproduced by exogenous noradrenaline (Me Gregor 1965). It is now widely 
thought that other biologically active compounds may coexist, and be 
co-released with noradrenaline in the sympathetic nervous system (Burnstock
1986, Campbell 1987). While the physiological role of such co-transmitters 
has not been fully established, their effects can clearly be seen when the 
main transmitter (noradrenaline) has been depleted (Campbell 1987).
There is evidence to suggest that co-transmission does occur in the 
mesenteric vascular bed, it has been suggested that adenosine triphosphate 
(ATP) (Burnstock 1985, 1986, 1988) and/or neuropeptide Y (NPY) (Campbell
1987, Lundberg & Hdkfelt 1985) are co-released with noradrenaline. Both 
these compounds are known to cause vasoconstriction, and either, or both of 
them may act to produce such an effect when the action of noradrenaline has 
been diminished.
It is possible that chronic treatment with the combination produces 
such a profound reduction in the release of noradrenaline via the 
interaction with the prostaglandin mediated system, out-lined above, that a 
co-transmitter is “unmasked". This would explain the absence of a 
decreased response to periarterial electrical stimulation in animals 
treated with the combination. The difference between the normotensive and 
hypertensive animals is, however, still not easily explained. It is 
possible that the co-transmitter is relatively less important in the SHR 
where there is greater noradrenaline release. Alternatively, the co-
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transmitter may play a larger part in the “normal” untreated SHR, possibly 
contributing to the cause and/or maintenance of the hypertension, while in 
the normotensive animal its role is “swamped” by noradrenaline. Thus, when 
it is “unmasked” there is a rebound increased response in the normotensive. 
Interestingly, the release of co-transmitters occurs preferentially at 
higher stimulation frequencies (Burnstock 1986), and the increase in 
mesenteric response to electrical stimulation observed following
combination treatment, occurred at the higher frequencies. This lends
further support to the theory that co-transmission may be involved in the 
unexpected findings observed with the combination.
In order to illustrate this theory, the schematic diagram on the
following page shows noradrenergic neurotransmission following chronic 
treatment with the combination (Figure 60). In this simplified example the 
putative co-transmitter ATP alone is included for clarity. The ATP is
thought to interact with post-synaptic P2-purinoceptors to cause 
vasoconstriction via electromechanical coupling to voltage dependent Ca""*- 
channels. Although these channels are blocked by nitrendipine, the
interaction with the P2-purinoceptor may change the state of the channel 
from “inactive” to “open”, and so displace the nitrendipine allowing the
excitation-contraction coupling to precede. To simplify the diagram, the
presynaptic P,-purinoceptor, which inhibits the release of ATP and
noradrenaline, is not included.
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FIGURE 60: A schematic diagram of noradrenergic neurotransmission
showing co-transmission and the effects of combination.





ATP = Adenosine triphosphate
ANG II = Angiotensin II
PG = Prostaglandin
VOC = Voltage operated calcium channel
U1 = Uptake 1
= a,-adrenoceptor
P2 = P2-purinocept or
( n ) = Nitrendipine
= Atenolol
Red arrow-head = Inhibitory effect. 
Green arrow-head = Facilitatory effect.
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It appears that following chronic administration, atenolol and the 
combination effect noradrenergic neurotransmission by interacting with a 
transmitter release “control” mechanism. Evidence suggests that locally 
produced prostaglandins and angiotensin II interact with the sympathetic 
nerve varicosities, perhaps to “fine tune” transmitter release. If this is 
the case, it is interesting to speculate on the role of this system in the 
control of blood pressure. It is possible that such a system may be 
involved with the cause and/or maintenance of hypertension. Also, as this 
local mediation would be unlikely to remain “intact" in isolated, Krebs 
perfused systems, it may, at least partially, explain the differences in 
sensitivity to nerve stimulation observed between Krebs and blood perfused 
mesentery preparations.
While the theories outlined above are supported by the experimental 
evidence of other authors, and are consistent with the results obtained in 
this work, they are not all directly shown by the present investigation.
This investigation has produced some interesting results, and has 
allowed a number of conclusions to be drawn. It has also raised many 
questions, a great deal of further work could be done to answer these 
questions, and this is discussed in the following section.
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5.6 Suggestions for further work.
Perhaps the most obvious direction for further work is to “complete" 
the initial work scheme in both rats and dogs. The diagram (Figure 1) on 
page 4, shows a flow chart of the work undertaken so far. It would be 
interesting to “fill in" the missing places in the flow chart for all the 
species, and perhaps include hypertensive dogs. This would complete the 
picture in terms of the present work, and allow further investigation of 
the trends observed in rats in another species.
The investigation of 3H-noradrenaline overflow could be extended to 
include all treatment groups and hypertensive animals. It would be 
particularly revealing to investigate the release of noradrenaline 
following treatment with the combination. Also, differences in release, 
and the treatment affects, in the hypertensive animal would be interesting.
As the presynaptic effects observed after treatment with both atenolol and 
the combination appear to occur after chronic administration, further 
investigation of the time course of the effect would seem appropriate. 
Changes in the mesenteric response and in the stimulus-induced release of 
transmitter could be investigated after a single acute dose of drug, 
perhaps 2 and 24 hours after such a dose. Also the length of time of 
chronic dosing could be varied from 2 to 21 days and perhaps longer. 
Investigation of adrenergic neurotransmission after such a dosing scheme 
would allow the time course of any chronic presynaptic effect to be 
charted. As there seems to be a change in the hypotensive mode of action 
of both atenolol and the combination between 7 and 21 days it would be 
informative to find out when this actually happened, and if the effect 
continued over a longer period.
209
The information obtained about transmitter release by using 3H- 
noradrenaline is useful, but it does not distinguish between labelled 
noradrenaline or labelled inactive metabolites. As it is possible that 
drug treatment may affect the metabolism of transmitter, another method of 
measuring catecholamine release (perhaps HPLC) could possibly be run in 
parallel with such studies.
The work undertaken so far has not provided any evidence of the effect of 
drug treatment on the uptake of noradrenaline. As it has been suggested 
that atenolol may effect this process, an investigation of the uptake of 
3H-noradrenaline into various tissues could be undertaken. This could be 
combined with a study of the effect of acute blockade of uptake 1 (with 
cocaine) on the effect of atenolol on neurotransmission in the mesentery.
The involvement of locally released angiotensin II and prostaglandins 
with the actions of the drugs could be investigated by examining the 
effects of acute doses of indomethacin (a prostaglandin synthesis 
inhibitor) and saralasin (an angiotensin II antagonist) alone and in 
combination in animals chronically pretreated with the three treatment 
regimes under investigation. Exogenous prostaglandins and angiotensin II 
could also be used together with their respective inhibitors to examine 
whether the prostaglandins exert their effect via inhibition of the 
angiotensin II potentiation of transmitter release, or directly. If locally 
released prostaglandins are involved in the control of noradrenaline 
release and perhaps blood pressure in the mesentery, it would be 
interesting to examine the effects of chronic administration of 
indomethacin and sulindac. Indomethacin inhibits all prostaglandin 
synthesis, while sulindac has been reported as inhibiting only systemic 
prostaglandin synthesis (Ciabattoni et al 1980). These drugs may therefore
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help to establish the importance of vascular as opposed to renal 
prostaglandins in the control of blood pressure.
The importance of the release of co-transmitters in the response to 
the combination could be investigated further, by using the appropriate 
antagonists to try and reverse the increased response to nerve stimulation 
observed after combination treatment. As the co-transmitter(s) involved 
are not known this would be a matter of some trial and error. As there 
seems to be evidence that ATP is an important co-transmitter, perhaps the 
P2-purinoceptor antagonist arylazido aminopropionyl-ATP <ANAPP3 ) would be 
an appropriate first choice. If this is found to reduce the increased 
response to nerve stimulation following chronic treatment with the 
combination, it would be interesting to investigate whether stimulation of 
P2-purinoceptors would allow Ca-'"*' entry through voltage operated channels 
in the presence of nitrendipine. This could be examined initially by 
observing the effects of exogenous ATP on the response to endogenous and 
exogenous noradrenaline following acute and chronic nitrendipine treatment. 
This could then be investigated in more detail using patch-clamping 
techniques to examine the actual fluxes of ions. If it was found that the 
combination was producing such a profound decrease in the release of 
noradrenaline that a co-transmitter was “unmasked”, it would be interesting 
to investigate the effects of lower doses of atenolol, nitrendipine and the 
combination. This may help to establish whether the hypotensive effects 
were additive when the reduction of noradrenaline release was less 
prof ound.
In addition to the previously discussed further work, the 
investigation of {3-adrenoceptor blockade using an anaesthetised animal 
preparation was questioned earlier in the study. It would, perhaps, be 
prudent to investigate the explanation of the anomalies proposed earlier by
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using an isolated heart preparation. This preparation would be free of the 
complications due to “whole animal” effects, and could be run in parallel 
with the anaesthetised animal method using isolated hearts from pretreated 
animals. However, isolated preparations contravene the aim of undertaking 
work in-sit is, a pithed rat preparation may, perhaps, be preferable.
The ultimate aim of these further investigations would be to fulfil 
the initial aims of the study and find out how these drugs were producing 
their antihypertensive effect following chronic administration. The 
evaluation of the interactions observed between these two drugs following 
their combined administration, may provide information that would allow 
their clinical use in combination to be more effective and safer.
In addition to this, throughout the work the results obtained from the 
various methods used have suggested that in situ blood perfused 
preparations are sensitive and consistent, but can produce complicated 
results. It appears that while isolated tissues produce results that are 
more easy to interpret, there may be considerable differences between such 
situations and the physiological norm. It follows therefore, that to 
provide results that are more physiologically applicable, preparations that 
provide conditions close to “life" should be used. To take this to its 
logical extreme, it would be advisable to develop, and use telemetric 
systems for measuring blood pressure and flow to various vascular beds. 
Such systems could then be used to examine the effects of treatment regimes 
in free living, conscious animals with relatively little interference by 
the investigator. While this sort of system would provide complex data 
that would be of little use on the molecular level of drug/receptor 
interaction, it would be invaluable for evaluating the effects of drugs on 
the “normal" physiology of animals, and may provide high quality data that 
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Program used to calculate change in resistance.
10 REM PROG TO CALC CHANGE IN RESISTANCE
20 D=0, REM D = dog number
30 B=0, REM B = mean control BP
40 F=0, REM F = control Flow
50 R=0, REM R = control Resistance
60 D$=0, REM DS = dose
70 B1=0, REM B1 = mean BP response
80 F1=0, REM FI = Flow response
90 R1=0, REM R1 = Resistance response
100 F2=0, REM F2 = change in Flow
110 R2=0, REM R2 = change in Resistance
120 PRINT “Input Dog Number (F to finish)”
130 INPUT D
140 IF D = F THEN 340
150 PRINT “Dog N u m b e r  ” D
160 PRINT “Dose ?”
170 INPUT DS
180 IF DS = No GOTO 120
190 PRINT “Input control Blood Pressure”
200 INPUT B
210 PRINT “Input control Flow”
220 INPUT F
230 PRINT “Input control response Blood Pressure”
240 INPUT B1
244
250 PRINT “Input response Flow”
260 INPUT FI
270 R = ( B * 79980 ) / F
280 R1 = ( B1 * 79980 ) / FI
290 R2 = R1 - R
300 F2 = FI - F
310 PRINT “Dose =” DS
320 PRINT “Change in minute Flow = ” F2,
“Change in Resistance =” R2 
330 GOTO 150




Summary of base-line conditions In the mesenteric vasculature.
1. Wistar Rats - 7 days treatment
Treatment iBP(mmHg) ffiBP (mmHg)
(Kdyne/s/cme )





155•7 ± 12•1 
1 1 9 • 7 ± 9 •8 
96•4 ± 6 •1
5238•7 ± 488•1 
6229-2±483-4 
4787♦4 ± 3 9 3 •2 
3856-2±242-8
2. Wistar Rats - 21 davs treatment.




N i t r e n d i p i n e  130-2±5*3
C o m b i n a t i o n  9 9 - 0±5-8
114-3±6-7 





5106-7 ± 2 2 2 •9 
5097-2+293-4
246
3. J a p a n e s e  O k a m o t o  SHR* s - 7 days treatment
Treatment sBP(mmHg) ^.BP (mmHg)
P E G  1 2 8 • 3± 5•8 1 1 7 - 2 ± 7 - 4
A t e n o l o l  1 5 4 - 7 ± 5 - 7  1 6 0 - 6 ± 1 2 - 3
N i t r e n d i p i n e  1 4 5 - 3 ± 4 - 8  1 5 2 - 5 ± 7 - 8
C o m b i n a t i o n  1 1 6 - 5 ± 6 * 1  1 2 7 - 0 ± 8 - 4
4. J a p a n e s e  O k a m o t o  S H R 1 s - 21 d a y s  t r e a t m e n t
Treatment fiBP(mmHg) mBPCmrnHg)
P E G  1 3 5 • 7 ± 10•7 1 2 6 • 7± 6• 1
A t e n o l o l  9 7 - 7 ± 7 - 3  9 9 - 7 ± 3 - 8
N i t r e n d i p i n e  9 6 - 7 + 7 - 0  9 5 - 3 + 1 - 7
C o m b i n a t i o n  1 0 4 - 7 ± 3 - 4  1 1 4 - 2 ± 3 - 3
LEGEND.
aiBP = S y s t e m i c  M e a n  B l o o d  P r e s s u r e  ( + SE) 
r-,BP = M e s e n t e r i c  M e a n  B l o o d  P r e s s u r e  (±SE) 
r,,R = M e s e n t e r i c  R e s i s t a n c e  (±SE)
(Kdyne/s/cms )
4 6 8 5 - 5 ± 2 9 4 - 2 
6 4 2 1 • 3 ± 4 9 1•0 
6 0 9 8 - 5 ± 3 1 1 - 8 
5 0 7 8 - 7 + 3 3 7 - 9
(Kdyne/s/cms )
5 0 6 5 - ± 2 4 4 - 5  
3 9 8 5 - 7 + 1 5 0 - 1  
3 8 1 2 - 4 ± 6 6 - 4 
4 5 6 7 - 7 ± 132•2
247
5. U n t r e a t e d  Normo t e n s i v e  Male Beagles.
D o g  No, H. R. »BP JBP ff,BP F R.
9 8 0 171 • 6 140-3 1 3 5 / 1 0 8 117 2 8 5 3 2 - 8
8 3 9 156 • 7 109-0 1 2 3 / 1 0 8 107 104 83- 1
1081 177-5 119-8 124 / 9 5 105 60 1 4 0 - 0
1488 167-8 142 - 8 1 5 8 / 1 2 4 135 92 1 1 6 - 9
1400 152-0 9 7 - 7 1 1 4 / 8 4 9 4 146 5 1 - 6
1486 199-0 144 - 3 1 6 0 / 1 3 0 140 154 7 2 - 6
M e a n 1 7 0 - 8 1 2 5 - 7 1 3 6 / 1 0 7 116 140 8 2 - 8
± SE ± 6 - 8 ±8- 1 7 - 9 / 7 - 2 ± 7 - 4 ± 3 2 - 3 ± 16-
6. N o r m o t e n s i v e  M a l e  Beasrles T r e a t e d  for 21 d a v s  w i t h At e n o l
(7-_5mg/Kg).
D o g  No. H. R. «BP mBP rV.BP F R.
1202 153-0 144-0 1 5 5 / 1 2 5 135 135 7 0 - 0
1369 150-5 146-5 1 6 2 / 1 2 8 139 150 74- 1
9 1 3 150-8 110 - 8 120 / 9 5 103 112 7 3 - 4
912 155-7 9 9 - 3 1 3 6 / 9 6 109 147 5 9 - 3
8 4 0 1 2 4-0 106-3 123/8 100 166 48- 1
M e a n 1 4 6 - 8 121 • 4 1 3 9 / 1 0 6 11-7 146 6 5 - 0
± SE ±5 • 8 ±9- 9 8 - 4 / 8 - 3 ±8- 2 ± 9 - 0 ± 5 - 0
LEGEND.
H. R. = H e a r t  R a t e  (b/min)
aaBP = S y s t e m i c  M e a n  B l o o d  P r e s s u r e  (mmHg)
rriBP = M e s e n t e r i c  B l o o d  P r e s s u r e  (mmHg)
r-,BP = M e s e n t e r i c  M e a n  B l o o d  P r e s s u r e  (mmHg)
F = M e s e n t e r i c  F l o w  (ml/min)
R = M e s e n t e r i c  R e s i s t a n c e  ( K d y n e / s / c m 6 )
248
Stimulus induced 3H—noradrenaline overflow results.
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CHRONIC EFFECTS OF ATENOLOL IN SPONTANEOUSLY HYPERTENSIVE RATS.
Kingsbury. M.P.. Draper. A.J.. Redfern. P.H. & Todd. M .H.1 University of Bath. Claverton Down. Bath, 
l ICI Pharmaceuticals. Mereside. Alderley Park. Cheshire.
Previous work has indicated that following chronic atenolol administration, changes in end-organ 
response are accompanied by altered presynaptic mechanisms. (Carr el al. 1983. Draper el al. 1986) The 
present study investigates this phenomenon in the spontaneously hypertensive rat (SHR).
Atenolol (50mg/kg) w as administered orally in 5% polyethylene glycol (PEG) to male SHR's (300-  
350g): control results were obtained from animals dosed with vehicle alone. Blood pressure was 
measured in the conscious rat by the "tail-cuff" technique using the schedule described previously. 
(Kingsbury el al. this meeting) Twenty-four hours after the last dose of atenolol or PEG the in silu 
blood-perfused mesentery was prepared according to the method of Jackson and Campbell (1980). 
Vasoconstricor responses to exogenous noradrenaline and periarterial electrical stimulation were assessed 
as previously described. (Kingsbury el al. this meeting)
After the first day o f dosing with atenolol, blood pressure in the conscious rat was significantly 
(p<0.001.n=4) reduced from 214.5 ±  3.4mmHg in control animals to 165.3 ±5.2m m H g in atenolol- 
treated animals. After 5 days the mean blood pressure of the control (PEG), group was 227±3.2m m H g  
while that of the atenolol-treated group was 165.3 ±5.2m m Hg. This reduction was maintained 
throughout the dosing period: after 19 
days atenolol-treated animals had a 
mean blood pressure of 
185.3 ±3.7mmHg compared to 
226 ±5.1 in controls. Results from the 
in situ  mesentery showed that 
treatment with atenolol for 7 days 
resulted in increased vasoconstriction  
in response to higher doses of
noradrenaline. After 21 days this 
potentiation had disappeared, and was 
replaced by a significant 
( p < 0.001.n=7) reduction in response 
to lower doses o f noradrenaline.
Response to periarterial electrical 
stimulation was unchanged after 7 
days atenolol treatment. This was in 
contrast to the highly significant
(p < 0 .0 0 l)  decrease in response after 
21 days atenolol treatment, (fig l )
Fig 1:
These results indicate that chronic administration o f atenolol caused a reduction in the blood pressure in 
the conscious SHR which reached a maximum after 3 days, and was maintained for at least 18 days 
thereafter. Although this reduction was highly significant, blood pressure in the SHR was still higher 
than in untreated normotensive animals. Results from the in situ  mesentery indicate that after 21 days 
atenolol administration, there is a significant reduction in transmitter release from the presynaptic 
terminal, as evidenced by the reduced response to periarterial electrical stim ulation. The time course 
and size of this effect suggests that it may be important in the antihypertensive effect of atenolol 
observed clinically.
Draper. A.J.. Kendall. H.E. & Redfern. P.H. (1986) J. Auton. Pharmac. 5 259-268  
Carr. S.R.. Draper. A.J.. Lamaa. M. & Redfern. P.H. (1983) J. Auton. Pharmac. 3. 7-12.
Jackson. E.K. & Campbell W.B. (1980) Eur. J. Pharmac. 66 217-224.
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Effect o f 21 days Atenolol p.o. on Electrical Stimulation.
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CHRONIC EFFECTS OF ATENOLOL IN WISTAR RATS.
Kingsbury. M.P., Draper, A.J., Redfern. P.H. & Todd. M.H.1 University of Bath, Claverton Down, Bath, 
l ICI Pharmaceuticals. Mereside. Alderley Park, Cheshire.
We have previously shown that after long-term administration of /3-adrenoceptor blocking drugs in the 
rat. complex changes are produced quite distinct from the blockade of post-synaptic /3-adrenoceptors. 
(Carr et al. 1983, Draper et al. 1986) These effects are more consistent with the time course of the 
antihypertensive action of /3-adrenoceptor blocking drugs. The present study investigates further the 
effect of chronic /3-adrenoceptor blockade on adrenergic neurotransmission using an in situ preparation to 
avoid complications arising from possible "wash-out” of antagonist following tissue removal.
Atenolol (50m g/kg) was administered daily p.o. to normotensive male Wistar rats (300-350g) in 5% 
polyethylene glycol (PEG). Control results were obtained from animals dosed with vehicle alone. Blood 
pressure was measured in the conscious rat by the "tail-cuff" technique and was recorded daily before 
and 2h after dosing. Twenty-four hours after the last dose of atenolol or PEG the degree of blockade 
was assesed by constructing dose response curves to isoprenaline injected as a bolus i.v. The in situ 
blood-perfused mesentery was prepared according to Jackson and Campbell (1980). Vasoconstrictor 
responses to exogenous noradrenaline (20-2000ng) and periarterial electrical stimulation (I5v  
rectangular pulses of 1ms duration for 20sec. 2-35Hz) were obtained 24h after the last dose.
During the first week of dosing with atenolol, blood pressure in the conscious rat was significantly 
reduced. After 5 days the mean blood pressure of the control (PEG), group was 153±2.9mmHg while 
that of the atenolol treated group was 128.5±2.8mmHg (p<0.001.n=8). This reduction was maintained 
throughout the dosing period; after 19 days, atenolol-treated animals had a mean blood pressure of 
130.1 ±2.0mmHg compared to 151.8± 1.7mmHg in controls. (p < 0 .0 0 l)
.0025 .005 .01
ISOPRENALINE (Mg) 






2.5 ±2.2  
0 
0
8.9 ±2.8  
8.8 ±5.1 
3.1 ± 1.5 
7.5 ±4.1
20 ±2.5 




30 ± 10.6 
35.6 ±9.9  
30 ±8.8
88.8± 13.6 




60 ± 15.8* 






Table 1 :- Mean Increase in Heart Rate (beats/min) ±SEM, n=4 atenolol. n=8 PEG.
*=p<0.05, **=p<0.01, ***=p<0.001
Results from the in situ mesentery showed that treatment with atenolol for 7 days resulted in increased 
vasoconstriction in response to higher doses of noradrenaline. This trend increased after 21 days 
treatment. In contrast, responses to higher frequencies of periarterial electrical stimulation were reduced 
after 21 days treatment with atenolol.
These results indicate that chronic administration of atenolol caused a reduction in blood pressure which 
reached a maximum after five days, and was maintained for at least 16 days thereafter. /3-adrenoceptor 
blockade was established within 7 days and was maintained up to 21 days of dosing with atenolol 
(Table 1). Results obtained from the in situ mesentery further suggest that atenolol exerts a presynaptic 
action apparent after 21 days but not after 7 days drug treatment.
Draper, A.J., Kendall. H.E. & Redfern, P.H. (1986) J. Auton. Pharmac. 5 259-268  
Carr, S.R.. Draper. A.J., Lamaa. M. & Redfern. P.H. (1983) J. Auton. Pharmac. 3. 7-12.
Jackson, E.K. & Campbell W.B. (1980) Eur. J. Pharmac. 66 217-224.
252
CHRONIC EFFECTS OF ATENOLOL ON MESENTERIC VASCULAR RESPONSES IN DOGS.
Kingsbury. M.P., Draper. A.J.. Redfern, P.H. & Todd. M .H.1 University of Bath. Claverton Down, Bath, 
l ICI Pharmaceuticals. Mereside, Alderley Park. Cheshire.
We have previously shown that, in the rat. chronic administration of /3-adrenoceptor blocking drugs 
produces changes distinct from the post-synaptic blockade of /3-adrenoceptors. (Carr et al. 1983. Draper 
et al. 1986) There is some evidence to suggest that atenolol may be acting presynaptically after chronic 
administration to normotensive and spontaneously hypertensive rats. (Kingsbury et al. 1988) These 
effects are consistent with the time course of the antihypertensive action of the /3-blocking drugs. This 
study investigates the effect of chronic /3-adrenoceptor blockade on adrenergic neurotransmission in 
normotensive dogs.
Atenolol (7.5m g/kg) was administered orally to male A lderley Park beagles ( l7 -2 0 k g ) daily for 21 days
(n=5). The animals were then anaesthatised with sodium pentobarbitone (30m g/kg i.v .) and maintained
with a lm g/m in  infusion. A laporotomy was performed and the superior mesenteric artery was cleared
to allow the location of a doppler flow probe. Bipolar platinum electrodes were placed around the vessel
distal to the probe; a suitable side-branch was cannulated to allow  administration of drugs and
measurement of mesenteric blood pressure. Following a 30min stabilisation period vasoconstrictor
responses to exogenous noradrenaline (l-4 0 0 n g ) and periarterial electrical stim ulation were obtained.
Control results were obtained from untreated animals (n=6). Resistance w as calculated using ;
R (dyns /sec /cm 5) = mean Mood pressure x 1330 f rom mesenteric blood pressure and flow which were
flow (mis / sec )
measured directly.
Changes in mesenteric pressure, flow  
and resistance to exogenous 
noradrenaline were not significantly 
different in control and drug treated 
animals. While there was some 
indication of a reduction following  
atenolol pretreatment in the response 
to electrical stimulation in terms of 
flow, this did not reach statistical 
significance. There was some evidence 
of a reduction in the mesenteric
pressure response to electrical
stimulation following atenolol
pretreatment. However, when this 
data was used to calculate resistance a 
significant decrease in the mesenteric 
resistance response to electrical
stimulation was observed. (p < 0 .0 5 )
1 2 0  - j Resistance
1 0 0  -
8 0  -
6 0  -
4 0  - T
h
2 0  - i
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Fig 1: Effect of 21 days atenolol p.o. 
electrical stim ulation
i i i i
2 0  2 5  3 0  3 5
S tim u lat ion  Frequency (Hz)
on resistance response to
In conclusion, it seems likely that as neither mesenteric flow or pressure w as kept constant during the 
experiment, animals were varying one or both of these parameters in response to stimulation. Only by 
using both these responses to calculate the response in terms of resistance did the overall trend become 
apparent. As chronic atenolol treatment produced no change in the response to exogenous noradrenaline 
but reduced the response to electrical stimulation, it is possible that, in accordance with our previous 
work in rats, it may be having some presynaptic effect.
Draper. A.J., Kendall. H.E. & Redfern. P.H. (1986) J. Auton. Pharmac. 5 259-268  
Carr. S R.. Draper. A.J.. Lamaa. M. & Redfern. P.H. (1983) J. Auton. Pharmac. 3. 7-12.
Kingsbury. M.P., Draper. A.J.. Redfern. P.H. & Todd. M.H. (1988) Br. J. Pharmac. in press.
Vascular responses to atenolol and nitrendepine in the
normotensive rat: evidence of a significant drug interaction.
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A. J. Draper, M.P. Kingsbury, P.H. Redfern, M. E. Todd,* School of Pharmacy and 
Pharmacology, University of Bath, Claverton Dcwn, Bath BA2 7 AY and *ICI 
Pharmaceuticals, Meresice, Alderly Park, Cheshire.
The 3-adrenoceptor blocking drugs and the calcium antagonists are both 
established as effective antihypertensive agents, and they are increasingly 
used in combination. We have previously shown (Kingsbury et al 1988) that, 
after chronic administration to normotensive rats, the 8-adrenoceptor blocking 
drug atenolol produces a significant reduction in the vasoconstrictor response 
to sympathetic nerve stimulation. This effect is in addition to the blockade 
of post-synaptic 8-adrenoceptors which is established in the first few days of 
treatment, and is apparently caused by a reduction in transmitter release.
In a similar series of experiments we have examined the effect of the calcium 
antagonist nitrendipine, alone and in combination with atenolol, on blood 
pressure and vascular reactivity.
-1 -1 
Atenolol 50mg kg and nitrendipine 3mg kg were orally administered alone or
in combination to groups of male Wistar rats (300-350g). The drugs were
administered in polyethylene glycol, and control groups received vehicle
alone. Blood pressure was monitored daily in the conscious animal by the
tail-cuff method before and 2-hours after dosing. After druc administration
for 21 days the responses to exogenous noradrenaline and to periarterial
electrical stimulation were measured in the in situ blood perfused mesentery,
(Jackson and Campbell 1980). The tissue was perfused at a constant rate and
increased vascular resistance was measured as an increase in perfusion pressure.
Treatment with nitrendipine alone did not significantly alter the dose response 
curve to noradrenaline, but slightly decreased the response cf the tissue to 
nerve stimulation over the range of frequencies used (2 - 3 5 Ez). This finding 
is consistent with the relatively small hypotensive effect of nitrendipine in 
these animals and with the suggestion that the calcium antagonists lower blood 
pressure effectively only when peripheral resistance is raised. After treatment 
for 21 days with the combination of drugs, vascular responses to noradrenaline 
were slightly but significantly decreased; in contrast, periarterial nerve 
stimulation now produced a significantly enhanced response. The responses to 
electrical stimulation are summarized in Table 1. Thus while treatment with 
either atenolol or nitrendipine alone resulted in a significant decrease in 
response to nerve stimulation, chronic administration of the two drugs in 
combination reversed this response. The mechanism responsible for this 
interaction is at present unknown. It may be suggested that the two,drugs 
together produce a reduction in vascular reactivity sufficiently profound as to 
trigger some compensatory change in presynaptic mechanisms - for instance an 
enhanced release of a vasoconstrictor peptide co-released with noradrenaline. 
Whatever the mechanism, it may account for the failure to observe any additive 
hypotensive effect of atenolol and nitrendipine in these experiments.
Table 1 Increase in mesenteric perfusion pressure (mm Hg ) after periarterial 
stimulation
Frequency (Hz) 2 4 8 16 35
Control 7 .4+1 .2 14.6+1.9 30.6+2 .7 62.4+4 .8 119.6+3 .9
Nitrendipine 1.5 +1.2 5.9+1.4 14 .9+2 .8 37 .9+9 .2 67.1+18.3
Combination 7.8+1 .7 17 .5+2 .5 33 .3+4 .8 100.4+8 .9 185 .3+11.7
Kingsburv, M. P. , Draper, A. J. et al, ( 1988) Er. J. Pharmac. 94: 420P,
Jackson, E. K. , Campbell, W. B. , ( 1980) Eur. J. Pharmac. 66: 217-224
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We have previously demonstrated a significant degree of interaction between the 
B-adrenoceptor blocking drug atenolol and the calcium antagonist nitrendipine in 
terms of vascular reactivity after chronic administration to normotensive rats, 
(Draper et al this meeting). Both classes of drug are more effectively 
depressor, and produce a more profound decrease in vascular reactivity when 
blood pressure and peripheral resistance are elevated; it was therefore of 
interest to examine the effects of these two drugs in hypertensive animals.
The design of the experiment and the methods used were exactly those previously 
employed, (Draper et al 1989), except that the animals ve;e spontaneously 
hypertensive rats of the Japanese Okamoto strain, weighing approximately 200g. 
With all three regimens - atenolol 5 0mg kg alone, nitrendipine 3mg kg alone, 
and the two drugs together, - blood pressure fell rapidly during the first week 
and was constant thereafter. As in normotensive animals, the fall in blood 
pressure caused by the combination was not significantly greater than that 
produced by either drug alone.
Vascular responses were measured after 7 and 21 days drug treatment in the blood 
perfused _i_n situ mesentery preparation, for clarity, only the results obtained 
after 21 days will be described here. The vasoconstriction produced by 
exogenous noradrenaline was significantly reduced by all three treatments and, 
as would be predicted, the effect was much greater than that seen in 
normotensive animals. In both the atenolol-treated and nitrendipine-treated 
groups, the response to periarterial nerve stimulation was significantly reduced 
compared to that seen in control preparations. In contrast, only a slight 
reduction, which did not reach statistical significance, was observed 
in animals treated with the combination.














Nitrendipine 5 .7+0 .4 13.2+1.8 28.2+4 .4 29.5+12.3 117.5+12.2
Combination 8.0+1.2 20.0+2 .9 41.5+6 .8 100.4+12.5 189+17.1
Thus the overall picture is the same in normcrensive and hypertensive animals in
that the decrease observed after either drug alone is significantly reduced 
after combined drug treatment. The difference in the magnitude of the 
interaction can probably be accounted for by the enhanced depressor responses 
obtained in the hypertensive animals. Thus we have demonstrated that in 
hypertensive as well as normotensive rats there is clear evidence of a 
significant degree of interaction between ater.olol and nitrendipine, leading to 
a smaller reduction in blood pressure than might be expected. Whether this 
interaction can also occur in man remains to be seen.
